Form 10-Q Amendment No. 1

Large accelerated filer

Accelerated filer

Non-accelerated filer

¨ (Do not check if smaller reporting company)

Smaller reporting company

0001193125-16-541467.txt : 20160414 0001193125-16-541467.hdr.sgml : 20160414 20160414163203 ACCESSION NUMBER: 0001193125-16-541467 CONFORMED SUBMISSION TYPE: 10-Q/A PUBLIC DOCUMENT COUNT: 55 CONFORMED PERIOD OF REPORT: 20150630 FILED AS OF DATE: 20160414 DATE AS OF CHANGE: 20160414 FILER: COMPANY DATA: COMPANY CONFORMED NAME: TAPIMMUNE INC CENTRAL INDEX KEY: 0001094038 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 880277072 STATE OF INCORPORATION: NV FISCAL YEAR END: 0220 FILING VALUES: FORM TYPE: 10-Q/A SEC ACT: 1934 Act SEC FILE NUMBER: 000-27239 FILM NUMBER: 161572084 BUSINESS ADDRESS: STREET 1: 50 N LAURA STREET STREET 2: SUITE 2500 CITY: JACKSONVILLE STATE: FL ZIP: 98102 BUSINESS PHONE: (206) 504-7278 MAIL ADDRESS: STREET 1: 50 N LAURA STREET STREET 2: SUITE 2500 CITY: JACKSONVILLE STATE: FL ZIP: 98102 FORMER COMPANY: FORMER CONFORMED NAME: GENEMAX CORP DATE OF NAME CHANGE: 20020718 FORMER COMPANY: FORMER CONFORMED NAME: EDUVERSE COM DATE OF NAME CHANGE: 19990827 10-Q/A 1 d179913d10qa.htm FORM 10-Q AMENDMENT NO. 1 Form 10-Q Amendment No. 1

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q/A

(Amendment No. 1)

x	Quarterly Report Under Section 13 or 15(d) of the Securities Exchange Act of 1934 for the quarterly period ended June 30, 2015

¨	Transition Report Under Section 13 or 15(d) of the Securities Exchange Act of 1934 for the transition period from to .

Commission File Number: 000-27239

TAPIMMUNE INC.

(Name of registrant in its charter)


NEVADA		88-0277072
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

50 N. Laura Street, Suite 2500 Jacksonville, FL 32202		98102
(Address of principal executive offices)		(Zip Code)

(206) 504 7267

(Issuer’s telephone number)

Indicate by check mark whether the registrant (1) filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x No ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, non-accelerated filer or a smaller reporting company. See definition of “accelerated filer”, “large accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act (check one):

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ¨ No x

As of August 14, 2015, the Company had 46,140,771 shares of common stock issued and outstanding.

EXPLANATORY NOTE

As a result, the Board of Directors of the Company has determined that the Company’s previously issued consolidated unaudited financial statements and reports filed with the SEC for the quarterly period ended June 30, 2015 should not be relied upon. For a more detailed description of the effects of the restatement, see further discussion in Note 1A, “Amendment to Previously Reported Quarterly Financial Statements” to our consolidated financial statements included in Part I, Item 1 of this report.

For the convenience of the reader, this Form 10-Q/A sets forth the Original Filings in their entirety. However, this Form 10-Q/A only amends and restates Items 1 and 2 of Part I of the Original Filing, in each case, solely as a result of, and to reflect, the restatement, and no other information in the Original Filing is amended hereby. The foregoing items have not been updated to reflect other events occurring after the Original Filings or to modify or update those disclosures affected by subsequent events. In addition, pursuant to the rules of the SEC, Item 6 of Part II of the Original Filings has been amended to contain currently dated certifications from the Company’s Chief Executive Officer and Chief Financial Officer, as required by Sections 302 and 906 of the Sarbanes-Oxley Act of 2002, and are attached as Exhibits 31.1 and 32.1 to this report. We have also updated our financial statements formatted in Extensible Business Reporting Language (XBRL) in Exhibits 101.

Except for the foregoing amended information, this Form 10-Q/A continues to speak as of the dates of the Original Filings, and the Company has not updated the disclosures contained herein to reflect events that occurred at a later date. Other events occurring after the filings of the Original Filings or other disclosures necessary to reflect subsequent events will be addressed in any reports filed with the SEC subsequent to the date of this filing.

PART I – FINANCIAL INFORMATION

Item 1.

Financial Statements


Description	Page

Condensed Interim Financial Statements

Condensed Consolidated Balance Sheets as of June 30, 2015 (Unaudited) and December 31, 2014		4

Condensed Consolidated Statements of Operations and Comprehensive Loss for the Three and Six Months Ended June 30, 2015 and 2014 (Unaudited)		5

Condensed Consolidated Statement of Stockholders’ Equity (Deficit) for the Six Months Ended June 30, 2015 (Unaudited)		6

Condensed Consolidated Statements of Cash Flows for the Three and Six Months Ended June 30, 2015 and 2014 (Unaudited)		7

Unaudited Notes to Condensed Consolidated Financial Statements		9

TAPIMMUNE INC.

CONDENSED CONSOLIDATED BALANCE SHEETS


	June 30, 2015 As Restated			December 31, 2014
	(Unaudited)
ASSETS
Current Assets
Cash	$	3,105,320		$	141,944
Prepaid expenses and deposits		142,590			82,504

	$	3,247,910		$	224,448

LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT)
Current Liabilities
Accounts payable and accrued liabilities	$	842,682		$	693,362
Research agreement obligations		492,365			492,365
Derivative liability – warrants		69,962,000			9,415
Promissory notes		52,942			52,942

		71,349,989			1,248,084

COMMITMENTS AND CONTINGENCIES
Stockholders’ Equity (Deficit)
Convertible preferred stock, $0.001 par value — 10,000,000 shares authorized:
Series A, $0.001 par value, 1,250,000 shares designated, -0- shares issued and outstanding as of June 30, 2015 and December 31, 2014		—			—
Series B, $0.001 par value, 1,500,000 shares designated, -0- shares issued and outstanding as of June 30, 2015 and December 31, 2014		—			—
Common stock, $0.001 par value, 500,000,000 shares authorized 38,038,921 shares issued and outstanding (2014 – 20,318,815)		38,039			20,319
Additional paid-in capital		92,218,937			85,265,776
Accumulated deficit		(160,359,055	)		(86,309,731	)

		(68,102,079	)		(1,023,636	)

	$	3,247,910		$	224,448

The accompanying notes are an integral part of these condensed consolidated financial statements.

TAPIMMUNE INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(UNAUDITED)


	Three Months Ended June 30,						Six Months Ended June 30,
	2015 As Restated						2015 As Restated
	2015 As Restated			2014			2015 As Restated			2014
Operating expenses:
General and administrative	$	936,887		$	488,427		$	1,355,673		$	1,687,794
Research and development		201,157			22,500			810,535			45,000

Loss from Operations		(1,138,044	)		(510,927	)		(2,166,208	)		(1,732,794	)
Other Income (Expense)
Accretion of interest on convertible debt		—			(8,660	)		—			(492,296	)
Changes in fair value of derivative liabilities		(59,079,025	)		352,834			(58,751,585	)		14,537
Foreign exchange		775			—			775			—
Gain (loss) on settlement of debt		—			920,233			—			(26,743,197	)

Net Income (Loss) for the Period	$	(60,216,294	)	$	753,480		$	(60,917,018	)	$	(28,953,750	)

Other comprehensive income (loss)
Foreign exchange translation adjustment		—			1,042			—			(207	)

TOTAL COMPREHENSIVE INCOME (LOSS)	$	(60,216,294	)	$	754,522		$	(60,917,018	)	$	(28,953,957	)

Basic and Diluted Net Income (Loss) per Share	$	(1.80	)	$	0.05		$	(1.99	)	$	(2.57	)

Weighted Average Number of Common Shares Outstanding		33,525,656			15,523,016			30,584,794			11,250,240

The accompanying notes are an integral part of these condensed consolidated financial statements.

TAPIMMUNE INC.

CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS’ EQUITY (DEFICIT)

AS RESTATED


					Additional
	Common Stock				Paid In			Accumulated
	Number of shares		Amount $		Capital $			Deficit $			Total $
Balance, December 31, 2014		20,318,816		20,319		85,265,776			(86,309,731	)		(1,023,636	)
Private placement (net of finders’ fee of $140,000)		12,319,995		12,320		2,313,694			—			2,326,014
Fair value of warrants recognized as derivative liabilities in January and March 2015 Financing		—		—		(2,313,694	)		(6,999,306	)		(9,313,000	)
Fair value of warrants issued on May 28, 2015		—		—		—			(6,133,000	)		(6,133,000	)
Exercise of warrants		5,000,000		5,000		2,495,000			—			2,500,000
Reclassification of derivative warrant liabilities to equity at exercise date		—		—		4,245,000			—			4,245,000
Finders’ fee on exercise of warrants		—		—		(35,000	)		—			(35,000	)
Stock- based compensation		400,110		400		248,161			—			248,561
Net loss		—		—		—			(60,917,018	)		(60,917,018	)

Balance, June 30, 2015		38,038,921		38,039		92,218,937			(160,359,055	)		(68,102,079	)

The accompanying notes are an integral part of these condensed consolidated financial statements.

TAPIMMUNE INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)


	Six Months Ended June 30, 2015 As Restated			Six Months Ended June 30, 2014
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$	(60,917,018	)	$	(28,953,750	)
Adjustments to reconcile net loss to net cash from operating activities:
Changes in fair value of derivative liabilities		58,751,585			(14,537	)
Loss on extinguishment of debt		—			26,743,197
Non-cash interest and finance charges		—			492,296
Stock based compensation		248,561			799,075
Changes in operating assets and liabilities:
Prepaid expenses		(60,086	)		—
Accounts payable and accrued liabilities		149,320			322,277

NET CASH USED IN OPERATING ACTIVITIES		(1,827,638	)		(611,442	)

CASH FLOWS FROM FINANCING ACTIVITIES
Issuance of shares, net of issuance costs of $173,000		2,326,014			583,000
Proceeds from loans payable		—			500
Proceeds from exercise of warrants		2,500,000			—
Finders’ fee on exercise of warrants		(35,000	)		—

NET CASH PROVIDED BY FINANCING ACTIVITIES		4,791,014			583,500

INCREASE (DECREASE) IN CASH		2,963,376			(27,942	)
CASH, BEGINNING OF PERIOD		141,944			48,589

CASH, END OF PERIOD	$	3,105,320		$	20,647

The accompanying notes are an integral part of these condensed consolidated financial statements.

TAPIMMUNE INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS


	Six Months Ended June 30, 2015 As Restated		Six Months Ended June 30, 2014
SUPPLEMENTAL SCHEDULE OF NON-CASH ACTIVITIES
Accounts payable settled in common stock	$	231,000	$	683,000
Fair value of issuance of warrants in January and March 2015 financing		9,313,000		—
Issuance of additional warrants in May 28, 2015 transaction		6,133,000		—
Reclassification of derivative warrant liabilities to equity at exercise date		4,245,000		—
Conversion of debt obligations into common stock:
Accrued interest		—		476,000
Convertible notes payable		—		3,797,000
Loans payable, related party		—		42,000
Promissory notes, related party		—		210,000
Due to related parties		—		369,000
Fair value derivative liability – conversion option at conversion		—		708,000

The accompanying notes are an integral part of these condensed consolidated financial statements.

TAPIMMUNE INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

June 30, 2015

(Unaudited)

NOTE 1: NATURE OF OPERATIONS

TapImmune Inc. (the “Company”), a Nevada corporation incorporated in 1992, is a biotechnology Company focusing on immunotherapy specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of oncology and infectious disease. Unlike other vaccine technologies that narrowly address the initiation of an immune response, TapImmune’s approach broadly stimulates the cellular immune system by enhancing the function of killer T-cells and T-helper cells and by restoring antigen presentation in tumor cells allowing their recognition and killing by the immune system.

NOTE 1A: AMENDMENT TO PREVIOUSLY REPORTED QUARTERLY FINANCIAL STATEMENTS

The Company’s previously issued consolidated financial statements for the three and six months ended June 30, 2015 have been restated related to the Company’s accounting for share purchase warrants issued as part of two registered transactions in January 2015 and March 2015. Previously, the fair value of certain series of the share purchase warrants (Series B, B-1, C, C-1, D, D-1, E and E-1) was concluded by management to be classified within stockholders’ equity (deficit). The Company has reviewed the terms and conditions underlying its outstanding share purchase warrants and determined that the accounting for certain series of the warrants should be amended.

Management reviewed ASC 480-10 Distinguishing liabilities from equity and ASC 815-40 Contracts in an Entity’s Own Equity to arrive at this conclusion that the common stock purchase warrants should be classified as a liability, not equity, as the Company cannot control their ability to gross settle the financial instruments with registered securities.

The Company has restated its accounting for certain series of the share purchase warrants and recorded the fair value of the warrants under “Derivative liability- warrants” on its balance sheet with changes in the fair value over time reflected in the statements of operations as “Changes in fair value of derivative liabilities”.

As a result of these adjustments, net loss for the three and six months ended June 30, 2015 was increased by $41,771,000 and $41,490,000, respectively. The Company has reported an amended net loss of $60,216,000 versus the previously reported net loss of approximately $18,446,000 for the three months ended June 30, 2015 and an amended net loss of $60,917,000 versus the previously reported net loss of approximately $19,427,000 for the six months ended June 30, 2015.

The following table summarizes the effect of the restatement on the consolidated statement of operations for the three and six months ended June 30, 2015:

TAPIMMUNE INC.

CONDENSED CONSOLIDATED BALANCE SHEETS


	June 30, 2015 (Unaudited)
	As Previously Reported			Adjustments			As Restated
ASSETS
Current Assets
Cash		3,105,320			—			3,105,320
Prepaid expenses and deposits		142,590			—			142,590

		3,247,910			—			3,247,910


LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT)
Current Liabilities
Accounts payable and accrued liabilities		842,682			—			842,682
Research agreement obligations		492,365			—			492,365
Derivative liability – warrants		11,673,347			58,288,653			69,962,000
Promissory notes		52,942			—			52,942

		13,061,336			58,288,653			71,349,989

COMMITMENTS AND CONTINGENCIES
Stockholders’ Equity (Deficit)
Convertible preferred stock, $0.001 par value — 10,000,000 shares authorized:
Series A, $0.001 par value, 1,250,000 shares designated, -0- shares issued and outstanding as of March 31, 2015 and December 31, 2014		—			—			—
Series B, $0.001 par value, 1,500,000 shares designated, -0- shares issued and outstanding as of March 31, 2015 and December 31, 2014		—			—			—
Common stock, $0.001 par value, 500,000,000 shares authorized 32,638,811 shares issued and outstanding (2014 – 20,318,815)		38,039			—			38,039
Additional paid-in capital		95,885,631			(3,666,694	)		92,218,937
Accumulated deficit		(105,737,096	)		(54,621,959	)		(160,359,055	)

		(9,813,426	)		(58,288,653	)		(68,102,079	)

		3,247,910			—			3,247,910

TAPIMMUNE INC.

CONDENSED CONSOLIDATED STATEMENTS OF

OPERATIONS AND COMPREHENSIVE LOSS

(UNAUDITED)


	Three Months Ended June 30, 2015
	As Previously Reported			Adjustments			As Restated
Operating expenses:
General and administrative		936,887			—			936,887
Research and development		201,157			—			201,157

Loss from Operations		(1,138,044	)		—			(1,138,044	)
Other Income (Expense)
Changes in fair value of derivative liabilities		(9,052,372	)		(50,026,653	)		(59,079,025	)
Foreign exchange		775			—			775
Inducement expense		(8,256,000	)		8,256,000			-

Net Loss for the Period		(18,445,641	)		(41,770,653	)		(60,216,294	)

Other comprehensive income
Foreign exchange translation adjustment		—			—			—

TOTAL COMPREHENSIVE LOSS		(18,445,641	)		(41,770,653	)		(60,216,294	)

Basic and Diluted Net Loss per Share		(0.55	)		(1.25	)		(1.80	)

Weighted Average Number of Common Shares Outstanding		33,525,656			33,525,656			33,525,656

TAPIMMUNE INC.

CONDENSED CONSOLIDATED STATEMENTS OF

OPERATIONS AND COMPREHENSIVE LOSS

(UNAUDITED)


	Six Months Ended June 30, 2015
	As Previously Reported			Adjustments			As Restated
Operating expenses:
General and administrative		1,355,673			—			1,355,673
Research and development		810,535			—			810,535

Loss from Operations		(2,166,208	)		—			(2,166,208	)
Other Income (Expense)
Changes in fair value of derivative liabilities		(9,005,932	)		(49,745,653	)		(58,751,585	)
Foreign exchange		775			—			775
Inducement expense		(8,256,000	)		8,256,000			—

Net Loss for the Period		(19,427,365	)		(41,489,653	)		(60,917,018	)
Other comprehensive income
Foreign exchange translation adjustment		—			—			—

TOTAL COMPREHENSIVE LOSS		(19,427,365	)		(41,489,653	)		(60,917,018	)

Basic and Diluted Net Loss per Share		(0.64	)		(1.36	)		(1.99	)

Weighted Average Number of Common Shares Outstanding		30,584,794			30,584,794			30,584,794

TAPIMMUNE INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)


	Six Months Ended June 30, 2015
	As Previously Reported			Adjustments			As Restated
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss		(19,427,365	)		(41,489,653	)		(60,917,018	)
Adjustments to reconcile net loss to net cash from operating activities:
Changes in fair value of derivative liabilities		9,005,932			49,745,653			58,751,585
Inducement expense		8,256,000			(8,256,000	)		—
Non-cash interest and finance charges		—			—			—
Stock based compensation		248,561			—			248,561
Changes in operating assets and liabilities:
Prepaid expenses		(60,086	)		—			(60,086	)
Accounts payable and accrued liabilities		149,320			—			149,320

NET CASH USED IN OPERATING ACTIVITIES		(1,827,638	)		—			(1,827,638	)

CASH FLOWS FROM FINANCING ACTIVITIES
Issuance of shares, net of issuance costs of $173,000		2,291,014			35,000			2,326,014
Proceeds from exercise of warrants		2,500,000						2,500,000
Finders’ fee on exercise of warrants		—			(35,000	)		(35,000	)

NET CASH PROVIDED BY FINANCING ACTIVITIES		4,791,014			—			4,791,014

INCREASE IN CASH		2,963,376			—			2,963,376
CASH, BEGINNING OF PERIOD		141,944			—			141,944

CASH, END OF PERIOD		3,105,320			—			3,105,320

NOTE 2: BASIS OF PRESENTATION

The accompanying unaudited condensed financial statements have been prepared in accordance with the accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and pursuant to the instructions to Form 10-Q and Article 8 of Regulation S-X of the Securities and Exchange Commission (“SEC”) and on the same basis as the Company prepares its annual audited consolidated financial statements. The condensed consolidated balance sheet as of June 30, 2015, condensed consolidated statements of interim financials include all adjustments, consisting only of normal recurring adjustments, which the Company considers necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented.

The results for the statement of operations are not necessarily indicative of results to be expected for the year ending December 31, 2015 or for any future interim period. The condensed balance sheet at December 31, 2014 has been derived from audited financial statements; however, it does not include all of the information and notes required by U.S. GAAP for complete financial statements. The accompanying condensed financial statements should be read in conjunction with the consolidated financial statements for the year ended December 31, 2014, and notes thereto included in the Company’s annual report on Form 10-K.

NOTE 3: LIQUIDITY AND FINANCIAL CONDITION

The Company’s activities since inception have consisted principally of acquiring product and technology rights, raising capital, and performing research and development. Successful completion of the Company’s development programs and, ultimately, the attainment of profitable operations are dependent on future events, including, among other things, its ability to access potential markets; secure financing, develop a customer base; attract, retain and motivate qualified personnel; and develop strategic alliances. From inception, the Company has been funded by a combination of equity and debt financings.

The Company expects to continue to incur substantial losses over the next several years during its development phase. To fully execute its business plan, the Company will need to complete certain research and development activities and clinical studies. Further, the Company’s product candidates will require regulatory approval prior to commercialization. These activities may span many years and require substantial expenditures to complete and may ultimately be unsuccessful. Any delays in completing these activities could adversely impact the Company. The Company plans to meet its capital requirements primarily through issuances of debt and equity securities and, in the longer term, revenue from product sales.

As of June 30, 2015, the Company had cash and cash equivalents of approximately $3,105,000. Historically, the Company has net losses and negative cash flows from operations. The Company believes its current capital resources are not sufficient to support its operations. Management intends to continue its research efforts and to finance operations of the Company through debt and/or equity financings. Management plans to seek additional debt and/or equity financing through private or public offerings or through a business combination or strategic partnership. There can be no assurance that the Company will be successful in obtaining additional financing on favorable terms, or at all. These matters raise substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of these uncertainties.

NOTE 4: SIGNIFICANT ACCOUNTING POLICIES

There have been no material changes in the Company’s significant accounting policies to those previously disclosed in the Company’s annual report on Form 10-K, which was filed with the SEC on April 15, 2015.

Prior Period Reclassifications

The expense categories of the comparable prior period have been reclassified for comparability with the June 30, 2015 presentation. These reclassifications had no effect on previously reported net loss.

NOTE 5: POTENTIALLY DILUTIVE SECURITIES

Options, warrants, and convertible debt outstanding were all considered anti-dilutive for the six months ended June 30, 2015 and 2014, due to net losses.

The following securities were not included in the diluted net loss per share calculation because their effect was anti-dilutive as of the periods presented:


	June 30,
	2015		2014
Common stock options		465,000		65,000
Common stock warrants - equity treatment		2,556,000		185,000
Common stock warrants - liability treatment		81,834,000		49,000
Convertible notes		—		7,000

Potentially dilutive securities		84,855,000		306,000

NOTE 6: DERIVATIVE LIABILITY - WARRANTS AND DERIVATIVE LIABILITY – CONVERSION OPTION, AS RESTATED

A summary of quantitative information with respect to valuation methodology and significant unobservable inputs used for the Company’s common stock purchase warrants that are categorized within Level 3 of the fair value hierarchy for the six months ended 2015 and 2014 is as follows:


Share Purchase Warrants	Weighted Average Inputs for the Period
Date of valuation	For the Six Months Ending June 30, 2015			For the Six Months Ending June 30, 2014
Fair market value of stock	$	0.96		$	0.02
Strike price	$	0.50		$	5.84
Volatility (annual)		148.00	%		159.00	%
Risk-free rate		1.1	%		1.08	%
Contractual term (years)		3.2			3.58
Dividend yield (per share)		0	%		0	%

The foregoing assumptions are reviewed quarterly and are subject to change based primarily on management’s assessment of the probability of the events described occurring. Accordingly, changes to these assessments could materially affect the valuations.

Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis

Financial assets and liabilities measured at fair value on a recurring basis are summarized below and disclosed on the balance sheet under Derivative liability – warrants:


	As of June 30, 2015
	Fair Value Measurements
	Fair Value		Level 1		Level 2		Level 3		Total
Derivative liability - warrants	$	69,962,000		—		—	$	69,962,000	$	69,962,000

Total	$	69,962,000		—		—	$	69,962,000	$	69,962,000


	As of December 31, 2014
	Fair Value Measurements
	Fair Value		Level 1		Level 2		Level 3		Total
Derivative liability - warrants	$	9,000		—		—	$	9,000	$	9,000

Total	$	9,000		—		—	$	9,000	$	9,000

There were no transfers between Level 1, 2 or 3 during the three months ended June 30, 2015.

The following table presents changes in Level 3 liabilities measured at fair value for the six months ended June 30, 2015:


	Derivative liability – warrants
Balance – December 31, 2014	$	9,000
Additions during the period		15,446,000
Exercise of warrants		(4,245,000	)
Change in fair value of warrant liability		58,752,000

Balance – June 30, 2015	$	69,962,000

The valuation of warrants is subjective and is affected by changes in inputs to the valuation model including the price per share of common stock, the historical volatility of the stock price, risk-free rates based on U.S. Treasury security yields, the expected term of the warrants and dividend yield. Changes in these assumptions can materially affect the fair value estimate. The Company could ultimately incur amounts to settle the warrant at a cash settlement value that is significantly different than the carrying value of the liability on the financial statements. The Company will continue to classify the fair value of the warrants as a liability until the warrants are exercised, expire, or are amended in a way that would no longer require these warrants to be classified as a liability. Changes in the fair value of the common stock warrants liability are recognized as a component of other income (expense) in the Statements of Operations.

During 2014 the Company entered into numerous extinguishment agreements with various holders. As a result the derivative liability associated with the bifurcated conversion options were extinguished at the date of conversion and recorded in the loss on extinguishment in the Statement of Operations. The inputs utilized in the final mark to market were as follows:


Conversion Option	Weighted Average Inputs for the Period
Date of valuation	For the Quarter Ending June 30, 2015			For the Quarter Ending June 30, 2014
Strike price	$	—		$	1.03
Volatility (annual)		—	%		199.00	%
Risk-free rate		—	%		0.05	%
Contractual term (years)		—			0.24
Dividend yield (per share)		—	%		—	%

Fair value of Conversion Option at extinguishment	$	—		$	708,000

NOTE 7: PROMISSORY NOTES, RELATED PARTY

The Company has outstanding promissory notes in the amount of $52,942 (December 31, 2014 - $52,942), of which $23,000 of promissory notes are from an officer and a director of the Company. The promissory notes bear no interest charges and have no fixed repayment terms.

NOTE 8: CAPITAL STOCK, AS RESTATED

2015 Share Transactions

Private placements

In January, 2015, the Company entered into a Securities Purchase Agreement with certain investors for the sale of 7,320,000 units at a purchase price of $0.20 per unit, for a total purchase price of approximately $1,250,000, net of finders’ fee and offering expenses of approximately $214,000. Each unit consisting of (i) one share of the Company’s Common Stock, (ii) one Series A warrant to purchase one share of common stock, (iii) one Series B warrant to purchase one share of common stock (iv) one Series C warrant to purchase one share of common stock, (v) one Series D warrant to purchase one share of common stock, and (vi) one Series E warrant to purchase one share of common stock (the Series A, B, C, D and E warrants are hereby collectively referred to as the “January 2015 Warrants”). Series A warrants are exercisable at $1.50 per share, with a five year term. Series B warrants are exercisable at $0.40 per share, with a six month term. Series C warrants are exercisable at $1.00 per share, with a five year term. Series D warrants are exercisable at $0.75 per share only if and to the extent that the Series B warrants are exercised, with a five year term from the date that the Series B warrants are exercised. Series E warrants are exercisable at $1.25 per share, only if and to the extent that the Series C warrants are exercised, with a five year term from the date that the Series C warrants are exercised.

Pursuant to a placement agent agreement, the Company agreed to issue warrants to purchase 366,000 common shares with substantially the same terms as the January 2015 Warrants.

In March, 2015, the Company entered into a Securities Purchase Agreement with certain accredited investors for the sale of 5,000,000 units at a purchase price of $0.20 per unit, for a total purchase price of approximately $950,000, net of finders’ fee and offering expenses of approximately $50,000. Each unit consisting of (i) one share of the Company’s Common Stock, (ii) one Series A warrant to purchase one share of common stock, (iii) one Series B warrant to purchase one share of common stock (iv) one Series C warrant to purchase one share of common stock, (v) one Series D warrant to purchase one share of common stock, and (vi) one Series E warrant to purchase one share of common stock (the Series A, B, C, D and E warrants are hereby collectively referred to as the “March 2015 Warrants”). The March 2015 Warrants have substantially the same terms as the January 2015 Warrants.

Pursuant to a placement agent agreement, the Company agreed to issue warrants to purchase 125,000 common shares with substantially the same terms as the March 2015 Warrants.

Initial Fair Value of Warrants Issued

Pursuant to ASC 480-10 Distinguishing liabilities from equity and ASC 815-40 Contracts in an Entity’s Own Equity, the common stock purchase warrants are classified as a derivative liability as the Company cannot control their ability to gross settle the financial instruments with registered securities. The fair value of the warrants issued pursuant to the January and March 2015 stock purchase agreement was $9,313,000. The weighted average inputs include contractual term of 5.0 years, volatility of 158% and risk free rate of 1.2%.

May 2015 Restructuring agreement

In May 2015, the Company entered into a restructuring agreement with the investors of the January 2015 and March 2015 private placements, where:

•

The exercise price of the Series A warrants was changed from $1.50 per warrant to $0.10 per warrant,

•

The exercise price of Series B warrants was changed from $0.40 per warrant to $0.20 per warrant,

•

Each warrant of Series B existing prior to the restructuring agreement was replaced with two warrants of such series,

•

The exercise price of the Series C warrants was changed from $1.00 per warrant to $0.50 per warrant, and

•

Each warrant of Series C existing prior to the restructuring agreement was replaced with two warrants of such series.

As a result of the restructuring agreement, the Company issued an additional 12,320,000 Series B warrants and 12,320,000 Series C Warrants. The fair value of the warrants issued pursuant to the May 2015 restructuring agreement was $6,133,000.

The weighted average inputs include contractual term of 2.46 years, volatility of 141% and risk free rate of 1.5%.

Share Purchase Warrants

During the six months ended June 30, 2015, a warrant holder exercised 5,000,000 of Series C warrants at $0.50 per warrant for a total of $2,500,000.

A summary of the Company’s share purchase warrants as of June 30, 2015 and changes during the period is presented below:


	Number of Warrants			Weighted Average Exercise Price		Weighted Average Remaining Life
Balance, December 31, 2014		2,659,417			1.83		4.15
Issued		86,730,975			0.54		3.25
Exercised		(5,000,000	)		0.50		—
Extinguished or expired		(7,500	)		50.00		—

Balance, June 30, 2015		84,382,892		$	0.54		3.26

Stock Compensation Plan

On October 14, 2009, the Company adopted the 2009 Stock Incentive Plan (the “2009 Plan”) which supersedes and replaces the 2007 Stock Plan. The 2009 Plan allows for the issuance of up to 10,000,000 common shares. Options granted under the Plan shall be at prices and for terms as determined by the Board of Directors.

On February 10, 2015, the Company granted 250,000 stock options at an exercise price of $0.145 per share, of which, 33,333 vested on May 31, 2015 and the remaining vesting monthly over a nine month period, to a consultant of the Company. The term of the options is five years. The fair value of the new grant was estimated at $33,000, or $0.133 per option, using the Black-Scholes Option Pricing Model with a risk free interest rate of 1.52%, a dividend yield of 0%, volatility of 154.6%, and life of 5 years. The expensed portion of the value of these options during the six months ended June 30, 2015 was $7,635, which was recorded as stock based consultant compensation.

On March 6, 2015, the Company granted 150,000 stock options at an exercise price of $0.20 per share, vesting monthly over a twenty four month period, to a director of the Company. The term of the options is five years. The fair value of the new grant was estimated at $29,000, or $0.194 per option, using the Black-Scholes Option Pricing Model with a risk free interest rate of 1.70%, a dividend yield of 0%, volatility of 155.2%, and life of 5 years. The expensed portion of the value of these options during the six months ended June 30, 2015 was $4,850, which was recorded as stock based management compensation.

Share purchase options

A summary of the Company’s stock options as of June 30, 2015 and changes during the period is presented below:


	Number of Options		Weighted Average Exercise Price		Weighted Average Remaining Life
Balance, December 31, 2013		65,430		18.00		5.04
Issued		—		—		—
Cancelled/Forfeited		—		—		—

Balance, December 31, 2014		65,430		18.00		4.04


	Number of Options		Weighted Average Exercise Price		Weighted Average Remaining Life
Issued		400,000		0.17		4.64

Balance, June 30, 2015		465,430	$	2.62		4.49

At June 30, 2015, the intrinsic value of the vested options was equal to $66,000 (2014 - $nil).

A summary of the status of the Company’s unvested options as of June 30, 2015 is presented below:


	Number of Shares			Weighted Average Grant-Date Fair Value
Unvested, December 31, 2014		278		$	18.00
Granted		400,000			0.16
Vested		(82,685	)		0.21
Cancelled		—			—

Unvested, June 30, 2015		317,593		$	0.16

NOTE 9: SUBSEQUENT EVENTS

Between July 16, 2015 and August 13, 2015, holders of the Series B warrant exercised 7,890,000 of the Series B Warrants registered under our recent registration statements on Form S-1 resulting in proceeds of $1,578,000 to the Company.

On July 21, 2015, the Company entered into a License and Assignment Agreement with the Mayo Foundation for Medical Education and Research (“Mayo Foundation”) pursuant to which we acquired certain intellectual property rights from the Mayo Foundation for the development and commercialization of certain products, methods and processes property relating to a folate receptor alpha immunotherapeutic vaccine comprised of a set of unique peptide epitopes targeting breast, lung and ovarian cancer. The Mayo Foundation granted us a license (with a right to sublicense) on a worldwide basis to make, sell and use products for therapeutic use against breast, ovarian, lung and other cancers that express folate receptor alpha. This license is an exclusive license for products that are based on the intellectual property and non-exclusive for products that are based on Mayo Foundation know–how and materials. The intellectual property that is being licensed includes (i) U.S. patent application numbers 12/303,054 and 13/202,236, (ii) U.S. patent number 8,486,412 and 8,858,952 and provisionals, (iii) divisionals including 13/917,410 and (iv) continuations including 14/484,057.

On July 31, 2015, the Company issued to its counsel 118,450 shares of common stock for legal services rendered through January 21, 2015. Such shares were authorized to be issued on January 23, 2015, but were not issued until July 31, 2015.

On August 10, 2015, the Company issued 50,000 shares of common stock as full settlement of a dispute with a marketing consultant that provided services to the Company in 2014 and 2015.

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

This quarterly report on Form 10-Q contains forward-looking statements within the meaning of Section 21E of the Securities and Exchange Act of 1934, as amended, that involve risks and uncertainties. All statements other than statements relating to historical matters including statements to the effect that we “believe”, “expect”, “anticipate”, “plan”, “target”, “intend” and similar expressions should be considered forward-looking statements. Our actual results could differ materially from those discussed in the forward-looking statements as a result of a number of important factors, including factors discussed in this section and elsewhere in this quarterly report on Form 10-Q, and the risks discussed in our other filings with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect management’s analysis, judgment, belief or expectation only as the date hereof. We assume no obligation to update these forward-looking statements to reflect events or circumstance that arise after the date hereof.

As used in this quarterly report: (i) the terms “we”, “us”, “our”, “TapImmune” and the “Company” mean TapImmune Inc. and its wholly owned subsidiary, GeneMax Pharmaceuticals Inc. which wholly owns GeneMax Pharmaceuticals Canada Inc., unless the context otherwise requires; (ii) “SEC” refers to the Securities and Exchange Commission; (iii) “Securities Act” refers to the Securities Act of 1933, as amended; (iv) “Exchange Act” refers to the Securities Exchange Act of 1934, as amended; and (v) all dollar amounts refer to United States dollars unless otherwise indicated.

The following should be read in conjunction with our unaudited consolidated interim financial statements and related notes for the three months ended June 30, 2015 included in this quarterly report, as well as our Annual Report on Form 10-K for the year ended December 31, 2014.

Company Overview

Our Cancer Vaccines

TapImmune is a biotechnology company focusing on immunotherapy specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer and infectious disease. The Company combines a set of proprietary technologies to improve the ability of the cellular immune system to destroy diseased cells. These are peptide antigen technologies and DNA expression technologies, Polystart and TAP.

To enhance shareholder value and taking into account development timelines, the Company plans to focus on advancing its clinical programs including our HER2/neu peptide antigen program and our Folate Receptor Alpha program for breast and ovarian trials into Phase II. In parallel, we plan to complete the preclinical development of our Polystart technology and to continue to develop the TAP-based franchise as an integral component of our prime-and-boost vaccine methodology.

The Immunotherapy Industry for Cancer

Immunotherapy has become the most rapidly growing sector in the pharmaceutical and biotech industry. The approval and success of checkpoint inhibitors Yervoy and Opdivo (Bristol Myers Squibb) and Keytruda (Merck) together with the development of CAR T-cell therapies (Juno, Kite) has provided much momentum in this sector. In addition, new evidence points to the increasing use of combination immunotherapies for the treatment of cancer. This has provided greater opportunities for the successful development of T-cell vaccines in combination with other approaches.

Products and Technology in Development

Clinical

Phase I Human Clinical Trials – HER2/neu+ Breast Cancer – Mayo Clinic

Patient dosing has been completed. Final safety analysis on all the patients treated is complete and shown to be safe. In addition, 19 out of 20 evaluable patients showed robust T-cell immune responses to the antigens in the vaccine composition providing a solid case for advancement to Phase II in 2015. An additional secondary endpoint incorporated into this Phase I Trial will be a two year follow on recording time to disease recurrence in the participating breast cancer patients.

For Phase I(b)/II studies, we plan to add a Class I peptide, licensed from the Mayo Clinic (April 16, 2012), to the four Class II peptides. Management believes that the combination of Class I and Class II HER2/neu antigens, gives us the leading HER2/neu vaccine platform. Therefore a key goal in 2015 is to progress the HER2/neu vaccine towards the above mentioned Phase 1(b)/II Clinical Trial.

Phase I Human Clinical Trials – Folate Alpha Breast and Ovarian Cancer – Mayo Clinic

Folate Receptor Alpha is expressed in over 80% of triple negative breast cancers, and in addition, over 90% of ovarian cancers, for which the only treatment options are surgery and chemotherapy, leaving a very important and urgent clinical need for a new therapeutic. Time to recurrence is relatively short for these types of cancer and survival prognosis is extremely poor after recurrence. In the United States alone, there are approximately 30,000 ovarian cancer patients and 40,000 triple negative breast cancer patients newly diagnosed every year.

A 24 patient Phase I clinical trial has been completed. The vaccine is well tolerated and safe and 20 out of 21 evaluable patients showed positive immune responses providing a strong rationale rational for progressing to phase 2 trials. GMP manufacturing for Phase II trials is underway and final analyses of clinical plans are near completion. TapImmune has now converted the exclusive license option into a full License Agreement.

Preclinical

Polystart

The Company has converted the previously filed U.S. Provisional Patent Application on Polystart into a full Patent Application, and will extend technology constructs as boost strategies for the current clinical programs in breast and ovarian cancer.

Current State of the Company

TapImmune is a clinical-stage immunotherapy company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer. The Company now has multiple clinical trials underway at the Mayo Clinic in Rochester, MN. In addition to our own sponsored clinical trials, a new grant-funded breast and ovarian cancer trial was started by Mayo using the same Folate Alpha Receptor peptides to which we have the exclusive commercial rights. Our development pipeline is extremely strong and provides us the opportunity to continue to expand on collaborations with leading institutions and corporations.

In Q1 and Q2 2015, we strengthened our cash position by raising additional $4.8 M in working capital giving us confidence in our ability to continue developing our products on the path to commercialization. The structure of this financing gives us additional opportunities to raise additional capital through the exercise of short-term and long-term warrants. The strength of our science and development approaches is becoming more widely appreciated, particularly as our clinical program has now generated positive interim data on both clinical programs in Breast and Ovarian Cancer. Also, we are pleased to report that our clinical programs are seeing positive outcomes and we expect to present more detailed findings at major symposia toward the end of the year.

We continue to be focused on our entry into Phase II Triple Negative Cancer Trials including application for Fast Track & Orphan Drug Status as well as planning for Phase II HER2/neu Breast Cancer Trials.

We will also produce new PolyStart constructs, in-house, to facilitate collaborative efforts in our current clinical indications and those where others have already indicated interest in combination therapies.

In addition, we will continue to work on deficit reduction and capital improvement in order to make the required benchmarks for an uplisting to the NASDAQ or another major US exchange. To that end we are also anticipating the result of grant applications submitted early this year.

Together, these fundamental programs and corporate activities have positioned TapImmune extremely well to capitalize on the acceptance of immunotherapy as a leading therapeutic strategy in cancer and infectious disease resulting in exploding valuations in the market.

TapImmune’s Pipeline

The Company has a deep pipeline of potential blockbuster immunotherapies under development. Two of the clinical programs are completing Phase I studies and are expected to advance to Phase II in 2015. These are major inflection and valuation events, and we believe that, in light of these assets, the Company is significantly undervalued. Over the past year a number of highly visible transactions and billion dollar acquisitions have taken place that validate the work we are doing. We believe that, if our treatment successfully reaches commercialization, our treatment is applicable to 50% of the HER2/neu Breast Cancer market, which is a $21 billion annual market. We further believe that if our Ovarian Cancer treatment reaches commercialization, it will be applicable to 95% of the market which Decision Resources, one of the world’s leading research firms for pharmaceuticals and healthcare, believes will triple in the next 10 years to at least $1.5 billion annually.

In addition to the exciting clinical developments, our peptide vaccine technology may be coupled with our recently developed in-house Polystart nucleic acid-based technology designed to make vaccines significantly more effective by producing four times the required peptides for the immune systems to recognize and act on. Our nucleic acid-based systems can also incorporate “TAP” which stands for Transporter associated with Antigen Presentation. Our technologies are also widely applicable to the treatment of emerging viral threats and pandemics. In particular, our highly versatile PolyStart technology

has application in these areas. With respect to validation of our technologies, it is important to note that the majority of our technologies have been published in leading peer-reviewed journals. The timing of such publications is consistent with the filing of patents.

A list of publications on our TAP technology can be found on our website (www.tapimmune.com). Publication of our data on PolyStart will occur after current patent filings have been completed.

A key component to success is having a comprehensive patent strategy that continually updates and extends patent coverage for key products. It is highly unlikely that early patents will extend through ultimate product marketing, so extending patent life is an important strategy for ensuring product protection. TapImmune has four patent estates, details of which can be found on our website: www.tapimmune.com

While the pathway to successful product development takes time, we believe we have put in place significant resources in technical and corporate fundamentals for success. The strength of our product pipeline and access to leading scientists and institutions gives us a unique opportunity to make a major contribution to global health care.

A number of early stage billion dollar pharma acquisitions and recent IPOs have highlighted the growing interest in investment in immunotherapy space. Looking at our current valuation and those of our peers and considering our pipeline of clinical programs with very near-term advancements and the value inflections those represent, we believe this is an excellent opportunity and presents exceptional entry point for those that have not yet become a shareholder.

With respect to the broader market, a major driver and positive influence on our activities has been the emergence and general acceptance of the potential of a new generation of immunotherapies that promise to change the standard of care for cancer. The immunotherapy sector has been greatly stimulated by the approval of Provenge^® for prostate cancer and Yervoy™ for metastatic melanoma, progression of the areas of checkpoint inhibitors and adoptive T-cell therapy and multiple approaches reaching Phase II and Phase III status.

We believe that through our combination of technologies, we are well positioned to be a leading player in this emerging market. It is important to note that many of the late stage immunotherapies currently in development do not represent competition to our programs, but instead offer synergistic opportunities to partner our antigen based immunotherapeutics, Polystart and/or TAP expression systems. Thus, the use of naturally processed T-cell antigens discovered using samples derived from cancer patients plus our Polystart expression technology to improve antigen presentation to T-cells could not only produce an effective cancer vaccines in its own right but also to enhance the efficacy of other immunotherapy approaches such as CAR-T and PD1 inhibitors for example.

Consistent with our corporate development and advancement of clinical trials we have made significant additions to our personnel through appointments of a Consultant Medical Director (Patrick Yeramian, M.D.) and a Consultant Regulatory Director (Dr. Stacy Suber). In addition, we have appointed Dr. John Bonfiglio as a Corporate Strategic Advisor and also to our Board of Directors and have appointed David Laskow-Pooley to our Board of Directors

On the technology and product pipeline side, management believes that the company is fundamentally strong and poised to be a leading company in a highly attractive, multi-billion dollar and expanding market, a position reinforced by our recruitment of top-class managers, advisors and investors who all share our vision.

Results of Operations

In this discussion of the Company’s results of operations and financial condition, amounts, other than per-share amounts, have been rounded to the nearest thousand dollars.

Three Months Ended June 30, 2015 Compared to Three Months Ended June 30, 2014

We recorded a net loss of $60,216,000 or ($1.80) per share during the three months ended June 30, 2015 compared to net income of $753,000 or $0.05 per share for the three months ended June 30, 2014.

Operating costs increased to $1,138,000 during the three months ended June 30, 2015 compared to $511,000 in the prior period. Significant changes in operating expenses are outlined as follows:

•

General and administrative expenses increased to $937,000 during the three months ended June 30, 2015 from $488,000 during the prior period. The increase was primarily due to increased investor relations activities and higher legal fee during the three months ended June 30, 2015 compared to the prior period. The decrease in non-cash consulting fees from the prior year was due to the Company curtailing its business development activities in the current year.

•

Research and development costs during the three months ended June 30, 2015 were $201,000 compared to $23,000 during the prior period. This was due to the Company’s plan to exercise its option to acquire Mayo Clinic technology as part of an agreement entered into in March 2014 and increased in in-house research activity in the current period.

The weighted average number of shares outstanding was 33,525,656 for the three months ended June 30, 2015 compared to 15,523,016 for the prior year.

Six Months Ended June 30, 2015 Compared to Six Months Ended June 30, 2014

We recorded a net loss of $60,917,000 or ($1.99) per share during the six months ended June 30, 2015 compared to $28,954,000 or ($2.57) per share for the six months ended June 30, 2014.

Operating costs increased to $2,166,000 during the six months ended June 30, 2015 compared to $1,733,000 in the prior period. Significant changes in operating expenses are outlined as follows:

•

General and administrative expenses decreased to $1,356,000 during the six months ended June 30, 2015 from $1,688,000 during the prior period. The decrease was primarily due to decrease in non-cash consulting fees paid as stock-based compensation during the six months ended June 30, 2015 compared to the prior period. The decrease in non-cash consulting fees from the prior year was due to the Company curtailing its business development activities in the current year.

•

Research and development costs during the six months ended June 30, 2015 were $811,000 compared to $45,000 during the prior period. This was due to the Company exercising its option to acquire Mayo Clinic technology as part of an agreement entered into in March 2014 and increased in in-house research activity in the current period.

The weighted average number of shares outstanding was 30,584,794 for the three months ended June 30, 2015 compared to 11,250,240 for the prior year.

Liquidity and Capital Resources

The following table sets forth our cash and working capital as of June 30, 2015 and December 31, 2014:


	June 30, 2015			December 31, 2014
Cash reserves	$	3,105,000		$	142,000
Working capital (deficit)	$	(68,102,000	)	$	(1,024,000	)

Subject to the availability of additional financing, we intend to spend approximately $7,500,000 over the next twelve months in carrying out our plan of operations. At June 30, 2015, we had $3,105,000 of cash on hand and a working capital deficit of $68,102,000. In January and March 2015, we raised approximately $2.33 million in private and brokered placements and another $2,500,000 in warrants exercised in May 2015.

Various conditions outside of our control may detract from our ability to raise additional capital needed to execute our plan of operations, including overall market conditions in the international and local economies. We recognize that the United States economy has suffered through a period of uncertainty during which the capital markets have been depressed, and that there is no certainty that these levels will stabilize or reverse despite the optics of an improving economy. Any of these factors could have a material impact upon our ability to raise financing and, as a result, upon our short-term or long-term liquidity.

Net Cash Used in Operating Activities

Net cash used in operating activities during the six months ended June 30, 2015 was $1,828,000 compared to $611,000 during the prior period. We had no revenues during the current or prior periods. Operating expenditures, excluding non-cash interest and stock-based charges during the current period primarily consisted of consulting and management fees, office and general expenditures, and professional fees.

Net Cash Provided by Financing Activities

Net cash provided by financing activities during the six months ended June 30, 2015 was $4,791,000 compared to $584,000 during the prior period. Current period financing consisted of proceeds from private placements and warrant exercises while prior period financing relates to proceeds from convertible notes.

As of June 30, 2015, we anticipate that we will need significant financing to enable us to meet our anticipated expenditures for the next twelve months, which are expected to be in the range of $7,500,000 assuming a single Phase 2 clinical trial.

Going Concern

We have no sources of revenue to provide incoming cash flows to sustain our future operations. As outlined above, our ability to pursue our planned business activities is dependent upon our successful efforts to raise additional financing. These factors raise substantial doubt regarding our ability to continue as a going concern. Our condensed consolidated financial statements have been prepared on a going concern basis, which implies that we will continue to realize our assets and discharge our liabilities in the normal course of business. As at June 30, 2015, we had accumulated losses of $160,359,000 since inception. Our financial statements do not include any adjustments to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should we be unable to continue as a going concern.

Off-Balance Sheet Arrangements

We have not entered into any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes of financial condition, revenues, expenses, results of operations, liquidity, capital expenditures or capital resources that is material to investors.

Item 3.

Quantitative and Qualitative Disclosures About Market Risk

We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information required under this item.

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

Our management, with the participation of our Principal Executive Officer and Principal Financial Officer, has evaluated the effectiveness of our disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, as of the end of the period covered by this report. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed in the reports we file or submit under the Exchange Act is accumulated and communicated to management, including our Principal Executive Officer and Principal Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. Based on such evaluation, our Chief Executive Officer and Chief Financial Officer has concluded that, as of the end of the period covered by this report, our disclosure controls and procedures are not effective in recording, processing, summarizing and reporting, on a timely basis, information required to be disclosed by us in the reports that we file or submit under the Exchange Act.

It should be noted that any system of controls is based in part upon certain assumptions designed to obtain reasonable (and not absolute) assurance as to its effectiveness, and there can be no assurance that any design will succeed in achieving its stated goals.

Changes in Internal Control Over Financial Reporting

There have been no changes in our internal control over financial reporting during the six months ended June 30, 2015 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II – OTHER INFORMATION

Item 1.

Legal Proceedings

Consultant Litigation

In May 2012, we issued what is now equal to 112,000 shares of our common stock to two consultants. We contested the validity of the issuances of this common stock based on our belief that the consultants did not perform the services agreed to under their respective consulting agreements. While we initially were able to delay the sale of the contested shares, we were not successful in clawing back the contested shares. A claim for perceived damages from Michael Gardner (one of the consultants) suffered as a result of our contesting the issuance under the consulting agreements has been filed in the Supreme Court of New York. He has based his claim for damages on the difference between market price at the time we were able to delay the sale of his shares and the market price at the time of the sale of all of his shares. As the result of a judicial decision in New York he received a bond payment of ($100,000) that the Company had used to secure a temporary restraining order against the issuance of stock to him.

On July 18, 2014, the International Center for Dispute Resolution International Arbitration Tribunal issued a Final Award in the matter of TapImmune Inc. vs. Michael Gardner awarding TapImmune $196,204 plus post-award interest at a rate of 9% per year. This award stemmed from the dispute discussed above with Mr. Gardner regarding the May 2012 consulting agreement. The arbitrator found that we were fraudulently induced into entering said agreement through “1) misrepresentations as to what he would or could do for the Company, including raising funds, and 2) omissions about his reputation and ability to obtain or assist in obtaining financing for TapImmune” among other reasons. We are attempting to collect the award from Mr. Gardner.

Vendor Litigation

One of our suppliers, Fischer Scientific was awarded a judgment against us for $51,000 which is equal to the amount owed to them. We intend on settling that matter in the third quarter of 2015.

Item 1A.

Risk Factors

Not required.

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

We have not issued any unregistered equity securities that we have not previously reported in a current or periodic report filed with the US Securities and Exchange Commission.

Item 3.

Defaults Upon Senior Securities

None.

Item 4.

Mine Safety Disclosure

Not Applicable.

Item 5.

Other Information

None.

Item 6.

Exhibits

The following exhibits are included with this Quarterly Report on Form 10-Q:


Exhibit Number		Description of Exhibit

31.1		Certification of Principal Executive Officer and Acting Principal Accounting Officer Pursuant to Rule 13a-14(a) or 15d-14(a) of the Securities Exchange Act of 1933, as amended.

32.1		Certification of Principal Executive Officer and Acting Principal Accounting Officer pursuant to 18 U.S.C. 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

Exhibit 101

101.INS - XBRL Instance Document

101.SCH - XBRL Taxonomy Extension Schema Document

101.CAL - XBRL Taxonomy Extension Calculation Linkbase Document

101.DEF - XBRL Taxonomy Extension Definition Linkbase Document

101.LAB - XBRL Taxonomy Extension Label Linkbase Document

101.PRE - XBRL Taxonomy Extension Presentation Linkbase Document

SIGNATURES

In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

TAPIMMUNE INC.


		/s/ Glynn Wilson
		Glynn Wilson
		Chairman, Chief Executive Officer, Principal Executive Officer and Chief Financial Officer
		Date: April 14, 2016

EX-31.1 2 d179913dex311.htm CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER Certification of Principal Executive Officer

Exhibit 31.1

CERTIFICATION

I, Glynn Wilson, certify that:

(1)	I have reviewed this Report on Form 10-Q for the quarterly period ended June 30, 2015 of TapImmune Inc.;

(2)	Based on my knowledge, this Report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this Report;

(3)	Based on my knowledge, the financial statements, and other financial information included in this Report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this Report;

(4)

The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)

Designed such internal control over financial reporting or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurances regarding the reliability of financial reporting in the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)

Disclosed in this Report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

(5)	The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of the internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: April 14, 2016


/s/ Glynn Wilson
By:		Glynn Wilson
Title:		Chairman, Chief Executive Officer, Principal Executive Officer and Acting Principal Accounting Officer

EX-32.1 3 d179913dex321.htm CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER Certification of Principal Executive Officer

Exhibit 32.1

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER

PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

The undersigned, Glynn Wilson, the Principal Executive Officer and Acting Principal Accounting Officer of TapImmune Inc. (the “Company”) hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to his or her knowledge, the Report on Form 10-Q of TapImmune Inc., for the quarterly period ended June 30, 2015 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and that the information contained in the Report on Form 10-Q fairly presents in all material respects the financial condition and results of operations of TapImmune Inc.

Date: April 14, 2016


		/s/ Glynn Wilson
		Glynn Wilson
		Chairman, Chief Executive Officer, Principal Executive Officer and Acting Principal Accounting Officer

EX-101.INS 4 tpiv-20150630.xml XBRL INSTANCE DOCUMENT 1

0.75

1.00

0.40

1.50

1.25

366000

118450

50000

46140771

1.00

0.40

1.50

0.50

0.20

0.10

10000000

20647

125000

84382892

500000000

0.54

38038921

0.001

38038921

0.001

10000000

69962000

-68102079

92218937

69962000

492365

69962000

23000

-160359055

3247910

38039

52942

71349989

842682

3105320

3247910

3105000

142590

69962000

500000000

32638811

0.001

10000000

32638811

0.001

11673347

-9813426

95885631

492365

-105737096

3247910

38039

52942

13061336

842682

3105320

3247910

142590

0.001

1500000

0.001

1250000

58288653

-58288653

-3666694

-54621959

58288653

38038921

38039

-160359055

1500000

0.001

465430

2.62

1250000

0.001

92218937

317593

0.16

0.50

12320000

6133000

48589

65430

18.00

2659417

500000000

1.83

20318815

0.001

20318815

0.001

10000000

9415

-1023636

85265776

9000

492365

9000

-86309731

224448

20319

52942

1248084

693362

52942

141944

224448

82504

9000

141944

20318816

20319

-86309731

1500000

0.001

65430

18.00

1250000

0.001

85265776

278

18.00

P5Y

0.0152

P5Y

0.00

1.546

250000

P9M 33000 2015-05-31 0.145 0.133

P5Y

0.0170

P5Y

0.00

1.552

150000

P24M 29000 0.20 0.194

33333

-2.57

306000

-611442

11250240

-28953750

-28953957

-492296

14537

-26743197

-207

-1732794

708000

3797000

-27942

799075

492296

45000

583500

583000

210000

500

322277

1687794

26743197

476000

-14537

42000

683000

369000

185000 49000 65000 7000

1.59

0.0108

5.84

0.00

P3Y6M29D

0.02 Q2

<div> NOTE 1:     NATURE OF OPERATIONS   TapImmune Inc. (the “Company”), a Nevada corporation incorporated in 1992, is a biotechnology Company focusing on immunotherapy specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of oncology and infectious disease. Unlike other vaccine technologies that narrowly address the initiation of an immune response, TapImmune’s approach broadly stimulates the cellular immune system by enhancing the function of killer T-cells and T-helper cells and by restoring antigen presentation in tumor cells allowing their recognition and killing by the immune system. </div>

7500

P4Y1M24D

2015 true

P3Y3M4D

<div> NOTE 2:     BASIS OF PRESENTATION   The accompanying unaudited condensed financial statements have been prepared in accordance with the accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and pursuant to the instructions to Form 10-Q and Article 8 of Regulation S-X of the Securities and Exchange Commission (“SEC”) and on the same basis as the Company prepares its annual audited consolidated financial statements. The condensed consolidated balance sheet as of June 30, 2015, condensed consolidated statements of interim financials include all adjustments, consisting only of normal recurring adjustments, which the Company considers necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented. The results for the statement of operations are not necessarily indicative of results to be expected for the year ending December 31, 2015 or for any future interim period. The condensed balance sheet at December 31, 2014 has been derived from audited financial statements; however, it does not include all of the information and notes required by U.S. GAAP for complete financial statements. The accompanying condensed financial statements should be read in conjunction with the consolidated financial statements for the year ended December 31, 2014, and notes thereto included in the Company’s annual report on Form 10-K. </div>

<div> A summary of the Company’s share purchase warrants as of June 30, 2015 and changes during the period is presented below:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"> <tr> <td width="57%"></td> <td valign="bottom" width="9%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="9%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="9%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Number of Warrants</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Weighted Average Exercise Price</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Weighted Average Remaining Life</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Balance, December 31, 2014 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,659,417</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1.83</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4.15</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Issued </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">86,730,975</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0.54</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3.25</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Exercised </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(5,000,000</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0.50</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Extinguished or expired </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(7,500</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">50.00</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Balance, June 30, 2015 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">84,382,892</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.54</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3.26</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

-1.99

84855000

10-Q/A 0001094038

<div> The following securities were not included in the diluted net loss per share calculation because their effect was anti-dilutive as of the periods presented:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="77%"></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">June 30,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2015</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2014</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Common stock options </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">465,000</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">65,000</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Common stock warrants - equity treatment </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,556,000</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">185,000</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Common stock warrants - liability treatment </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">81,834,000</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">49,000</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Convertible notes </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">7,000</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Potentially dilutive securities </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">84,855,000</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">306,000</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

0.50

Smaller Reporting Company

50.00

P3Y3M

<div> The following table summarizes the effect of the restatement on the consolidated statement of operations for the three and six months ended June 30, 2015:   TAPIMMUNE INC. CONDENSED CONSOLIDATED BALANCE SHEETS   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"> <tr> <td width="68%"></td> <td valign="bottom" width="1%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="1%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="1%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" align="center"> June 30, 2015 (Unaudited)</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">As Previously Reported</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" nowrap="nowrap" align="center">Adjustments</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">As Restated</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top" align="center">ASSETS</td> <td valign="bottom">  </td> <td valign="top"></td> <td valign="top"></td> <td valign="top"></td> <td valign="bottom"> </td> <td valign="top"></td> <td valign="top"></td> <td valign="top"></td> <td valign="bottom"> </td> <td valign="top"></td> <td valign="top"></td> <td valign="top"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Current Assets </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Cash </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,105,320</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,105,320</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Prepaid expenses and deposits </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">142,590</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">142,590</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"></td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,247,910</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,247,910</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top" align="center">LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT)</td> <td valign="bottom">  </td> <td valign="top"></td> <td valign="top"></td> <td valign="top"></td> <td valign="bottom"> </td> <td valign="top"></td> <td valign="top"></td> <td valign="top"></td> <td valign="bottom"> </td> <td valign="top"></td> <td valign="top"></td> <td valign="top"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Current Liabilities </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Accounts payable and accrued liabilities </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">842,682</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">842,682</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Research agreement obligations </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">492,365</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">492,365</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Derivative liability – warrants </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">11,673,347</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">58,288,653</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">69,962,000</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Promissory notes </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">52,942</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">52,942</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"></td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">13,061,336</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">58,288,653</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">71,349,989</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> COMMITMENTS AND CONTINGENCIES </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Stockholders’ Equity (Deficit) </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Convertible preferred stock, $0.001 par value — 10,000,000 shares authorized: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Series A, $0.001 par value, 1,250,000 shares designated, -0- shares issued and outstanding as of March 31, 2015 and December 31, 2014 </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Series B, $0.001 par value, 1,500,000 shares designated, -0- shares issued and outstanding as of March 31, 2015 and December 31, 2014 </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Common stock, $0.001 par value, 500,000,000 shares authorized 32,638,811 shares issued and outstanding (2014 – 20,318,815) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">38,039</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">38,039</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Additional paid-in capital </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">95,885,631</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(3,666,694</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">92,218,937</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Accumulated deficit </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(105,737,096</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(54,621,959</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(160,359,055</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"></td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(9,813,426</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(58,288,653</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(68,102,079</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"></td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,247,910</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,247,910</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table>   TAPIMMUNE INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (UNAUDITED)   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"> <tr> <td width="70%"></td> <td valign="bottom" width="1%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="1%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="1%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="10" align="center">Three Months Ended June 30, 2015</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" nowrap="nowrap" align="center">As Previously Reported</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Adjustments</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">As Restated</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Operating expenses: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> General and administrative </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">936,887</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">936,887</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Research and development </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">201,157</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">201,157</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Loss from Operations </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(1,138,044</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(1,138,044</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Other Income (Expense) </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Changes in fair value of derivative liabilities </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(9,052,372</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(50,026,653</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(59,079,025</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Foreign exchange </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">775</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">775</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Inducement expense </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(8,256,000</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">8,256,000</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right">-</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Net Loss for the Period </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(18,445,641</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(41,770,653</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(60,216,294</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Other comprehensive income </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Foreign exchange translation adjustment </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> TOTAL COMPREHENSIVE LOSS </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(18,445,641</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(41,770,653</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(60,216,294</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Basic and Diluted Net Loss per Share </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(0.55</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(1.25</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(1.80</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Weighted Average Number of Common Shares Outstanding </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">33,525,656</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">33,525,656</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">33,525,656</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table>   TAPIMMUNE INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (UNAUDITED)   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"> <tr> <td width="70%"></td> <td valign="bottom" width="1%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="1%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="1%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="10" align="center">Six Months Ended June 30, 2015</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">As Previously Reported</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Adjustments</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">As Restated</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Operating expenses: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> General and administrative </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,355,673</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,355,673</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Research and development </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">810,535</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">810,535</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Loss from Operations </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(2,166,208</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(2,166,208</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Other Income (Expense) </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Changes in fair value of derivative liabilities </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(9,005,932</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(49,745,653</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(58,751,585</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Foreign exchange </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">775</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">775</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Inducement expense </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(8,256,000</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">8,256,000</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Net Loss for the Period </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(19,427,365</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(41,489,653</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(60,917,018</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Other comprehensive income </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Foreign exchange translation adjustment </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> TOTAL COMPREHENSIVE LOSS </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(19,427,365</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(41,489,653</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(60,917,018</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Basic and Diluted Net Loss per Share </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(0.64</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(1.36</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(1.99</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Weighted Average Number of Common Shares Outstanding </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">30,584,794</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">30,584,794</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">30,584,794</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table>     TAPIMMUNE INC. CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"> <tr> <td width="70%"></td> <td valign="bottom" width="1%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="1%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="1%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="10" align="center"> Six Months Ended June 30, 2015 </td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">As Previously Reported</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Adjustments</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">As Restated</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> CASH FLOWS FROM OPERATING ACTIVITIES </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Net loss </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(19,427,365</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(41,489,653</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(60,917,018</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Adjustments to reconcile net loss to net cash from operating activities: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Changes in fair value of derivative liabilities </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">9,005,932</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">49,745,653</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">58,751,585</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Inducement expense </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">8,256,000</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(8,256,000</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Non-cash interest and finance charges </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Stock based compensation </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">248,561</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">248,561</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Changes in operating assets and liabilities: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Prepaid expenses </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(60,086</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(60,086</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Accounts payable and accrued liabilities </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">149,320</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">149,320</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> NET CASH USED IN OPERATING ACTIVITIES </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(1,827,638</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(1,827,638</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> CASH FLOWS FROM FINANCING ACTIVITIES </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Issuance of shares, net of issuance costs of $173,000 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,291,014</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">35,000</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,326,014</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Proceeds from exercise of warrants </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,500,000</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,500,000</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Finders’ fee on exercise of warrants </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(35,000</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(35,000</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> NET CASH PROVIDED BY FINANCING ACTIVITIES </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4,791,014</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4,791,014</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> INCREASE IN CASH </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,963,376</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,963,376</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> CASH, BEGINNING OF PERIOD </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">141,944</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">141,944</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> CASH, END OF PERIOD </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,105,320</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,105,320</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> </tr> </table> </div>

0.54

--12-31

-1827638

TAPIMMUNE INC

<div> NOTE 1A:     AMENDMENT TO PREVIOUSLY REPORTED QUARTERLY FINANCIAL STATEMENTS The Company’s previously issued consolidated financial statements for the three and six months ended June 30, 2015 have been restated related to the Company’s accounting for share purchase warrants issued as part of two registered transactions in January 2015 and March 2015. Previously, the fair value of certain series of the share purchase warrants (Series B, B-1, C, C-1, D, D-1, E and E-1) was concluded by management to be classified within stockholders’ equity (deficit). The Company has reviewed the terms and conditions underlying its outstanding share purchase warrants and determined that the accounting for certain series of the warrants should be amended. Management reviewed ASC 480-10 Distinguishing liabilities from equity and ASC 815-40 Contracts in an Entity’s Own Equity to arrive at this conclusion that the common stock purchase warrants should be classified as a liability, not equity, as the Company cannot control their ability to gross settle the financial instruments with registered securities. The Company has restated its accounting for certain series of the share purchase warrants and recorded the fair value of the warrants under “Derivative liability- warrants” on its balance sheet with changes in the fair value over time reflected in the statements of operations as “Changes in fair value of derivative liabilities”. As a result of these adjustments, net loss for the three and six months ended June 30, 2015 was increased by $41,771,000 and $41,490,000, respectively. The Company has reported an amended net loss of $60,216,000 versus the previously reported net loss of approximately $18,446,000 for the three months ended June 30, 2015 and an amended net loss of $60,917,000 versus the previously reported net loss of approximately $19,427,000 for the six months ended June 30, 2015. The following table summarizes the effect of the restatement on the consolidated statement of operations for the three and six months ended June 30, 2015:   TAPIMMUNE INC. CONDENSED CONSOLIDATED BALANCE SHEETS   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"> <tr> <td width="68%"></td> <td valign="bottom" width="1%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="1%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="1%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" align="center"> June 30, 2015 (Unaudited)</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">As Previously Reported</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" nowrap="nowrap" align="center">Adjustments</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">As Restated</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top" align="center">ASSETS</td> <td valign="bottom">  </td> <td valign="top"></td> <td valign="top"></td> <td valign="top"></td> <td valign="bottom"> </td> <td valign="top"></td> <td valign="top"></td> <td valign="top"></td> <td valign="bottom"> </td> <td valign="top"></td> <td valign="top"></td> <td valign="top"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Current Assets </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Cash </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,105,320</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,105,320</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Prepaid expenses and deposits </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">142,590</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">142,590</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"></td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,247,910</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,247,910</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top" align="center">LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT)</td> <td valign="bottom">  </td> <td valign="top"></td> <td valign="top"></td> <td valign="top"></td> <td valign="bottom"> </td> <td valign="top"></td> <td valign="top"></td> <td valign="top"></td> <td valign="bottom"> </td> <td valign="top"></td> <td valign="top"></td> <td valign="top"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Current Liabilities </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Accounts payable and accrued liabilities </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">842,682</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">842,682</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Research agreement obligations </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">492,365</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">492,365</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Derivative liability – warrants </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">11,673,347</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">58,288,653</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">69,962,000</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Promissory notes </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">52,942</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">52,942</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"></td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">13,061,336</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">58,288,653</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">71,349,989</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> COMMITMENTS AND CONTINGENCIES </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Stockholders’ Equity (Deficit) </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Convertible preferred stock, $0.001 par value — 10,000,000 shares authorized: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Series A, $0.001 par value, 1,250,000 shares designated, -0- shares issued and outstanding as of March 31, 2015 and December 31, 2014 </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Series B, $0.001 par value, 1,500,000 shares designated, -0- shares issued and outstanding as of March 31, 2015 and December 31, 2014 </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Common stock, $0.001 par value, 500,000,000 shares authorized 32,638,811 shares issued and outstanding (2014 – 20,318,815) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">38,039</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">38,039</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Additional paid-in capital </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">95,885,631</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(3,666,694</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">92,218,937</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Accumulated deficit </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(105,737,096</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(54,621,959</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(160,359,055</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"></td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(9,813,426</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(58,288,653</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(68,102,079</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"></td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,247,910</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,247,910</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table>   TAPIMMUNE INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (UNAUDITED)   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"> <tr> <td width="70%"></td> <td valign="bottom" width="1%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="1%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="1%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="10" align="center">Three Months Ended June 30, 2015</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" nowrap="nowrap" align="center">As Previously Reported</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Adjustments</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">As Restated</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Operating expenses: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> General and administrative </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">936,887</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">936,887</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Research and development </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">201,157</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">201,157</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Loss from Operations </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(1,138,044</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(1,138,044</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Other Income (Expense) </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Changes in fair value of derivative liabilities </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(9,052,372</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(50,026,653</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(59,079,025</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Foreign exchange </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">775</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">775</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Inducement expense </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(8,256,000</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">8,256,000</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right">-</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Net Loss for the Period </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(18,445,641</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(41,770,653</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(60,216,294</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Other comprehensive income </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Foreign exchange translation adjustment </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> TOTAL COMPREHENSIVE LOSS </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(18,445,641</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(41,770,653</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(60,216,294</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Basic and Diluted Net Loss per Share </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(0.55</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(1.25</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(1.80</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Weighted Average Number of Common Shares Outstanding </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">33,525,656</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">33,525,656</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">33,525,656</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table>   TAPIMMUNE INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (UNAUDITED)   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"> <tr> <td width="70%"></td> <td valign="bottom" width="1%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="1%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="1%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="10" align="center">Six Months Ended June 30, 2015</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">As Previously Reported</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Adjustments</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">As Restated</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Operating expenses: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> General and administrative </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,355,673</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,355,673</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Research and development </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">810,535</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">810,535</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Loss from Operations </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(2,166,208</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(2,166,208</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Other Income (Expense) </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Changes in fair value of derivative liabilities </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(9,005,932</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(49,745,653</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(58,751,585</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Foreign exchange </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">775</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">775</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Inducement expense </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(8,256,000</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">8,256,000</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Net Loss for the Period </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(19,427,365</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(41,489,653</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(60,917,018</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Other comprehensive income </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Foreign exchange translation adjustment </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> TOTAL COMPREHENSIVE LOSS </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(19,427,365</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(41,489,653</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(60,917,018</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Basic and Diluted Net Loss per Share </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(0.64</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(1.36</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(1.99</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Weighted Average Number of Common Shares Outstanding </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">30,584,794</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">30,584,794</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">30,584,794</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table>     TAPIMMUNE INC. CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"> <tr> <td width="70%"></td> <td valign="bottom" width="1%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="1%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="1%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="10" align="center"> Six Months Ended June 30, 2015 </td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">As Previously Reported</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Adjustments</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">As Restated</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> CASH FLOWS FROM OPERATING ACTIVITIES </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Net loss </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(19,427,365</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(41,489,653</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(60,917,018</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Adjustments to reconcile net loss to net cash from operating activities: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Changes in fair value of derivative liabilities </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">9,005,932</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">49,745,653</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">58,751,585</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Inducement expense </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">8,256,000</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(8,256,000</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Non-cash interest and finance charges </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Stock based compensation </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">248,561</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">248,561</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Changes in operating assets and liabilities: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Prepaid expenses </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(60,086</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(60,086</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Accounts payable and accrued liabilities </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">149,320</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">149,320</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> NET CASH USED IN OPERATING ACTIVITIES </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(1,827,638</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(1,827,638</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> CASH FLOWS FROM FINANCING ACTIVITIES </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Issuance of shares, net of issuance costs of $173,000 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,291,014</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">35,000</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,326,014</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Proceeds from exercise of warrants </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,500,000</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,500,000</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Finders’ fee on exercise of warrants </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(35,000</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(35,000</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> NET CASH PROVIDED BY FINANCING ACTIVITIES </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4,791,014</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4,791,014</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> INCREASE IN CASH </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,963,376</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,963,376</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> CASH, BEGINNING OF PERIOD </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">141,944</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">141,944</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> CASH, END OF PERIOD </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,105,320</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,105,320</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> </tr> </table> </div>

<div> A summary of the status of the Company’s unvested options as of June 30, 2015 is presented below:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="72%"></td> <td valign="bottom" width="8%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="8%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Number of Shares</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Weighted Average Grant-Date Fair Value</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Unvested, December 31, 2014 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">278</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">18.00</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Granted </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">400,000</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0.16</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Vested </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(82,685</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0.21</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Cancelled </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Unvested, June 30, 2015 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">317,593</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.16</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

This Amendment No. 1 on Form 10-Q/A (the “Form 10-Q/A”) to the Quarterly Report on Form 10-Q for TapImmune Inc. (“we” or the “Company”) for the quarterly period ended June 30, 2015, initially filed with the Securities and Exchange Commission (the “SEC”) on August 14, 2015 (the “Original Filing”), is being filed to restate accounting for the share purchase warrants and recording the fair value of the warrants under “Derivative liability- warrants” on its balance sheet with changes in the fair value over time reflected in the statements of operations as “Changes in fair value of derivative liabilities”. The restatement of the Company’s accounting for the share purchase warrants arose after a review by the Company’s management. As a result, the Board of Directors of the Company has determined that the Company’s previously issued consolidated unaudited financial statements and reports filed with the SEC for the quarterly period ended June 30, 2015 should not be relied upon. For a more detailed description of the effects of the restatement, see further discussion in Note 1A, “Amendment to Previously Reported Quarterly Financial Statements” to our consolidated financial statements included in Part I, Item 1 of this report. For the convenience of the reader, this Form 10-Q/A sets forth the Original Filings in their entirety. However, this Form 10-Q/A only amends and restates Items 1 and 2 of Part I of the Original Filing, in each case, solely as a result of, and to reflect, the restatement, and no other information in the Original Filing is amended hereby. The foregoing items have not been updated to reflect other events occurring after the Original Filings or to modify or update those disclosures affected by subsequent events. In addition, pursuant to the rules of the SEC, Item 6 of Part II of the Original Filings has been amended to contain currently dated certifications from the Company’s Chief Executive Officer and Chief Financial Officer, as required by Sections 302 and 906 of the Sarbanes-Oxley Act of 2002, and are attached as Exhibits 31.1 and 32.1 to this report. We have also updated our financial statements formatted in Extensible Business Reporting Language (XBRL) in Exhibits 101. Except for the foregoing amended information, this Form 10-Q/A continues to speak as of the dates of the Original Filings, and the Company has not updated the disclosures contained herein to reflect events that occurred at a later date. Other events occurring after the filings of the Original Filings or other disclosures necessary to reflect subsequent events will be addressed in any reports filed with the SEC subsequent to the date of this filing.

86730975

<div> Prior Period Reclassifications The expense categories of the comparable prior period have been reclassified for comparability with the June 30, 2015 presentation. These reclassifications had no effect on previously reported net loss. </div>

2015-06-30

5000000

<div> NOTE 4:     SIGNIFICANT ACCOUNTING POLICIES   There have been no material changes in the Company’s significant accounting policies to those previously disclosed in the Company’s annual report on Form 10-K, which was filed with the SEC on April 15, 2015. Prior Period Reclassifications The expense categories of the comparable prior period have been reclassified for comparability with the June 30, 2015 presentation. These reclassifications had no effect on previously reported net loss. </div>

TPIV

30584794

<div> NOTE 9:     SUBSEQUENT EVENTS     <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td width="4%"> </td> <td valign="top" width="4%" align="left">1.</td> <td valign="top" align="left">Between July 16, 2015 and August 13, 2015, holders of the Series B warrant exercised 7,890,000 of the Series B Warrants registered under our recent registration statements on Form S-1 resulting in proceeds of $1,578,000 to the Company.</td> </tr> </table>   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td width="4%"> </td> <td valign="top" width="4%" align="left">2.</td> <td valign="top" align="left">On July 21, 2015, the Company entered into a License and Assignment Agreement with the Mayo Foundation for Medical Education and Research (“Mayo Foundation”) pursuant to which we acquired certain intellectual property rights from the Mayo Foundation for the development and commercialization of certain products, methods and processes property relating to a folate receptor alpha immunotherapeutic vaccine comprised of a set of unique peptide epitopes targeting breast, lung and ovarian cancer. The Mayo Foundation granted us a license (with a right to sublicense) on a worldwide basis to make, sell and use products for therapeutic use against breast, ovarian, lung and other cancers that express folate receptor alpha. This license is an exclusive license for products that are based on the intellectual property and non-exclusive for products that are based on Mayo Foundation know–how and materials. The intellectual property that is being licensed includes (i) U.S. patent application numbers 12/303,054 and 13/202,236, (ii) U.S. patent number 8,486,412 and 8,858,952 and provisionals, (iii) divisionals including 13/917,410 and (iv) continuations including 14/484,057.</td> </tr> </table>   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td width="4%"> </td> <td valign="top" width="4%" align="left">3.</td> <td valign="top" align="left">On July 31, 2015, the Company issued to its counsel 118,450 shares of common stock for legal services rendered through January 21, 2015. Such shares were authorized to be issued on January 23, 2015, but were not issued until July 31, 2015.</td> </tr> </table>   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td width="4%"> </td> <td valign="top" width="4%" align="left">4.</td> <td valign="top" align="left">On August 10, 2015, the Company issued 50,000 shares of common stock as full settlement of a dispute with a marketing consultant that provided services to the Company in 2014 and 2015.</td> </tr> </table> </div>

-60917018

-58751585

-60917018

2500000

35000

60086

248561

-2166208

-9313000

58752000

2963376

248561

2500000

810535

4791014

2326014

149320

173000

1355673

58751585

231000

66000

-775

P2Y5M16D 0.015 <div> NOTE 8:     CAPITAL STOCK, AS RESTATED   2015 Share Transactions Private placements In January, 2015, the Company entered into a Securities Purchase Agreement with certain investors for the sale of 7,320,000 units at a purchase price of $0.20 per unit, for a total purchase price of approximately $1,250,000, net of finders’ fee and offering expenses of approximately $214,000. Each unit consisting of (i) one share of the Company’s Common Stock, (ii) one Series A warrant to purchase one share of common stock, (iii) one Series B warrant to purchase one share of common stock (iv) one Series C warrant to purchase one share of common stock, (v) one Series D warrant to purchase one share of common stock, and (vi) one Series E warrant to purchase one share of common stock (the Series A, B, C, D and E warrants are hereby collectively referred to as the “January 2015 Warrants”). Series A warrants are exercisable at $1.50 per share, with a five year term. Series B warrants are exercisable at $0.40 per share, with a six month term. Series C warrants are exercisable at $1.00 per share, with a five year term. Series D warrants are exercisable at $0.75 per share only if and to the extent that the Series B warrants are exercised, with a five year term from the date that the Series B warrants are exercised. Series E warrants are exercisable at $1.25 per share, only if and to the extent that the Series C warrants are exercised, with a five year term from the date that the Series C warrants are exercised. Pursuant to a placement agent agreement, the Company agreed to issue warrants to purchase 366,000 common shares with substantially the same terms as the January 2015 Warrants. In March, 2015, the Company entered into a Securities Purchase Agreement with certain accredited investors for the sale of 5,000,000 units at a purchase price of $0.20 per unit, for a total purchase price of approximately $950,000, net of finders’ fee and offering expenses of approximately $50,000. Each unit consisting of (i) one share of the Company’s Common Stock, (ii) one Series A warrant to purchase one share of common stock, (iii) one Series B warrant to purchase one share of common stock (iv) one Series C warrant to purchase one share of common stock, (v) one Series D warrant to purchase one share of common stock, and (vi) one Series E warrant to purchase one share of common stock (the Series A, B, C, D and E warrants are hereby collectively referred to as the “March 2015 Warrants”). The March 2015 Warrants have substantially the same terms as the January 2015 Warrants. Pursuant to a placement agent agreement, the Company agreed to issue warrants to purchase 125,000 common shares with substantially the same terms as the March 2015 Warrants. Initial Fair Value of Warrants Issued Pursuant to ASC 480-10 Distinguishing liabilities from equity and ASC 815-40 Contracts in an Entity’s Own Equity, the common stock purchase warrants are classified as a derivative liability as the Company cannot control their ability to gross settle the financial instruments with registered securities. The fair value of the warrants issued pursuant to the January and March 2015 stock purchase agreement was $9,313,000. The weighted average inputs include contractual term of 5.0 years, volatility of 158% and risk free rate of 1.2%.   May 2015 Restructuring agreement In May 2015, the Company entered into a restructuring agreement with the investors of the January 2015 and March 2015 private placements, where:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td width="5%"> </td> <td valign="top" width="2%" align="left">•</td> <td valign="top" width="1%"> </td> <td valign="top" align="left">The exercise price of the Series A warrants was changed from $1.50 per warrant to $0.10 per warrant,</td> </tr> </table>   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td width="5%"> </td> <td valign="top" width="2%" align="left">•</td> <td valign="top" width="1%"> </td> <td valign="top" align="left">The exercise price of Series B warrants was changed from $0.40 per warrant to $0.20 per warrant,</td> </tr> </table>   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td width="5%"> </td> <td valign="top" width="2%" align="left">•</td> <td valign="top" width="1%"> </td> <td valign="top" align="left">Each warrant of Series B existing prior to the restructuring agreement was replaced with two warrants of such series,</td> </tr> </table>   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td width="5%"> </td> <td valign="top" width="2%" align="left">•</td> <td valign="top" width="1%"> </td> <td valign="top" align="left">The exercise price of the Series C warrants was changed from $1.00 per warrant to $0.50 per warrant, and</td> </tr> </table>   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td width="5%"> </td> <td valign="top" width="2%" align="left">•</td> <td valign="top" width="1%"> </td> <td valign="top" align="left">Each warrant of Series C existing prior to the restructuring agreement was replaced with two warrants of such series.</td> </tr> </table> As a result of the restructuring agreement, the Company issued an additional 12,320,000 Series B warrants and 12,320,000 Series C Warrants. The fair value of the warrants issued pursuant to the May 2015 restructuring agreement was $6,133,000. The weighted average inputs include contractual term of 2.46 years, volatility of 141% and risk free rate of 1.5%. Share Purchase Warrants During the six months ended June 30, 2015, a warrant holder exercised 5,000,000 of Series C warrants at $0.50 per warrant for a total of $2,500,000. A summary of the Company’s share purchase warrants as of June 30, 2015 and changes during the period is presented below:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"> <tr> <td width="57%"></td> <td valign="bottom" width="9%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="9%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="9%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Number of Warrants</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Weighted Average Exercise Price</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Weighted Average Remaining Life</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Balance, December 31, 2014 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,659,417</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1.83</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4.15</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Issued </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">86,730,975</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0.54</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3.25</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Exercised </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(5,000,000</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0.50</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Extinguished or expired </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(7,500</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">50.00</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Balance, June 30, 2015 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">84,382,892</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.54</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3.26</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> Stock Compensation Plan On October 14, 2009, the Company adopted the 2009 Stock Incentive Plan (the “2009 Plan”) which supersedes and replaces the 2007 Stock Plan. The 2009 Plan allows for the issuance of up to 10,000,000 common shares. Options granted under the Plan shall be at prices and for terms as determined by the Board of Directors. On February 10, 2015, the Company granted 250,000 stock options at an exercise price of $0.145 per share, of which, 33,333 vested on May 31, 2015 and the remaining vesting monthly over a nine month period, to a consultant of the Company. The term of the options is five years. The fair value of the new grant was estimated at $33,000, or $0.133 per option, using the Black-Scholes Option Pricing Model with a risk free interest rate of 1.52%, a dividend yield of 0%, volatility of 154.6%, and life of 5 years. The expensed portion of the value of these options during the six months ended June 30, 2015 was $7,635, which was recorded as stock based consultant compensation. On March 6, 2015, the Company granted 150,000 stock options at an exercise price of $0.20 per share, vesting monthly over a twenty four month period, to a director of the Company. The term of the options is five years. The fair value of the new grant was estimated at $29,000, or $0.194 per option, using the Black-Scholes Option Pricing Model with a risk free interest rate of 1.70%, a dividend yield of 0%, volatility of 155.2%, and life of 5 years. The expensed portion of the value of these options during the six months ended June 30, 2015 was $4,850, which was recorded as stock based management compensation. Share purchase options A summary of the Company’s stock options as of June 30, 2015 and changes during the period is presented below:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"> <tr> <td width="61%"></td> <td valign="bottom" width="9%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="9%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="9%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Number of Options</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Weighted Average Exercise Price</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Weighted Average Remaining Life</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Balance, December 31, 2013 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">65,430</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">18.00</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5.04</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Issued </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Cancelled/Forfeited </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Balance, December 31, 2014 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">65,430</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">18.00</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4.04</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> </table>   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"> <tr> <td width="60%"></td> <td valign="bottom" width="9%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="9%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="9%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Number of Options</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Weighted Average Exercise Price</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Weighted Average Remaining Life</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Issued </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">400,000</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0.17</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4.64</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Balance, June 30, 2015 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">465,430</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2.62</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4.49</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> At June 30, 2015, the intrinsic value of the vested options was equal to $66,000 (2014 - $nil). A summary of the status of the Company’s unvested options as of June 30, 2015 is presented below:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="72%"></td> <td valign="bottom" width="8%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="8%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Number of Shares</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Weighted Average Grant-Date Fair Value</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Unvested, December 31, 2014 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">278</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">18.00</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Granted </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">400,000</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0.16</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Vested </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(82,685</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0.21</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Cancelled </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Unvested, June 30, 2015 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">317,593</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.16</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div> 6133000 1.41 4245000 4245000 6133000 9313000 4245000 2326014 2556000 81834000 <div> NOTE 7:     PROMISSORY NOTES, RELATED PARTY   The Company has outstanding promissory notes in the amount of $52,942 (December 31, 2014 - $52,942), of which $23,000 of promissory notes are from an officer and a director of the Company. The promissory notes bear no interest charges and have no fixed repayment terms. </div> <div> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="68%"></td> <td valign="bottom" width="14%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="14%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom" nowrap="nowrap"> Share Purchase Warrants </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"> Weighted Average Inputs for the Period</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom" nowrap="nowrap"> Date of valuation </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" nowrap="nowrap" align="center">For the Six Months Ending June 30, 2015</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" nowrap="nowrap" align="center">For the Six Months Ending June 30, 2014</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Fair market value of stock </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.96</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.02</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Strike price </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.50</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">5.84</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Volatility (annual) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">148.00</td> <td valign="bottom" nowrap="nowrap">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">159.00</td> <td valign="bottom" nowrap="nowrap">% </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Risk-free rate </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1.1</td> <td valign="bottom" nowrap="nowrap">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1.08</td> <td valign="bottom" nowrap="nowrap">% </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Contractual term (years) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3.2</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3.58</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Dividend yield (per share) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0</td> <td valign="bottom" nowrap="nowrap">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0</td> <td valign="bottom" nowrap="nowrap">% </td> </tr> </table> </div> <div> Financial assets and liabilities measured at fair value on a recurring basis are summarized below and disclosed on the balance sheet under Derivative liability – warrants:   <table style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"> <tr> <td width="62%"></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="18" align="center">As of June 30, 2015</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="18" align="center">Fair Value Measurements</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center">Fair Value</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" nowrap="nowrap" align="center"> Level 1</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" nowrap="nowrap" align="center"> Level 2</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" nowrap="nowrap" align="center"> Level 3</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center">Total</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Derivative liability - warrants </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">69,962,000</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">69,962,000</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">69,962,000</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Total </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">69,962,000</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">69,962,000</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">69,962,000</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="16"></td> <td height="16" colspan="20"></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="18" align="center">As of December 31, 2014</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="18" align="center">Fair Value Measurements</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center">Fair Value</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center"> Level 1</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center"> Level 2</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center">Level 3</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center">Total</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Derivative liability - warrants </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">9,000</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">9,000</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">9,000</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Total </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">9,000</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">9,000</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">9,000</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div> <div> The following table presents changes in Level 3 liabilities measured at fair value for the six months ended June 30, 2015:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"> <tr> <td width="71%"></td> <td valign="bottom" width="18%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"> Derivative liability – warrants</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Balance – December 31, 2014 </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">9,000</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Additions during the period </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">15,446,000</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Exercise of warrants </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(4,245,000</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Change in fair value of warrant liability </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">58,752,000</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Balance – June 30, 2015 </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">69,962,000</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div> <div> A summary of the Company’s stock options as of June 30, 2015 and changes during the period is presented below:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"> <tr> <td width="61%"></td> <td valign="bottom" width="9%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="9%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="9%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Number of Options</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Weighted Average Exercise Price</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Weighted Average Remaining Life</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Balance, December 31, 2013 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">65,430</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">18.00</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5.04</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Issued </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Cancelled/Forfeited </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Balance, December 31, 2014 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">65,430</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">18.00</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4.04</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> </table>   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"> <tr> <td width="60%"></td> <td valign="bottom" width="9%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="9%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="9%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Number of Options</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Weighted Average Exercise Price</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Weighted Average Remaining Life</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Issued </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">400,000</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0.17</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4.64</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Balance, June 30, 2015 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">465,430</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2.62</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4.49</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div> 35000 15446000 465000 <div> NOTE 6:     DERIVATIVE LIABILITY - WARRANTS AND DERIVATIVE LIABILITY – CONVERSION OPTION, AS RESTATED      A summary of quantitative information with respect to valuation methodology and significant unobservable inputs used for the Company’s common stock purchase warrants that are categorized within Level 3 of the fair value hierarchy for the six months ended 2015 and 2014 is as follows:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="68%"></td> <td valign="bottom" width="14%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="14%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom" nowrap="nowrap"> Share Purchase Warrants </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"> Weighted Average Inputs for the Period</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom" nowrap="nowrap"> Date of valuation </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" nowrap="nowrap" align="center">For the Six Months Ending June 30, 2015</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" nowrap="nowrap" align="center">For the Six Months Ending June 30, 2014</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Fair market value of stock </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.96</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.02</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Strike price </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.50</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">5.84</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Volatility (annual) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">148.00</td> <td valign="bottom" nowrap="nowrap">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">159.00</td> <td valign="bottom" nowrap="nowrap">% </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Risk-free rate </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1.1</td> <td valign="bottom" nowrap="nowrap">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1.08</td> <td valign="bottom" nowrap="nowrap">% </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Contractual term (years) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3.2</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3.58</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Dividend yield (per share) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0</td> <td valign="bottom" nowrap="nowrap">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0</td> <td valign="bottom" nowrap="nowrap">% </td> </tr> </table> The foregoing assumptions are reviewed quarterly and are subject to change based primarily on management’s assessment of the probability of the events described occurring. Accordingly, changes to these assessments could materially affect the valuations.   Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis Financial assets and liabilities measured at fair value on a recurring basis are summarized below and disclosed on the balance sheet under Derivative liability – warrants:   <table style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"> <tr> <td width="62%"></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="18" align="center">As of June 30, 2015</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="18" align="center">Fair Value Measurements</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center">Fair Value</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" nowrap="nowrap" align="center"> Level 1</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" nowrap="nowrap" align="center"> Level 2</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" nowrap="nowrap" align="center"> Level 3</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center">Total</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Derivative liability - warrants </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">69,962,000</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">69,962,000</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">69,962,000</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Total </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">69,962,000</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">69,962,000</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">69,962,000</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="16"></td> <td height="16" colspan="20"></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="18" align="center">As of December 31, 2014</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="18" align="center">Fair Value Measurements</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center">Fair Value</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center"> Level 1</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center"> Level 2</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center">Level 3</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center">Total</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Derivative liability - warrants </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">9,000</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">9,000</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">9,000</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Total </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">9,000</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">9,000</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">9,000</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> There were no transfers between Level 1, 2 or 3 during the three months ended June 30, 2015. The following table presents changes in Level 3 liabilities measured at fair value for the six months ended June 30, 2015:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"> <tr> <td width="71%"></td> <td valign="bottom" width="18%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"> Derivative liability – warrants</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Balance – December 31, 2014 </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">9,000</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Additions during the period </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">15,446,000</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Exercise of warrants </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(4,245,000</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Change in fair value of warrant liability </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">58,752,000</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Balance – June 30, 2015 </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">69,962,000</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> The valuation of warrants is subjective and is affected by changes in inputs to the valuation model including the price per share of common stock, the historical volatility of the stock price, risk-free rates based on U.S. Treasury security yields, the expected term of the warrants and dividend yield. Changes in these assumptions can materially affect the fair value estimate. The Company could ultimately incur amounts to settle the warrant at a cash settlement value that is significantly different than the carrying value of the liability on the financial statements. The Company will continue to classify the fair value of the warrants as a liability until the warrants are exercised, expire, or are amended in a way that would no longer require these warrants to be classified as a liability. Changes in the fair value of the common stock warrants liability are recognized as a component of other income (expense) in the Statements of Operations.   During 2014 the Company entered into numerous extinguishment agreements with various holders. As a result the derivative liability associated with the bifurcated conversion options were extinguished at the date of conversion and recorded in the loss on extinguishment in the Statement of Operations. The inputs utilized in the final mark to market were as follows:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"> <tr> <td width="77%"></td> <td valign="bottom" width="8%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="8%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom" nowrap="nowrap"> Conversion Option </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"> Weighted Average Inputs for the Period</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom" nowrap="nowrap"> Date of valuation </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" nowrap="nowrap" align="center">For the Quarter Ending June 30, 2015</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" nowrap="nowrap" align="center">For the Quarter Ending June 30, 2014</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Strike price </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1.03</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Volatility (annual) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">199.00</td> <td valign="bottom" nowrap="nowrap">% </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Risk-free rate </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0.05</td> <td valign="bottom" nowrap="nowrap">% </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Contractual term (years) </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0.24</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Dividend yield (per share) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">% </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Fair value of Conversion Option at extinguishment </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">708,000</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> </tr> </table> </div> <div> NOTE 3:     LIQUIDITY AND FINANCIAL CONDITION   The Company’s activities since inception have consisted principally of acquiring product and technology rights, raising capital, and performing research and development. Successful completion of the Company’s development programs and, ultimately, the attainment of profitable operations are dependent on future events, including, among other things, its ability to access potential markets; secure financing, develop a customer base; attract, retain and motivate qualified personnel; and develop strategic alliances. From inception, the Company has been funded by a combination of equity and debt financings.   The Company expects to continue to incur substantial losses over the next several years during its development phase. To fully execute its business plan, the Company will need to complete certain research and development activities and clinical studies. Further, the Company’s product candidates will require regulatory approval prior to commercialization. These activities may span many years and require substantial expenditures to complete and may ultimately be unsuccessful. Any delays in completing these activities could adversely impact the Company. The Company plans to meet its capital requirements primarily through issuances of debt and equity securities and, in the longer term, revenue from product sales. As of June 30, 2015, the Company had cash and cash equivalents of approximately $3,105,000. Historically, the Company has net losses and negative cash flows from operations. The Company believes its current capital resources are not sufficient to support its operations. Management intends to continue its research efforts and to finance operations of the Company through debt and/or equity financings. Management plans to seek additional debt and/or equity financing through private or public offerings or through a business combination or strategic partnership. There can be no assurance that the Company will be successful in obtaining additional financing on favorable terms, or at all. These matters raise substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of these uncertainties. </div> 140000 <div> The inputs utilized in the final mark to market were as follows:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"> <tr> <td width="77%"></td> <td valign="bottom" width="8%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="8%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom" nowrap="nowrap"> Conversion Option </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"> Weighted Average Inputs for the Period</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom" nowrap="nowrap"> Date of valuation </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" nowrap="nowrap" align="center">For the Quarter Ending June 30, 2015</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" nowrap="nowrap" align="center">For the Quarter Ending June 30, 2014</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Strike price </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1.03</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Volatility (annual) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">199.00</td> <td valign="bottom" nowrap="nowrap">% </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Risk-free rate </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0.05</td> <td valign="bottom" nowrap="nowrap">% </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Contractual term (years) </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0.24</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Dividend yield (per share) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">% </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Fair value of Conversion Option at extinguishment </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">708,000</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div> <div> NOTE 5:    POTENTIALLY DILUTIVE SECURITIES   Options, warrants, and convertible debt outstanding were all considered anti-dilutive for the six months ended June 30, 2015 and 2014, due to net losses. The following securities were not included in the diluted net loss per share calculation because their effect was anti-dilutive as of the periods presented:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="77%"></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">June 30,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2015</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2014</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Common stock options </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">465,000</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">65,000</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Common stock warrants - equity treatment </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,556,000</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">185,000</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Common stock warrants - liability treatment </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">81,834,000</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">49,000</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Convertible notes </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">7,000</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Potentially dilutive securities </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">84,855,000</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">306,000</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

7635

4850

-0.64

-1827638

30584794

-19427365

-9005932

60086

-2166208

2963376

248561

8256000

2500000

810535

4791014

2291014

149320

1355673

9005932

8256000

-775

-1.36

30584794

-41489653

-49745653

35000

-8256000

35000

49745653

-8256000

P5Y

0.012

1.58

9313000

5000000

400110

5000

400

12320 12319995

-60917018

-6999306

6133000

P4Y5M27D

0.17

400000

P4Y7M21D

2495000

248161

-2313694

4245000 2313694 35000

1.48

0.0110

0.50

0.00

P3Y2M12D

0.96

0.21

82685

400000

0.16

5000000 2500000 950000 50000 0.20 5000000

1578000

7890000 1250000 214000 0.20 7320000 P5Y P5Y P6M P5Y P5Y 2

P5Y15D

P4Y15D

1.03

0.0005

0.05

P2M27D

1.99

15523016

753480

754522

-8660

352834

920233

1042

-510927

22500

488427

708000

-1.80

33525656

-60216294

-59079025

-1138044

201157

936887

-775

-0.55

33525656

-18445641

-9052372

-1138044

201157

936887

8256000

-775

-1.25

33525656

-41770653

-50026653

-8256000

0001094038 us-gaap:RestatementAdjustmentMember 2015-04-01 2015-06-30 0001094038 us-gaap:ScenarioPreviouslyReportedMember 2015-04-01 2015-06-30 0001094038 2015-04-01 2015-06-30 0001094038 2014-04-01 2014-06-30 0001094038 us-gaap:StockOptionMember 2014-01-01 2014-12-31 0001094038 us-gaap:StockOptionMember 2013-01-01 2013-12-31 0001094038 tpiv:SeriesCWarrantMember 2015-05-01 2015-05-31 0001094038 tpiv:SeriesEWarrantMember us-gaap:PrivatePlacementMember 2015-01-01 2015-01-31 0001094038 tpiv:SeriesAWarrantMember us-gaap:PrivatePlacementMember 2015-01-01 2015-01-31 0001094038 tpiv:SeriesBWarrantMember us-gaap:PrivatePlacementMember 2015-01-01 2015-01-31 0001094038 tpiv:SeriesCWarrantMember us-gaap:PrivatePlacementMember 2015-01-01 2015-01-31 0001094038 tpiv:SeriesDWarrantMember us-gaap:PrivatePlacementMember 2015-01-01 2015-01-31 0001094038 us-gaap:PrivatePlacementMember 2015-01-01 2015-01-31 0001094038 tpiv:SeriesBWarrantMember us-gaap:SubsequentEventMember 2015-07-16 2015-08-13 0001094038 us-gaap:PrivatePlacementMember 2015-03-07 2015-03-31 0001094038 tpiv:SeriesCWarrantMember 2015-01-01 2015-06-30 0001094038 tpiv:UnvestedOptionsMember 2015-01-01 2015-06-30 0001094038 tpiv:SharePurchaseWarrantsMember 2015-01-01 2015-06-30 0001094038 us-gaap:AdditionalPaidInCapitalMember 2015-01-01 2015-06-30 0001094038 us-gaap:StockOptionMember 2015-01-01 2015-06-30 0001094038 us-gaap:RetainedEarningsMember 2015-01-01 2015-06-30 0001094038 us-gaap:CommonStockMember 2015-01-01 2015-06-30 0001094038 us-gaap:WarrantMember 2015-01-01 2015-06-30 0001094038 us-gaap:RestatementAdjustmentMember 2015-01-01 2015-06-30 0001094038 us-gaap:ScenarioPreviouslyReportedMember 2015-01-01 2015-06-30 0001094038 tpiv:ManagementConsultingServicesMember 2015-01-01 2015-06-30 0001094038 tpiv:ConsultantMember 2015-01-01 2015-06-30 0001094038 2015-01-01 2015-06-30 0001094038 tpiv:SharePurchaseWarrantsMember 2014-01-01 2014-06-30 0001094038 2014-01-01 2014-06-30 0001094038 2015-05-31 2015-05-31 0001094038 2015-03-06 2015-03-06 0001094038 2015-02-10 2015-02-10 0001094038 tpiv:UnvestedOptionsMember 2014-12-31 0001094038 us-gaap:AdditionalPaidInCapitalMember 2014-12-31 0001094038 us-gaap:SeriesAPreferredStockMember 2014-12-31 0001094038 us-gaap:StockOptionMember 2014-12-31 0001094038 us-gaap:SeriesBPreferredStockMember 2014-12-31 0001094038 us-gaap:RetainedEarningsMember 2014-12-31 0001094038 us-gaap:CommonStockMember 2014-12-31 0001094038 us-gaap:ScenarioPreviouslyReportedMember 2014-12-31 0001094038 tpiv:FairValueHedging1Member 2014-12-31 0001094038 us-gaap:FairValueInputsLevel1Member 2014-12-31 0001094038 us-gaap:FairValueInputsLevel2Member 2014-12-31 0001094038 us-gaap:FairValueInputsLevel3Member 2014-12-31 0001094038 2014-12-31 0001094038 us-gaap:StockOptionMember 2013-12-31 0001094038 2013-12-31 0001094038 tpiv:SeriesBAndCWarrantsMember 2015-06-30 0001094038 tpiv:SeriesBWarrantMember 2015-06-30 0001094038 tpiv:SeriesCWarrantMember 2015-06-30 0001094038 tpiv:UnvestedOptionsMember 2015-06-30 0001094038 us-gaap:AdditionalPaidInCapitalMember 2015-06-30 0001094038 us-gaap:SeriesAPreferredStockMember 2015-06-30 0001094038 us-gaap:StockOptionMember 2015-06-30 0001094038 us-gaap:SeriesBPreferredStockMember 2015-06-30 0001094038 us-gaap:RetainedEarningsMember 2015-06-30 0001094038 us-gaap:CommonStockMember 2015-06-30 0001094038 us-gaap:SeriesAPreferredStockMember us-gaap:RestatementAdjustmentMember 2015-06-30 0001094038 us-gaap:SeriesBPreferredStockMember us-gaap:RestatementAdjustmentMember 2015-06-30 0001094038 us-gaap:RestatementAdjustmentMember 2015-06-30 0001094038 us-gaap:SeriesAPreferredStockMember us-gaap:ScenarioPreviouslyReportedMember 2015-06-30 0001094038 us-gaap:SeriesBPreferredStockMember us-gaap:ScenarioPreviouslyReportedMember 2015-06-30 0001094038 us-gaap:ScenarioPreviouslyReportedMember 2015-06-30 0001094038 tpiv:FairValueHedging1Member 2015-06-30 0001094038 us-gaap:FairValueInputsLevel1Member 2015-06-30 0001094038 us-gaap:FairValueInputsLevel2Member 2015-06-30 0001094038 us-gaap:FairValueInputsLevel3Member 2015-06-30 0001094038 2015-06-30 0001094038 tpiv:SubsequentWarrantIssuanceMember us-gaap:PrivatePlacementMember 2015-03-31 0001094038 tpiv:SeriesEWarrantMember us-gaap:PrivatePlacementMember 2015-03-31 0001094038 tpiv:SeriesAWarrantMember us-gaap:PrivatePlacementMember 2015-03-31 0001094038 tpiv:SeriesBWarrantMember us-gaap:PrivatePlacementMember 2015-03-31 0001094038 tpiv:SeriesCWarrantMember us-gaap:PrivatePlacementMember 2015-03-31 0001094038 tpiv:SeriesDWarrantMember us-gaap:PrivatePlacementMember 2015-03-31 0001094038 us-gaap:PrivatePlacementMember 2015-03-31 0001094038 2014-06-30 0001094038 tpiv:OmnibusStockPlanTwoThousandFourteenMember 2009-10-14 0001094038 tpiv:SeriesAWarrantMember 2015-05-31 0001094038 tpiv:SeriesBWarrantMember 2015-05-31 0001094038 tpiv:SeriesCWarrantMember 2015-05-31 0001094038 tpiv:SeriesAWarrantMember us-gaap:ScenarioPreviouslyReportedMember 2015-05-31 0001094038 tpiv:SeriesBWarrantMember us-gaap:ScenarioPreviouslyReportedMember 2015-05-31 0001094038 tpiv:SeriesCWarrantMember us-gaap:ScenarioPreviouslyReportedMember 2015-05-31 0001094038 2015-08-14 0001094038 us-gaap:SubsequentEventMember 2015-08-10 0001094038 us-gaap:SubsequentEventMember 2015-07-31 0001094038 tpiv:SubsequentWarrantIssuanceMember us-gaap:PrivatePlacementMember 2015-01-31 0001094038 tpiv:SeriesEWarrantMember us-gaap:PrivatePlacementMember 2015-01-31 0001094038 tpiv:SeriesAWarrantMember us-gaap:PrivatePlacementMember 2015-01-31 0001094038 tpiv:SeriesBWarrantMember us-gaap:PrivatePlacementMember 2015-01-31 0001094038 tpiv:SeriesCWarrantMember us-gaap:PrivatePlacementMember 2015-01-31 0001094038 tpiv:SeriesDWarrantMember us-gaap:PrivatePlacementMember 2015-01-31 0001094038 us-gaap:PrivatePlacementMember 2015-01-31 shares iso4217:USD shares iso4217:USD pure iso4217:USD tpiv:Equity tpiv:Warrant

EX-101.SCH 5 tpiv-20150630.xsd XBRL TAXONOMY EXTENSION SCHEMA 101 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink 103 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS link:calculationLink link:presentationLink link:definitionLink 104 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) link:calculationLink link:presentationLink link:definitionLink 105 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS link:calculationLink link:presentationLink link:definitionLink 106 - Statement - CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (DEFICIT) AS RESTATED link:calculationLink link:presentationLink link:definitionLink 107 - Statement - CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (DEFICIT) AS RESTATED (Parenthetical) link:calculationLink link:presentationLink link:definitionLink 108 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS link:calculationLink link:presentationLink link:definitionLink 109 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical) link:calculationLink link:presentationLink link:definitionLink 110 - Disclosure - NATURE OF OPERATIONS link:calculationLink link:presentationLink link:definitionLink 111 - Disclosure - AMENDMENT TO PREVIOUSLY REPORTED QUARTERLY FINANCIAL STATEMENTS link:calculationLink link:presentationLink link:definitionLink 112 - Disclosure - BASIS OF PRESENTATION link:calculationLink link:presentationLink link:definitionLink 113 - Disclosure - LIQUIDITY AND FINANCIAL CONDITION link:calculationLink link:presentationLink link:definitionLink 114 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES link:calculationLink link:presentationLink link:definitionLink 115 - Disclosure - POTENTIALLY DILUTIVE SECURITIES link:calculationLink link:presentationLink link:definitionLink 116 - Disclosure - DERIVATIVE LIABILITY - WARRANTS AND DERIVATIVE LIABILITY - CONVERSION OPTION link:calculationLink link:presentationLink link:definitionLink 117 - Disclosure - PROMISSORY NOTE link:calculationLink link:presentationLink link:definitionLink 118 - Disclosure - CAPITAL STOCK link:calculationLink link:presentationLink link:definitionLink 119 - Disclosure - SUBSEQUENT EVENTS link:calculationLink link:presentationLink link:definitionLink 120 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies) link:calculationLink link:presentationLink link:definitionLink 121 - Disclosure - AMENDMENT TO PREVIOUSLY REPORTED QUARTERLY FINANCIAL STATEMENTS (Tables) link:calculationLink link:presentationLink link:definitionLink 122 - Disclosure - POTENTIALLY DILUTIVE SECURITIES (Tables) link:calculationLink link:presentationLink link:definitionLink 123 - Disclosure - DERIVATIVE LIABILITY - WARRANTS AND DERIVATIVE LIABILITY - CONVERSION OPTION (Tables) link:calculationLink link:presentationLink link:definitionLink 124 - Disclosure - CAPITAL STOCK (Tables) link:calculationLink link:presentationLink link:definitionLink 125 - Disclosure - Amendment to Previously Reported Quarterly Financial Statements - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 126 - Disclosure - Restatement of Condensed Consolidated Balance Sheets (Unaudited) (Detail) link:calculationLink link:presentationLink link:definitionLink 127 - Disclosure - Restatement of Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) (Detail) link:calculationLink link:presentationLink link:definitionLink 128 - Disclosure - Restatement of Condensed Consolidated statements of Operation and Comprehensive Loss (Unaudited) (Detail) link:calculationLink link:presentationLink link:definitionLink 129 - Disclosure - Restatement of Consolidated statements of Cash Flows (Unaudited) (Detail) link:calculationLink link:presentationLink link:definitionLink 130 - Disclosure - Restatement of Consolidated statements of Cash Flows (Unaudited) (Parenthetical) (Detail) link:calculationLink link:presentationLink link:definitionLink 131 - Disclosure - LIQUIDITY AND FINANCIAL CONDITION (Narrative) (Detail) link:calculationLink link:presentationLink link:definitionLink 132 - Disclosure - POTENTIALLY DILUTIVE SECURITIES - shares (Detail) link:calculationLink link:presentationLink link:definitionLink 133 - Disclosure - DERIVATIVE LIABILITY - WARRANTS AND DERIVATIVE LIABILITY - CONVERSION OPTION (Detail) link:calculationLink link:presentationLink link:definitionLink 134 - Disclosure - DERIVATIVE LIABILITY - WARRANTS AND DERIVATIVE LIABILITY - CONVERSION OPTION(1) (Detail) link:calculationLink link:presentationLink link:definitionLink 135 - Disclosure - DERIVATIVE LIABILITY - WARRANTS AND DERIVATIVE LIABILITY - CONVERSION OPTION(2) (Detail) link:calculationLink link:presentationLink link:definitionLink 136 - Disclosure - DERIVATIVE LIABILITY - WARRANTS AND DERIVATIVE LIABILITY - CONVERSION OPTION(3) (Detail) link:calculationLink link:presentationLink link:definitionLink 137 - Disclosure - PROMISSORY NOTES, RELATED PARTY (Detail) link:calculationLink link:presentationLink link:definitionLink 138 - Disclosure - Capital Stock - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 139 - Disclosure - CAPITAL STOCK(1) (Detail) link:calculationLink link:presentationLink link:definitionLink 140 - Disclosure - CAPITAL STOCK(2) (Detail) link:calculationLink link:presentationLink link:definitionLink 141 - Disclosure - CAPITAL STOCK(3) (Detail) link:calculationLink link:presentationLink link:definitionLink 142 - Disclosure - Subsequent Events - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink EX-101.CAL 6 tpiv-20150630_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 7 tpiv-20150630_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 8 tpiv-20150630_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Accounting Changes and Error Corrections [Abstract] Accounting Changes and Error Corrections [Abstract] Accounting Policies [Abstract] Accounting Policies [Abstract] Accounts Payable and Accrued Liabilities, Fair Value Disclosure Accounts payable and accrued liabilities Additional Paid in Capital Additional paid-in capital Additional Paid-in Capital [Member] Additional Paid-In Capital Additions during year. Additions During Year Additions during the period Adjustments to Additional Paid in Capital, Warrant Issued Exercise of warrants, Amount Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Adjustments to reconcile net loss to net cash from operating activities: Aggregate purchase price of shares agreed to purchase under stock purchase agreement. Aggregate Purchase Price Of Shares Agreed To Purchase Under Stock Purchase Agreement Aggregate purchase price Allocated Share-based Compensation Expense Stock based compensation Amendment Description Amendment Description Amendment Flag Amendment Flag Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Potentially dilutive securities Assets [Abstract] ASSETS Assets, Current Total Assets Total Current Assets Assets, Current [Abstract] Current Assets Award Type [Axis] Award Type [Axis] Basis of Accounting [Text Block] BASIS OF PRESENTATION The entire disclosure for the capital stock. Capital Stock [Text Block] CAPITAL STOCK Cash CASH, END OF PERIOD CASH, BEGINNING OF PERIOD Cash Cash and Cash Equivalents [Abstract] Cash and Cash Equivalents [Abstract] Cash Equivalents, at Carrying Value Cash and cash equivalents Cash, Period Increase (Decrease) INCREASE IN CASH INCREASE (DECREASE) IN CASH Change In Fair Value Of Derivative Liabilities Change In Fair Value Of Derivative Liabilities Reclassification of derivative warrant liabilities to equity at exercise date Class of Warrant or Right [Axis] Class of Warrant or Right [Axis] Class of Warrant or Right [Domain] Class of Warrant or Right [Domain] Class Of Warrant Or Right Exercised Class Of Warrant Or Right Exercised Number of warrant exercised Class of Warrant or Right, Exercise Price of Warrants or Rights Exercise price of warrants Class of warrant or right expiration period. Class Of Warrant Or Right Expiration Period Warrant expiration period Class Of Warrant Or Right Fair Value Assumptions Expected Volatility Rate Class Of Warrant Or Right Fair Value Assumptions Expected Volatility Rate Volatility Class Of Warrant Or Right Fair Value Assumptions Risk Free Interest Rate Class Of Warrant Or Right Fair Value Assumptions Risk Free Interest Rate Risk free Rate Class of Warrant or Right, Number of Securities Called by Each Warrant or Right Number of securities callable by each warrant or right warrants Class of Warrant or Right, Number of Securities Called by Warrants or Rights Class of warrant or right, number of securities called by warrants or rights Class of Warrant or Right, Outstanding Number of warrants issued Class Of Warrant Or Right Warrants Contractual Term Class Of Warrant Or Right Warrants Contractual Term Contractual term Class Of Warrants Or Right Exercised Class Of Warrants Or Right Exercised Exercise of warrants Commitment, Contingency And Related Party Transactions [Abstract] Commitment, Contingency And Related Party Transactions [Abstract] Commitment, Contingency And Related Party Transactions [Abstract] Commitments and Contingencies COMMITMENTS AND CONTINGENCIES Common Stock Capital Shares Reserved For Future Issuance [Line Items] Common Stock Capital Shares Reserved For Future Issuance [Line Items] Common Stock Capital Shares Reserved For Future Issuance [Line Items] Common Stock Capital Shares Reserved For Future Issuance [Table] Common Stock Capital Shares Reserved For Future Issuance [Table] Common Stock Capital Shares Reserved For Future Issuance [Table] Common Stock [Member] Common Stock Common Stock Options Common Stock Options Common stock options Common Stock, Par or Stated Value Per Share Common stock par value Common Stock, Shares Authorized Common stock shares authorized Common Stock, Shares, Issued Common stock shares issued Common Stock, Shares, Issued as full of a dispute Common Stock, Shares, Outstanding Common stock shares outstanding Common Stock, Value, Issued Common stock, $0.001 par value, 500,000,000 shares authorized 32,638,811 shares issued and outstanding (2014 - 20,318,815) Common stock, $0.001 par value, 500,000,000 shares authorized 38,038,921 shares issued and outstanding (2014 - 20,318,815) Common stock warrants - equity treatment. Common Stock Warrants Equity Treatment Common stock warrants - equity treatment Common stock warrants - liability treatment. Common Stock Warrants Liability Treatment Common stock warrants - liability treatment Consultant [Member] Consultant [Member] Consultant [Member] Conversion Of Debt Obligations Into Common Stock [Abstract] Conversion Of Debt Obligations Into Common Stock [Abstract] Conversion of debt obligations into common stock: Convertible notes. Convertible Notes Convertible notes Convertible Preferred Stock, Nonredeemable or Redeemable, Issuer Option, Value Convertible preferred stock Costs and Expenses [Abstract] Operating expenses: Current Fiscal Year End Date Current Fiscal Year End Date Debt Conversion, Converted Instrument, Amount Convertible notes payable Debt Issuance Cost Issuance costs Deferred Sales Inducements, Additions Inducement expense Deferred Sales Inducements, Amortization Expense Inducement expense Defined Benefit Plan, Foreign Currency Exchange Rate Changes, Plan Assets Foreign exchange Derivative Liability, Fair Value, Gross Liability Derivative liability - warrants Derivative, Fair Value, Net Total Derivative, Gain (Loss) on Derivative, Net Changes in fair value of derivative liabilities Derivative Instruments and Hedging Activities Disclosure [Abstract] Derivative Instruments and Hedging Activities Disclosure [Abstract] Derivative Instruments Not Designated as Hedging Instruments, Gain Fair value derivative liability - conversion option at conversion Derivative Liability, Current Derivative liability - warrants Derivative Liability Warrants And Derivative Liability Conversion Option [Text Block] Derivative Liability Warrants And Derivative Liability Conversion Option [Text Block] DERIVATIVE LIABILITY - WARRANTS AND DERIVATIVE LIABILITY - CONVERSION OPTION Liquidity And Financial Condition Details Narrtive Disclosure Disclosure Liquidity And Financial Condition Details Narrtive [Abstract] Liquidity And Financial Condition Details Narrtive Potentially Dilutive Securities Details Disclousure Potentially Dilutive Securities Details [Abstract] Potentially Dilutive Securities Details Document And Entity Information [Abstract] Document And Entity Information [Abstract] Document And Entity Information [Abstract] Document Fiscal Period Focus Document Fiscal Period Focus Document Fiscal Year Focus Document Fiscal Year Focus Document Period End Date Document Period End Date Document Type Document Type Earnings Per Share [Abstract] Earnings Per Share [Abstract] Earnings Per Share, Basic and Diluted Basic and Diluted Net Income (Loss) per Share Basic and Diluted Net Loss per Share Entity Central Index Key Entity Central Index Key Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Entity Filer Category Entity Filer Category Entity Registrant Name Entity Registrant Name Equity [Abstract] Equity [Abstract] Equity Component [Domain] Equity Component [Domain] Equity, Fair Value Disclosure Fair value of warrants Equity units issued price per unit. Equity Units Issued Price Per Unit Sales price per unit Error Corrections and Prior Period Adjustments Restatement [Line Items] Error Corrections and Prior Period Adjustments Restatement [Line Items] Extinguishment of Debt, Amount Fair value of Conversion Option at extinguishment Extinguishment of Debt, Gain (Loss), Income Tax Loss on extinguishment of debt Fair Market Value Of Stock Fair Market Value Of Stock Fair market value of stock Fair Value Assumptions, Expected Dividend Rate Dividend yield Fair Value Assumptions, Expected Term Contractual Life (Years) Fair Value Assumptions, Expected Volatility Rate Volatility Fair Value Assumptions, Risk Free Interest Rate Risk free Rate Fair Value, Hierarchy [Axis] Fair Value, Hierarchy [Axis] Fair Value Hedging 1 [Member] Fair Value Hedging 1 [Member] Carrying Value [Member] Fair Value, Inputs, Level 1 [Member] Fair Value, Inputs, Level 1 [Member] Fair Value, Inputs, Level 2 [Member] Fair Value, Inputs, Level 2 [Member] Fair Value, Inputs, Level 3 [Member] Fair Value, Inputs, Level 3 [Member] Fair Value Hierarchy [Domain] Fair Value Hierarchy [Domain] Additional Fair Value Of Common Stock Warrants Issued Fair Value Of Additional Common Stock Warrants Issued Issuance of additional warrants in May 28, 2015 transaction Fair Value Of Common Stock Warrant Issued Fair Value Of Common Stock Warrant Issued Fair value of issuance of warrants in January and March 2015 financing Fair Value Of Warrants Exercised Fair Value Of Warrants Exercised Reclassification of derivative warrant liabilities to equity at exercise date Fair Value, Option, Changes in Fair Value, Gain (Loss) Change in fair value of warrant liability Fair Values Of Warrant Issued Fair Values Of Warrant Issued Fair value of warrants issued on May 28, 2015 Financial assets and liabilities measured at fair value on recurring basis. Financial Assets And Liabilities Measured At Fair Value On Recurring Basis Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis Gain (Loss) on Derivative Instruments, Net, Pretax Fair value of warrants recognized as derivative liabilities in January and March 2015 Financing Gain (Loss) Related to Litigation Settlement Gain (loss) on settlement of debt General and Administrative Expense General and administrative Income Statement [Abstract] Income Statement [Abstract] Increase (Decrease) in Accounts Payable and Accrued Liabilities Accounts payable and accrued liabilities Increase (Decrease) in Derivative Liabilities Changes in fair value of derivative liabilities Increase (Decrease) in Due to Related Parties Due to related parties Increase (Decrease) in Interest Payable, Net Accrued interest Increase (Decrease) in Notes Payable, Related Parties Promissory notes, related party Increase (Decrease) in Operating Capital [Abstract] Changes in operating assets and liabilities: Increase (Decrease) in Other Accounts Payable Accounts payable settled in common stock Increase (Decrease) in Prepaid Expense Prepaid expenses Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants Exercise of warrants, Share Interest and Debt Expense Non-cash interest and finance charges Interest on Convertible Debt, Net of Tax Accretion of interest on convertible debt Liabilities and Equity Total LIABILITIES AND STOCKHOLDERS' DEFICIT Total LIABILITIES AND STOCKHOLDERS' DEFICIT Liabilities and Equity [Abstract] LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT) Liabilities, Current Total Current Liabilities Total Current Liabilities Liabilities, Current [Abstract] Current Liabilities Financial and Nonfinancial Liabilities, Fair Value Disclosure Balance - June 30, 2015 Balance - December 31, 2014 Liquidity And Financial Condition [Text Block] Liquidity And Financial Condition [Text Block] LIQUIDITY AND FINANCIAL CONDITION Management Consulting Services [Member] Management Consulting Services [Member] Management Compensation [Member] Measured at fair value. Measured At Fair Value Measured at fair value Nature of Operations [Text Block] NATURE OF OPERATIONS Net Cash Provided by (Used in) Financing Activities NET CASH PROVIDED BY FINANCING ACTIVITIES Net Cash Provided by (Used in) Financing Activities [Abstract] CASH FLOWS FROM FINANCING ACTIVITIES Net Cash Provided by (Used in) Operating Activities NET CASH USED IN OPERATING ACTIVITIES Net Cash Provided by (Used in) Operating Activities [Abstract] CASH FLOWS FROM OPERATING ACTIVITIES Net Income (Loss) Attributable to Parent Net loss Net Income (Loss) for the Period Net Loss for the Period Net Of Finders Fee Net Of Finders Fee Net of finders' fee Nonoperating Income (Expense) [Abstract] Other Income (Expense) Notes Payable Promissory notes Notes Payable, Current Outstanding promissory notes Notes Payable, Related Parties, Noncurrent Promissory notes officer and a director Notes To Financial Statements Notes To Financial Statements [Abstract] Notes to Financial Statements Number of common stock included in unit offering. Number Of Common Stock Included In Unit Offering Number of common stock included in equity unit Number of equity units issued. Number Of Equity Units Issued Units issued Number Of Warrants [Abstract] Number Of Warrants [Abstract] Number of Warrants Numerous Extinguishment Agreements Numerous Extinguishment Agreements Numerous extinguishment agreements Omnibus Stock Plan Two Thousand Fourteen [Member] Omnibus Stock Plan Two Thousand Fourteen [Member] 2014 Omnibus Stock Option Plan [Member] Option Indexed to Issuer's Equity, Strike Price Strike price Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Other Comprehensive (Income) Loss, Pension and Other Postretirement Benefit Plans, Tax [Abstract] Other comprehensive income Other comprehensive income (loss) Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax Foreign exchange translation adjustment Other Comprehensive Income (Loss), Net of Tax TOTAL COMPREHENSIVE LOSS TOTAL COMPREHENSIVE INCOME (LOSS) Other Extraordinary Gain (Loss) Loss from Operations Loss from Operations Other Liabilities, Current Research agreement obligations Payment of Financing and Stock Issuance Costs Finders' fee on exercise of warrants Potentially Dilutive Securities [Text Block] Potentially Dilutive Securities [Text Block] POTENTIALLY DILUTIVE SECURITIES Preferred Stock, Par or Stated Value Per Share Preferred stock par value Preferred Stock, Shares Authorized Convertible preferred stock Preferred stock shares designated Preferred Stock Shares Designated Preferred Stock Shares Designated Preferred stock shares designated Preferred Stock, Shares Issued Preferred stock issued Preferred Stock, Shares Outstanding Preferred stock outstanding Preferred Stock, Value, Issued Convertible preferred stock, $0.001 par value - 10,000,000 shares authorized: Prepaid Expense, Noncurrent Prepaid expenses and deposits Reclassification, Policy [Policy Text Block] Prior Period Reclassifications Private placement amount. Private Placement Amount Private placement, Amount Private Placement [Member] Private Placement [Member] Private placement share. Private Placement Share Private placement, Share Proceeds from Construction Loans Payable Proceeds from loans payable Proceeds from Issuance of Common Stock Issuance of shares, net of issuance costs of $173,000 Proceeds from Related Party Debt Loans payable, related party Proceeds from Warrant Exercises Proceeds from exercise of warrants Proceeds from Warrant Exercises Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Net loss Promissory Note [Text Block] Promissory Note [Text Block] PROMISSORY NOTE Reclassifications [Text Block] AMENDMENT TO PREVIOUSLY REPORTED QUARTERLY FINANCIAL STATEMENTS Research and Development Expense Research and development Restatement Adjustment [Member] Adjustments [Member] Restatement to Prior Year Income [Table Text Block] Restatemnet of The Company's Consolidated Statements Restructuring Agreement Number Of Warrants Issued Restructuring Agreement Number Of Warrants Issued Replacement of warrants Retained Earnings (Accumulated Deficit) Accumulated deficit Retained Earnings [Member] Accumulated Deficit Sale of Stock [Domain] Sale of Stock [Domain] Scenario, Previously Reported [Member] As Previously Reported [Member] Scenario, Unspecified [Domain] Scenario, Unspecified [Domain] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Securities not Included in Diluted Net Loss Per Share Calculation Schedule of Error Corrections and Prior Period Adjustment Restatement [Table] Schedule of Error Corrections and Prior Period Adjustment Restatement [Table] Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block] Share Purchase Warrants Schedule of Unvested Restricted Stock Units Roll Forward [Table Text Block] Share purchase options Series A Preferred Stock [Member] Series A Series A Warrant [Member] Series A Warrant [Member] Seriesa Warrant [Member] Series B And C Warrant [Member] Series B And C Warrants [Member] Series B And C Warrants [Member] Series B Preferred Stock [Member] Series B Series B Warrant [Member] Series B Warrant [Member] Series B Warrant [Member] Series C Warrant [Member] Series C Warrant [Member] Series C Warrant [Member] Series D Warrant [Member] Series D Warrant [Member] Series D Warrant [Member] Series E Warrant [Member] Series E Warrant [Member] Series E Warrant [Member] Share-based Compensation Stock based compensation Share Based Compensation Arrangement By Share Based Payment Award Award Remaining Vesting Period Share Based Compensation Arrangement By Share Based Payment Award Award Remaining Vesting Period Stock options remaining vesting period EX-101.PRE 9 tpiv-20150630_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 10 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	6 Months Ended
Document and Entity Information - shares	Jun. 30, 2015	Aug. 14, 2015
Document And Entity Information [Abstract]
Document Type	10-Q/A
Amendment Flag	true
Amendment Description	This Amendment No. 1 on Form 10-Q/A (the “Form 10-Q/A”) to the Quarterly Report on Form 10-Q for TapImmune Inc. (“we” or the “Company”) for the quarterly period ended June 30, 2015, initially filed with the Securities and Exchange Commission (the “SEC”) on August 14, 2015 (the “Original Filing”), is being filed to restate accounting for the share purchase warrants and recording the fair value of the warrants under “Derivative liability- warrants” on its balance sheet with changes in the fair value over time reflected in the statements of operations as “Changes in fair value of derivative liabilities”. The restatement of the Company’s accounting for the share purchase warrants arose after a review by the Company’s management. As a result, the Board of Directors of the Company has determined that the Company’s previously issued consolidated unaudited financial statements and reports filed with the SEC for the quarterly period ended June 30, 2015 should not be relied upon. For a more detailed description of the effects of the restatement, see further discussion in Note 1A, “Amendment to Previously Reported Quarterly Financial Statements” to our consolidated financial statements included in Part I, Item 1 of this report. For the convenience of the reader, this Form 10-Q/A sets forth the Original Filings in their entirety. However, this Form 10-Q/A only amends and restates Items 1 and 2 of Part I of the Original Filing, in each case, solely as a result of, and to reflect, the restatement, and no other information in the Original Filing is amended hereby. The foregoing items have not been updated to reflect other events occurring after the Original Filings or to modify or update those disclosures affected by subsequent events. In addition, pursuant to the rules of the SEC, Item 6 of Part II of the Original Filings has been amended to contain currently dated certifications from the Company’s Chief Executive Officer and Chief Financial Officer, as required by Sections 302 and 906 of the Sarbanes-Oxley Act of 2002, and are attached as Exhibits 31.1 and 32.1 to this report. We have also updated our financial statements formatted in Extensible Business Reporting Language (XBRL) in Exhibits 101. Except for the foregoing amended information, this Form 10-Q/A continues to speak as of the dates of the Original Filings, and the Company has not updated the disclosures contained herein to reflect events that occurred at a later date. Other events occurring after the filings of the Original Filings or other disclosures necessary to reflect subsequent events will be addressed in any reports filed with the SEC subsequent to the date of this filing.
Document Period End Date	Jun. 30, 2015
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	Q2
Trading Symbol	TPIV
Entity Registrant Name	TAPIMMUNE INC
Entity Central Index Key	0001094038
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		46,140,771

XML 11 R2.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)	Jun. 30, 2015	Dec. 31, 2014	Jun. 30, 2014	Dec. 31, 2013
Current Assets
Cash	$ 3,105,320	$ 141,944	$ 20,647	$ 48,589
Prepaid expenses and deposits	142,590	82,504
Total Current Assets	3,247,910	224,448
Current Liabilities
Accounts payable and accrued liabilities	842,682	693,362
Research agreement obligations	492,365	492,365
Derivative liability - warrants	69,962,000	9,415
Promissory notes	52,942	52,942
Total Current Liabilities	$ 71,349,989	$ 1,248,084
Stockholders' Equity (Deficit)
Convertible preferred stock, $0.001 par value - 10,000,000 shares authorized:
Common stock, $0.001 par value, 500,000,000 shares authorized 38,038,921 shares issued and outstanding (2014 - 20,318,815)	$ 38,039	$ 20,319
Additional paid-in capital	92,218,937	85,265,776
Accumulated deficit	(160,359,055)	(86,309,731)
Total Stockholders' Deficit	(68,102,079)	(1,023,636)
Total LIABILITIES AND STOCKHOLDERS' DEFICIT	$ 3,247,910	$ 224,448
Series A
Stockholders' Equity (Deficit)
Convertible preferred stock, $0.001 par value - 10,000,000 shares authorized:
Series B
Stockholders' Equity (Deficit)
Convertible preferred stock, $0.001 par value - 10,000,000 shares authorized:

XML 12 R3.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($)	Jun. 30, 2015	Dec. 31, 2014
Preferred stock par value	$ 0.001	$ 0.001
Convertible preferred stock	$ 10,000,000	$ 10,000,000
Common stock par value	$ 0.001	$ 0.001
Common stock shares authorized	500,000,000	500,000,000
Common stock shares issued	38,038,921	20,318,815
Common stock shares outstanding	38,038,921	20,318,815
Series A
Preferred stock par value	$ 0.001	$ 0.001
Preferred stock shares designated	1,250,000	1,250,000
Preferred stock issued	0	0
Preferred stock outstanding	0	0
Series B
Preferred stock par value	$ 0.001	$ 0.001
Preferred stock shares designated	1,500,000	1,500,000
Preferred stock issued	0	0
Preferred stock outstanding	0	0

XML 13 R4.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Operating expenses:
General and administrative	$ 936,887	$ 488,427	$ 1,355,673	$ 1,687,794
Research and development	201,157	22,500	810,535	45,000
Loss from Operations	(1,138,044)	(510,927)	(2,166,208)	(1,732,794)
Other Income (Expense)
Accretion of interest on convertible debt	0	(8,660)	0	(492,296)
Changes in fair value of derivative liabilities	(59,079,025)	352,834	(58,751,585)	14,537
Foreign exchange	775	0	775	0
Gain (loss) on settlement of debt	0	920,233	0	(26,743,197)
Net Income (Loss) for the Period	(60,216,294)	753,480	(60,917,018)	(28,953,750)
Other comprehensive income (loss)
Foreign exchange translation adjustment	0	1,042	0	(207)
TOTAL COMPREHENSIVE INCOME (LOSS)	$ (60,216,294)	$ 754,522	$ (60,917,018)	$ (28,953,957)
Basic and Diluted Net Income (Loss) per Share	$ (1.80)	$ 0.05	$ (1.99)	$ (2.57)
Weighted Average Number of Common Shares Outstanding, basic and diluted	33,525,656	15,523,016	30,584,794	11,250,240

XML 14 R5.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (DEFICIT) AS RESTATED - 6 months ended Jun. 30, 2015 - USD ($)	Total	Common Stock	Additional Paid-In Capital	Accumulated Deficit
Balance, Shares at Dec. 31, 2014		20,318,816
Balance Amount at Dec. 31, 2014	$ (1,023,636)	$ 20,319	$ 85,265,776	$ (86,309,731)
Private placement, Share		12,319,995
Private placement, Amount	2,326,014	$ 12,320	2,313,694
Fair value of warrants recognized as derivative liabilities in January and March 2015 Financing	(9,313,000)		(2,313,694)	(6,999,306)
Fair value of warrants issued on May 28, 2015	(6,133,000)			(6,133,000)
Exercise of warrants, Share		5,000,000
Exercise of warrants, Amount	2,500,000	$ 5,000	2,495,000
Reclassification of derivative warrant liabilities to equity at exercise date	4,245,000		4,245,000
Finders' fee on exercise of warrants	(35,000)		(35,000)
Stock- based compensation, Share		400,110
Stock- based compensation, Amount	248,561	$ 400	248,161
Net loss	(60,917,018)			(60,917,018)
Balance Amount at Jun. 30, 2015	$ (68,102,079)	$ 38,039	$ 92,218,937	$ (160,359,055)
Balance, Shares at Jun. 30, 2015		38,038,921

XML 15 R6.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (DEFICIT) AS RESTATED (Parenthetical)	6 Months Ended
	Jun. 30, 2015 USD ($)
Statement of Stockholders' Equity [Abstract]
Net of finders' fee	$ 140,000

XML 16 R7.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$ (60,917,018)	$ (28,953,750)
Adjustments to reconcile net loss to net cash from operating activities:
Changes in fair value of derivative liabilities	58,751,585	(14,537)
Loss on extinguishment of debt		26,743,197
Non-cash interest and finance charges	0	492,296
Stock based compensation	248,561	799,075
Changes in operating assets and liabilities:
Prepaid expenses	(60,086)
Accounts payable and accrued liabilities	149,320	322,277
NET CASH USED IN OPERATING ACTIVITIES	(1,827,638)	(611,442)
CASH FLOWS FROM FINANCING ACTIVITIES
Issuance of shares, net of issuance costs of $173,000	2,326,014	583,000
Proceeds from loans payable		500
Proceeds from exercise of warrants	2,500,000
Finders' fee on exercise of warrants	(35,000)
NET CASH PROVIDED BY FINANCING ACTIVITIES	4,791,014	583,500
INCREASE (DECREASE) IN CASH	2,963,376	(27,942)
CASH, BEGINNING OF PERIOD	141,944	48,589
CASH, END OF PERIOD	3,105,320	20,647
SUPPLEMENTAL SCHEDULE OF NON-CASH ACTIVITIES
Accounts payable settled in common stock	231,000	683,000
Fair value of issuance of warrants in January and March 2015 financing	9,313,000
Issuance of additional warrants in May 28, 2015 transaction	6,133,000
Reclassification of derivative warrant liabilities to equity at exercise date	$ 4,245,000
Conversion of debt obligations into common stock:
Accrued interest		476,000
Convertible notes payable		3,797,000
Loans payable, related party		42,000
Promissory notes, related party		210,000
Due to related parties		369,000
Fair value derivative liability - conversion option at conversion		$ 708,000

XML 17 R8.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical)	6 Months Ended
	Jun. 30, 2015 USD ($)
Statement of Cash Flows [Abstract]
Issuance costs	$ 173,000

XML 18 R9.htm IDEA: XBRL DOCUMENT

NATURE OF OPERATIONS	6 Months Ended
NATURE OF OPERATIONS	Jun. 30, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
NATURE OF OPERATIONS	NOTE 1: NATURE OF OPERATIONS TapImmune Inc. (the “Company”), a Nevada corporation incorporated in 1992, is a biotechnology Company focusing on immunotherapy specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of oncology and infectious disease. Unlike other vaccine technologies that narrowly address the initiation of an immune response, TapImmune’s approach broadly stimulates the cellular immune system by enhancing the function of killer T-cells and T-helper cells and by restoring antigen presentation in tumor cells allowing their recognition and killing by the immune system.

XML 19 R10.htm IDEA: XBRL DOCUMENT

AMENDMENT TO PREVIOUSLY REPORTED QUARTERLY FINANCIAL STATEMENTS

6 Months Ended

Jun. 30, 2015

Organization, Consolidation and Presentation of Financial Statements [Abstract]

AMENDMENT TO PREVIOUSLY REPORTED QUARTERLY FINANCIAL STATEMENTS

NOTE 1A: AMENDMENT TO PREVIOUSLY REPORTED QUARTERLY FINANCIAL STATEMENTS

The following table summarizes the effect of the restatement on the consolidated statement of operations for the three and six months ended June 30, 2015:

TAPIMMUNE INC.

CONDENSED CONSOLIDATED BALANCE SHEETS


	June 30, 2015 (Unaudited)
	As Previously Reported			Adjustments			As Restated
ASSETS
Current Assets
Cash		3,105,320			—			3,105,320
Prepaid expenses and deposits		142,590			—			142,590

		3,247,910			—			3,247,910


LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT)
Current Liabilities
Accounts payable and accrued liabilities		842,682			—			842,682
Research agreement obligations		492,365			—			492,365
Derivative liability – warrants		11,673,347			58,288,653			69,962,000
Promissory notes		52,942			—			52,942

		13,061,336			58,288,653			71,349,989

COMMITMENTS AND CONTINGENCIES
Stockholders’ Equity (Deficit)
Convertible preferred stock, $0.001 par value — 10,000,000 shares authorized:
Series A, $0.001 par value, 1,250,000 shares designated, -0- shares issued and outstanding as of March 31, 2015 and December 31, 2014		—			—			—
Series B, $0.001 par value, 1,500,000 shares designated, -0- shares issued and outstanding as of March 31, 2015 and December 31, 2014		—			—			—
Common stock, $0.001 par value, 500,000,000 shares authorized 32,638,811 shares issued and outstanding (2014 – 20,318,815)		38,039			—			38,039
Additional paid-in capital		95,885,631			(3,666,694	)		92,218,937
Accumulated deficit		(105,737,096	)		(54,621,959	)		(160,359,055	)

		(9,813,426	)		(58,288,653	)		(68,102,079	)

		3,247,910			—			3,247,910

TAPIMMUNE INC.

CONDENSED CONSOLIDATED STATEMENTS OF

OPERATIONS AND COMPREHENSIVE LOSS

(UNAUDITED)


	Three Months Ended June 30, 2015
	As Previously Reported			Adjustments			As Restated
Operating expenses:
General and administrative		936,887			—			936,887
Research and development		201,157			—			201,157

Loss from Operations		(1,138,044	)		—			(1,138,044	)
Other Income (Expense)
Changes in fair value of derivative liabilities		(9,052,372	)		(50,026,653	)		(59,079,025	)
Foreign exchange		775			—			775
Inducement expense		(8,256,000	)		8,256,000			-

Net Loss for the Period		(18,445,641	)		(41,770,653	)		(60,216,294	)

Other comprehensive income
Foreign exchange translation adjustment		—			—			—

TOTAL COMPREHENSIVE LOSS		(18,445,641	)		(41,770,653	)		(60,216,294	)

Basic and Diluted Net Loss per Share		(0.55	)		(1.25	)		(1.80	)

Weighted Average Number of Common Shares Outstanding		33,525,656			33,525,656			33,525,656

TAPIMMUNE INC.

CONDENSED CONSOLIDATED STATEMENTS OF

OPERATIONS AND COMPREHENSIVE LOSS

(UNAUDITED)


	Six Months Ended June 30, 2015
	As Previously Reported			Adjustments			As Restated
Operating expenses:
General and administrative		1,355,673			—			1,355,673
Research and development		810,535			—			810,535

Loss from Operations		(2,166,208	)		—			(2,166,208	)
Other Income (Expense)
Changes in fair value of derivative liabilities		(9,005,932	)		(49,745,653	)		(58,751,585	)
Foreign exchange		775			—			775
Inducement expense		(8,256,000	)		8,256,000			—

Net Loss for the Period		(19,427,365	)		(41,489,653	)		(60,917,018	)
Other comprehensive income
Foreign exchange translation adjustment		—			—			—

TOTAL COMPREHENSIVE LOSS		(19,427,365	)		(41,489,653	)		(60,917,018	)

Basic and Diluted Net Loss per Share		(0.64	)		(1.36	)		(1.99	)

Weighted Average Number of Common Shares Outstanding		30,584,794			30,584,794			30,584,794

TAPIMMUNE INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)


	Six Months Ended June 30, 2015
	As Previously Reported			Adjustments			As Restated
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss		(19,427,365	)		(41,489,653	)		(60,917,018	)
Adjustments to reconcile net loss to net cash from operating activities:
Changes in fair value of derivative liabilities		9,005,932			49,745,653			58,751,585
Inducement expense		8,256,000			(8,256,000	)		—
Non-cash interest and finance charges		—			—			—
Stock based compensation		248,561			—			248,561
Changes in operating assets and liabilities:
Prepaid expenses		(60,086	)		—			(60,086	)
Accounts payable and accrued liabilities		149,320			—			149,320

NET CASH USED IN OPERATING ACTIVITIES		(1,827,638	)		—			(1,827,638	)

CASH FLOWS FROM FINANCING ACTIVITIES
Issuance of shares, net of issuance costs of $173,000		2,291,014			35,000			2,326,014
Proceeds from exercise of warrants		2,500,000						2,500,000
Finders’ fee on exercise of warrants		—			(35,000	)		(35,000	)

NET CASH PROVIDED BY FINANCING ACTIVITIES		4,791,014			—			4,791,014

INCREASE IN CASH		2,963,376			—			2,963,376
CASH, BEGINNING OF PERIOD		141,944			—			141,944

CASH, END OF PERIOD		3,105,320			—			3,105,320

XML 20 R11.htm IDEA: XBRL DOCUMENT

BASIS OF PRESENTATION	6 Months Ended
BASIS OF PRESENTATION	Jun. 30, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
BASIS OF PRESENTATION	NOTE 2: BASIS OF PRESENTATION The accompanying unaudited condensed financial statements have been prepared in accordance with the accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and pursuant to the instructions to Form 10-Q and Article 8 of Regulation S-X of the Securities and Exchange Commission (“SEC”) and on the same basis as the Company prepares its annual audited consolidated financial statements. The condensed consolidated balance sheet as of June 30, 2015, condensed consolidated statements of interim financials include all adjustments, consisting only of normal recurring adjustments, which the Company considers necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented. The results for the statement of operations are not necessarily indicative of results to be expected for the year ending December 31, 2015 or for any future interim period. The condensed balance sheet at December 31, 2014 has been derived from audited financial statements; however, it does not include all of the information and notes required by U.S. GAAP for complete financial statements. The accompanying condensed financial statements should be read in conjunction with the consolidated financial statements for the year ended December 31, 2014, and notes thereto included in the Company’s annual report on Form 10-K.

XML 21 R12.htm IDEA: XBRL DOCUMENT

LIQUIDITY AND FINANCIAL CONDITION	6 Months Ended
LIQUIDITY AND FINANCIAL CONDITION	Jun. 30, 2015
Text Block [Abstract]
LIQUIDITY AND FINANCIAL CONDITION	NOTE 3: LIQUIDITY AND FINANCIAL CONDITION The Company’s activities since inception have consisted principally of acquiring product and technology rights, raising capital, and performing research and development. Successful completion of the Company’s development programs and, ultimately, the attainment of profitable operations are dependent on future events, including, among other things, its ability to access potential markets; secure financing, develop a customer base; attract, retain and motivate qualified personnel; and develop strategic alliances. From inception, the Company has been funded by a combination of equity and debt financings. The Company expects to continue to incur substantial losses over the next several years during its development phase. To fully execute its business plan, the Company will need to complete certain research and development activities and clinical studies. Further, the Company’s product candidates will require regulatory approval prior to commercialization. These activities may span many years and require substantial expenditures to complete and may ultimately be unsuccessful. Any delays in completing these activities could adversely impact the Company. The Company plans to meet its capital requirements primarily through issuances of debt and equity securities and, in the longer term, revenue from product sales. As of June 30, 2015, the Company had cash and cash equivalents of approximately $3,105,000. Historically, the Company has net losses and negative cash flows from operations. The Company believes its current capital resources are not sufficient to support its operations. Management intends to continue its research efforts and to finance operations of the Company through debt and/or equity financings. Management plans to seek additional debt and/or equity financing through private or public offerings or through a business combination or strategic partnership. There can be no assurance that the Company will be successful in obtaining additional financing on favorable terms, or at all. These matters raise substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of these uncertainties.

XML 22 R13.htm IDEA: XBRL DOCUMENT

SIGNIFICANT ACCOUNTING POLICIES	6 Months Ended
SIGNIFICANT ACCOUNTING POLICIES	Jun. 30, 2015
Accounting Policies [Abstract]
SIGNIFICANT ACCOUNTING POLICIES	NOTE 4: SIGNIFICANT ACCOUNTING POLICIES There have been no material changes in the Company’s significant accounting policies to those previously disclosed in the Company’s annual report on Form 10-K, which was filed with the SEC on April 15, 2015. *Prior Period Reclassifications* The expense categories of the comparable prior period have been reclassified for comparability with the June 30, 2015 presentation. These reclassifications had no effect on previously reported net loss.

XML 23 R14.htm IDEA: XBRL DOCUMENT

POTENTIALLY DILUTIVE SECURITIES

6 Months Ended

Jun. 30, 2015

Text Block [Abstract]

POTENTIALLY DILUTIVE SECURITIES

NOTE 5: POTENTIALLY DILUTIVE SECURITIES

Options, warrants, and convertible debt outstanding were all considered anti-dilutive for the six months ended June 30, 2015 and 2014, due to net losses.

The following securities were not included in the diluted net loss per share calculation because their effect was anti-dilutive as of the periods presented:


	June 30,
	2015		2014
Common stock options		465,000		65,000
Common stock warrants - equity treatment		2,556,000		185,000
Common stock warrants - liability treatment		81,834,000		49,000
Convertible notes		—		7,000

Potentially dilutive securities		84,855,000		306,000

XML 24 R15.htm IDEA: XBRL DOCUMENT

DERIVATIVE LIABILITY - WARRANTS AND DERIVATIVE LIABILITY - CONVERSION OPTION

6 Months Ended

Jun. 30, 2015

Text Block [Abstract]

DERIVATIVE LIABILITY - WARRANTS AND DERIVATIVE LIABILITY - CONVERSION OPTION

NOTE 6: DERIVATIVE LIABILITY - WARRANTS AND DERIVATIVE LIABILITY – CONVERSION OPTION, AS RESTATED


Share Purchase Warrants	Weighted Average Inputs for the Period
Date of valuation	For the Six Months Ending June 30, 2015			For the Six Months Ending June 30, 2014
Fair market value of stock	$	0.96		$	0.02
Strike price	$	0.50		$	5.84
Volatility (annual)		148.00	%		159.00	%
Risk-free rate		1.1	%		1.08	%
Contractual term (years)		3.2			3.58
Dividend yield (per share)		0	%		0	%

Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis

Financial assets and liabilities measured at fair value on a recurring basis are summarized below and disclosed on the balance sheet under Derivative liability – warrants:


	As of June 30, 2015
	Fair Value Measurements
	Fair Value		Level 1		Level 2		Level 3		Total
Derivative liability - warrants	$	69,962,000		—		—	$	69,962,000	$	69,962,000

Total	$	69,962,000		—		—	$	69,962,000	$	69,962,000


	As of December 31, 2014
	Fair Value Measurements
	Fair Value		Level 1		Level 2		Level 3		Total
Derivative liability - warrants	$	9,000		—		—	$	9,000	$	9,000

Total	$	9,000		—		—	$	9,000	$	9,000

There were no transfers between Level 1, 2 or 3 during the three months ended June 30, 2015.

The following table presents changes in Level 3 liabilities measured at fair value for the six months ended June 30, 2015:


	Derivative liability – warrants
Balance – December 31, 2014	$	9,000
Additions during the period		15,446,000
Exercise of warrants		(4,245,000	)
Change in fair value of warrant liability		58,752,000

Balance – June 30, 2015	$	69,962,000


Conversion Option	Weighted Average Inputs for the Period
Date of valuation	For the Quarter Ending June 30, 2015			For the Quarter Ending June 30, 2014
Strike price	$	—		$	1.03
Volatility (annual)		—	%		199.00	%
Risk-free rate		—	%		0.05	%
Contractual term (years)		—			0.24
Dividend yield (per share)		—	%		—	%

Fair value of Conversion Option at extinguishment	$	—		$	708,000

XML 25 R16.htm IDEA: XBRL DOCUMENT

PROMISSORY NOTE	6 Months Ended
PROMISSORY NOTE	Jun. 30, 2015
Text Block [Abstract]
PROMISSORY NOTE	NOTE 7: PROMISSORY NOTES, RELATED PARTY The Company has outstanding promissory notes in the amount of $52,942 (December 31, 2014 - $52,942), of which $23,000 of promissory notes are from an officer and a director of the Company. The promissory notes bear no interest charges and have no fixed repayment terms.

XML 26 R17.htm IDEA: XBRL DOCUMENT

CAPITAL STOCK

6 Months Ended

Jun. 30, 2015

Text Block [Abstract]

CAPITAL STOCK

NOTE 8: CAPITAL STOCK, AS RESTATED

2015 Share Transactions

Private placements

Pursuant to a placement agent agreement, the Company agreed to issue warrants to purchase 366,000 common shares with substantially the same terms as the January 2015 Warrants.

Pursuant to a placement agent agreement, the Company agreed to issue warrants to purchase 125,000 common shares with substantially the same terms as the March 2015 Warrants.

Initial Fair Value of Warrants Issued

May 2015 Restructuring agreement

In May 2015, the Company entered into a restructuring agreement with the investors of the January 2015 and March 2015 private placements, where:

•

The exercise price of the Series A warrants was changed from $1.50 per warrant to $0.10 per warrant,

•

The exercise price of Series B warrants was changed from $0.40 per warrant to $0.20 per warrant,

•

Each warrant of Series B existing prior to the restructuring agreement was replaced with two warrants of such series,

•

The exercise price of the Series C warrants was changed from $1.00 per warrant to $0.50 per warrant, and

•

Each warrant of Series C existing prior to the restructuring agreement was replaced with two warrants of such series.

The weighted average inputs include contractual term of 2.46 years, volatility of 141% and risk free rate of 1.5%.

Share Purchase Warrants

During the six months ended June 30, 2015, a warrant holder exercised 5,000,000 of Series C warrants at $0.50 per warrant for a total of $2,500,000.

A summary of the Company’s share purchase warrants as of June 30, 2015 and changes during the period is presented below:


	Number of Warrants			Weighted Average Exercise Price		Weighted Average Remaining Life
Balance, December 31, 2014		2,659,417			1.83		4.15
Issued		86,730,975			0.54		3.25
Exercised		(5,000,000	)		0.50		—
Extinguished or expired		(7,500	)		50.00		—

Balance, June 30, 2015		84,382,892		$	0.54		3.26

Stock Compensation Plan

Share purchase options

A summary of the Company’s stock options as of June 30, 2015 and changes during the period is presented below:


	Number of Options		Weighted Average Exercise Price		Weighted Average Remaining Life
Balance, December 31, 2013		65,430		18.00		5.04
Issued		—		—		—
Cancelled/Forfeited		—		—		—

Balance, December 31, 2014		65,430		18.00		4.04


	Number of Options		Weighted Average Exercise Price		Weighted Average Remaining Life
Issued		400,000		0.17		4.64

Balance, June 30, 2015		465,430	$	2.62		4.49

At June 30, 2015, the intrinsic value of the vested options was equal to $66,000 (2014 - $nil).

A summary of the status of the Company’s unvested options as of June 30, 2015 is presented below:


	Number of Shares			Weighted Average Grant-Date Fair Value
Unvested, December 31, 2014		278		$	18.00
Granted		400,000			0.16
Vested		(82,685	)		0.21
Cancelled		—			—

Unvested, June 30, 2015		317,593		$	0.16

XML 27 R18.htm IDEA: XBRL DOCUMENT

SUBSEQUENT EVENTS

6 Months Ended

Jun. 30, 2015

Subsequent Events [Abstract]

SUBSEQUENT EVENTS

NOTE 9: SUBSEQUENT EVENTS

On August 10, 2015, the Company issued 50,000 shares of common stock as full settlement of a dispute with a marketing consultant that provided services to the Company in 2014 and 2015.

XML 28 R19.htm IDEA: XBRL DOCUMENT

SIGNIFICANT ACCOUNTING POLICIES (Policies)	6 Months Ended
SIGNIFICANT ACCOUNTING POLICIES (Policies)	Jun. 30, 2015
Accounting Policies [Abstract]
Prior Period Reclassifications	*Prior Period Reclassifications* The expense categories of the comparable prior period have been reclassified for comparability with the June 30, 2015 presentation. These reclassifications had no effect on previously reported net loss.

XML 29 R20.htm IDEA: XBRL DOCUMENT

AMENDMENT TO PREVIOUSLY REPORTED QUARTERLY FINANCIAL STATEMENTS (Tables)

6 Months Ended

Jun. 30, 2015

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Restatemnet of The Company's Consolidated Statements

The following table summarizes the effect of the restatement on the consolidated statement of operations for the three and six months ended June 30, 2015:

TAPIMMUNE INC.

CONDENSED CONSOLIDATED BALANCE SHEETS


	June 30, 2015 (Unaudited)
	As Previously Reported			Adjustments			As Restated
ASSETS
Current Assets
Cash		3,105,320			—			3,105,320
Prepaid expenses and deposits		142,590			—			142,590

		3,247,910			—			3,247,910


LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT)
Current Liabilities
Accounts payable and accrued liabilities		842,682			—			842,682
Research agreement obligations		492,365			—			492,365
Derivative liability – warrants		11,673,347			58,288,653			69,962,000
Promissory notes		52,942			—			52,942

		13,061,336			58,288,653			71,349,989

COMMITMENTS AND CONTINGENCIES
Stockholders’ Equity (Deficit)
Convertible preferred stock, $0.001 par value — 10,000,000 shares authorized:
Series A, $0.001 par value, 1,250,000 shares designated, -0- shares issued and outstanding as of March 31, 2015 and December 31, 2014		—			—			—
Series B, $0.001 par value, 1,500,000 shares designated, -0- shares issued and outstanding as of March 31, 2015 and December 31, 2014		—			—			—
Common stock, $0.001 par value, 500,000,000 shares authorized 32,638,811 shares issued and outstanding (2014 – 20,318,815)		38,039			—			38,039
Additional paid-in capital		95,885,631			(3,666,694	)		92,218,937
Accumulated deficit		(105,737,096	)		(54,621,959	)		(160,359,055	)

		(9,813,426	)		(58,288,653	)		(68,102,079	)

		3,247,910			—			3,247,910

TAPIMMUNE INC.

CONDENSED CONSOLIDATED STATEMENTS OF

OPERATIONS AND COMPREHENSIVE LOSS

(UNAUDITED)


	Three Months Ended June 30, 2015
	As Previously Reported			Adjustments			As Restated
Operating expenses:
General and administrative		936,887			—			936,887
Research and development		201,157			—			201,157

Loss from Operations		(1,138,044	)		—			(1,138,044	)
Other Income (Expense)
Changes in fair value of derivative liabilities		(9,052,372	)		(50,026,653	)		(59,079,025	)
Foreign exchange		775			—			775
Inducement expense		(8,256,000	)		8,256,000			-

Net Loss for the Period		(18,445,641	)		(41,770,653	)		(60,216,294	)

Other comprehensive income
Foreign exchange translation adjustment		—			—			—

TOTAL COMPREHENSIVE LOSS		(18,445,641	)		(41,770,653	)		(60,216,294	)

Basic and Diluted Net Loss per Share		(0.55	)		(1.25	)		(1.80	)

Weighted Average Number of Common Shares Outstanding		33,525,656			33,525,656			33,525,656

TAPIMMUNE INC.

CONDENSED CONSOLIDATED STATEMENTS OF

OPERATIONS AND COMPREHENSIVE LOSS

(UNAUDITED)


	Six Months Ended June 30, 2015
	As Previously Reported			Adjustments			As Restated
Operating expenses:
General and administrative		1,355,673			—			1,355,673
Research and development		810,535			—			810,535

Loss from Operations		(2,166,208	)		—			(2,166,208	)
Other Income (Expense)
Changes in fair value of derivative liabilities		(9,005,932	)		(49,745,653	)		(58,751,585	)
Foreign exchange		775			—			775
Inducement expense		(8,256,000	)		8,256,000			—

Net Loss for the Period		(19,427,365	)		(41,489,653	)		(60,917,018	)
Other comprehensive income
Foreign exchange translation adjustment		—			—			—

TOTAL COMPREHENSIVE LOSS		(19,427,365	)		(41,489,653	)		(60,917,018	)

Basic and Diluted Net Loss per Share		(0.64	)		(1.36	)		(1.99	)

Weighted Average Number of Common Shares Outstanding		30,584,794			30,584,794			30,584,794

TAPIMMUNE INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)


	Six Months Ended June 30, 2015
	As Previously Reported			Adjustments			As Restated
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss		(19,427,365	)		(41,489,653	)		(60,917,018	)
Adjustments to reconcile net loss to net cash from operating activities:
Changes in fair value of derivative liabilities		9,005,932			49,745,653			58,751,585
Inducement expense		8,256,000			(8,256,000	)		—
Non-cash interest and finance charges		—			—			—
Stock based compensation		248,561			—			248,561
Changes in operating assets and liabilities:
Prepaid expenses		(60,086	)		—			(60,086	)
Accounts payable and accrued liabilities		149,320			—			149,320

NET CASH USED IN OPERATING ACTIVITIES		(1,827,638	)		—			(1,827,638	)

CASH FLOWS FROM FINANCING ACTIVITIES
Issuance of shares, net of issuance costs of $173,000		2,291,014			35,000			2,326,014
Proceeds from exercise of warrants		2,500,000						2,500,000
Finders’ fee on exercise of warrants		—			(35,000	)		(35,000	)

NET CASH PROVIDED BY FINANCING ACTIVITIES		4,791,014			—			4,791,014

INCREASE IN CASH		2,963,376			—			2,963,376
CASH, BEGINNING OF PERIOD		141,944			—			141,944

CASH, END OF PERIOD		3,105,320			—			3,105,320

XML 30 R21.htm IDEA: XBRL DOCUMENT

POTENTIALLY DILUTIVE SECURITIES (Tables)

6 Months Ended

Jun. 30, 2015

Text Block [Abstract]

Securities not Included in Diluted Net Loss Per Share Calculation

The following securities were not included in the diluted net loss per share calculation because their effect was anti-dilutive as of the periods presented:


	June 30,
	2015		2014
Common stock options		465,000		65,000
Common stock warrants - equity treatment		2,556,000		185,000
Common stock warrants - liability treatment		81,834,000		49,000
Convertible notes		—		7,000

Potentially dilutive securities		84,855,000		306,000

XML 31 R22.htm IDEA: XBRL DOCUMENT

DERIVATIVE LIABILITY - WARRANTS AND DERIVATIVE LIABILITY - CONVERSION OPTION (Tables)

6 Months Ended

Jun. 30, 2015

Text Block [Abstract]

Valuation methodology


Share Purchase Warrants	Weighted Average Inputs for the Period
Date of valuation	For the Six Months Ending June 30, 2015			For the Six Months Ending June 30, 2014
Fair market value of stock	$	0.96		$	0.02
Strike price	$	0.50		$	5.84
Volatility (annual)		148.00	%		159.00	%
Risk-free rate		1.1	%		1.08	%
Contractual term (years)		3.2			3.58
Dividend yield (per share)		0	%		0	%

Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis

Financial assets and liabilities measured at fair value on a recurring basis are summarized below and disclosed on the balance sheet under Derivative liability – warrants:


	As of June 30, 2015
	Fair Value Measurements
	Fair Value		Level 1		Level 2		Level 3		Total
Derivative liability - warrants	$	69,962,000		—		—	$	69,962,000	$	69,962,000

Total	$	69,962,000		—		—	$	69,962,000	$	69,962,000


	As of December 31, 2014
	Fair Value Measurements
	Fair Value		Level 1		Level 2		Level 3		Total
Derivative liability - warrants	$	9,000		—		—	$	9,000	$	9,000

Total	$	9,000		—		—	$	9,000	$	9,000

Measured at fair value

The following table presents changes in Level 3 liabilities measured at fair value for the six months ended June 30, 2015:


	Derivative liability – warrants
Balance – December 31, 2014	$	9,000
Additions during the period		15,446,000
Exercise of warrants		(4,245,000	)
Change in fair value of warrant liability		58,752,000

Balance – June 30, 2015	$	69,962,000

Numerous extinguishment agreements

The inputs utilized in the final mark to market were as follows:


Conversion Option	Weighted Average Inputs for the Period
Date of valuation	For the Quarter Ending June 30, 2015			For the Quarter Ending June 30, 2014
Strike price	$	—		$	1.03
Volatility (annual)		—	%		199.00	%
Risk-free rate		—	%		0.05	%
Contractual term (years)		—			0.24
Dividend yield (per share)		—	%		—	%

Fair value of Conversion Option at extinguishment	$	—		$	708,000

XML 32 R23.htm IDEA: XBRL DOCUMENT

CAPITAL STOCK (Tables)

6 Months Ended

Jun. 30, 2015

Text Block [Abstract]

Share Purchase Warrants

A summary of the Company’s share purchase warrants as of June 30, 2015 and changes during the period is presented below:


	Number of Warrants			Weighted Average Exercise Price		Weighted Average Remaining Life
Balance, December 31, 2014		2,659,417			1.83		4.15
Issued		86,730,975			0.54		3.25
Exercised		(5,000,000	)		0.50		—
Extinguished or expired		(7,500	)		50.00		—

Balance, June 30, 2015		84,382,892		$	0.54		3.26

Share purchase options

A summary of the Company’s stock options as of June 30, 2015 and changes during the period is presented below:


	Number of Options		Weighted Average Exercise Price		Weighted Average Remaining Life
Balance, December 31, 2013		65,430		18.00		5.04
Issued		—		—		—
Cancelled/Forfeited		—		—		—

Balance, December 31, 2014		65,430		18.00		4.04


	Number of Options		Weighted Average Exercise Price		Weighted Average Remaining Life
Issued		400,000		0.17		4.64

Balance, June 30, 2015		465,430	$	2.62		4.49

Share purchase options

A summary of the status of the Company’s unvested options as of June 30, 2015 is presented below:


	Number of Shares			Weighted Average Grant-Date Fair Value
Unvested, December 31, 2014		278		$	18.00
Granted		400,000			0.16
Vested		(82,685	)		0.21
Cancelled		—			—

Unvested, June 30, 2015		317,593		$	0.16

- Definition

Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.

+ References + Details

XML 33 R24.htm IDEA: XBRL DOCUMENT

Amendment to Previously Reported Quarterly Financial Statements - Additional Information (Detail) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net Loss for the Period	$ (60,216,294)	$ 753,480	$ (60,917,018)	$ (28,953,750)
As Previously Reported [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net Loss for the Period	(18,445,641)		(19,427,365)
Adjustments [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net Loss for the Period	$ (41,770,653)		$ (41,489,653)

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

XML 34 R25.htm IDEA: XBRL DOCUMENT

Restatement of Condensed Consolidated Balance Sheets (Unaudited) (Detail) - USD ($)	Jun. 30, 2015	Dec. 31, 2014	Jun. 30, 2014	Dec. 31, 2013
Current Assets
Cash	$ 3,105,320	$ 141,944	$ 20,647	$ 48,589
Prepaid expenses and deposits	142,590	82,504
Total Assets	3,247,910	224,448
Current Liabilities
Accounts payable and accrued liabilities	842,682	693,362
Research agreement obligations	492,365	492,365
Derivative liability - warrants	69,962,000	9,415
Promissory notes	52,942	52,942
Total Current Liabilities	$ 71,349,989	$ 1,248,084
COMMITMENTS AND CONTINGENCIES
Stockholders' Equity (Deficit)
Convertible preferred stock, $0.001 par value - 10,000,000 shares authorized:
Common stock, $0.001 par value, 500,000,000 shares authorized 32,638,811 shares issued and outstanding (2014 - 20,318,815)	$ 38,039	$ 20,319
Additional paid-in capital	92,218,937	85,265,776
Accumulated deficit	(160,359,055)	(86,309,731)
Total Stockholders' Deficit	(68,102,079)	(1,023,636)
Total LIABILITIES AND STOCKHOLDERS' DEFICIT	$ 3,247,910	$ 224,448
Series A
Stockholders' Equity (Deficit)
Convertible preferred stock, $0.001 par value - 10,000,000 shares authorized:
Series B
Stockholders' Equity (Deficit)
Convertible preferred stock, $0.001 par value - 10,000,000 shares authorized:
As Previously Reported [Member]
Current Assets
Cash	$ 3,105,320	$ 141,944
Prepaid expenses and deposits	142,590
Total Assets	3,247,910
Current Liabilities
Accounts payable and accrued liabilities	842,682
Research agreement obligations	492,365
Derivative liability - warrants	11,673,347
Promissory notes	52,942
Total Current Liabilities	$ 13,061,336
COMMITMENTS AND CONTINGENCIES
Stockholders' Equity (Deficit)
Convertible preferred stock, $0.001 par value - 10,000,000 shares authorized:
Common stock, $0.001 par value, 500,000,000 shares authorized 32,638,811 shares issued and outstanding (2014 - 20,318,815)	$ 38,039
Additional paid-in capital	95,885,631
Accumulated deficit	(105,737,096)
Total Stockholders' Deficit	(9,813,426)
Total LIABILITIES AND STOCKHOLDERS' DEFICIT	$ 3,247,910
As Previously Reported [Member] \| Series A
Stockholders' Equity (Deficit)
Convertible preferred stock, $0.001 par value - 10,000,000 shares authorized:
As Previously Reported [Member] \| Series B
Stockholders' Equity (Deficit)
Convertible preferred stock, $0.001 par value - 10,000,000 shares authorized:
Adjustments [Member]
Current Liabilities
Derivative liability - warrants	$ 58,288,653
Total Current Liabilities	$ 58,288,653
COMMITMENTS AND CONTINGENCIES
Stockholders' Equity (Deficit)
Convertible preferred stock, $0.001 par value - 10,000,000 shares authorized:
Additional paid-in capital	$ (3,666,694)
Accumulated deficit	(54,621,959)
Total Stockholders' Deficit	$ (58,288,653)
Adjustments [Member] \| Series A
Stockholders' Equity (Deficit)
Convertible preferred stock, $0.001 par value - 10,000,000 shares authorized:
Adjustments [Member] \| Series B
Stockholders' Equity (Deficit)
Convertible preferred stock, $0.001 par value - 10,000,000 shares authorized:

XML 35 R26.htm IDEA: XBRL DOCUMENT

Restatement of Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) (Detail) - $ / shares	Jun. 30, 2015	Dec. 31, 2014
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Preferred stock par value	$ 0.001	$ 0.001
Common stock par value	$ 0.001	$ 0.001
Common stock shares authorized	500,000,000	500,000,000
Common stock shares issued	38,038,921	20,318,815
Common stock shares outstanding	38,038,921	20,318,815
Series A
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Preferred stock par value	$ 0.001	$ 0.001
Convertible preferred stock	1,250,000	1,250,000
Preferred stock issued	0	0
Preferred stock outstanding	0	0
Series B
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Preferred stock par value	$ 0.001	$ 0.001
Convertible preferred stock	1,500,000	1,500,000
Preferred stock issued	0	0
Preferred stock outstanding	0	0
As Previously Reported [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Preferred stock par value	$ 0.001
Convertible preferred stock	10,000,000
Common stock par value	$ 0.001
Common stock shares authorized	500,000,000
Common stock shares issued	32,638,811
Common stock shares outstanding	32,638,811
As Previously Reported [Member] \| Series A
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Preferred stock par value	$ 0.001
Preferred stock shares designated	1,250,000
Preferred stock issued	0
Preferred stock outstanding	0
As Previously Reported [Member] \| Series B
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Preferred stock par value	$ 0.001
Preferred stock shares designated	1,500,000
Preferred stock issued	0
Preferred stock outstanding	0

XML 36 R27.htm IDEA: XBRL DOCUMENT

Restatement of Condensed Consolidated statements of Operation and Comprehensive Loss (Unaudited) (Detail) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Operating expenses:
General and administrative	$ 936,887	$ 488,427	$ 1,355,673	$ 1,687,794
Research and development	201,157	22,500	810,535	45,000
Loss from Operations	(1,138,044)	(510,927)	(2,166,208)	(1,732,794)
Other Income (Expense)
Changes in fair value of derivative liabilities	(59,079,025)	352,834	(58,751,585)	14,537
Foreign exchange	775	0	775	0
Net Income (Loss) for the Period	(60,216,294)	753,480	(60,917,018)	(28,953,750)
Other comprehensive income
Foreign exchange translation adjustment	0	1,042	0	(207)
TOTAL COMPREHENSIVE LOSS	$ (60,216,294)	$ 754,522	$ (60,917,018)	$ (28,953,957)
Basic and Diluted Net Loss per Share	$ (1.80)	$ 0.05	$ (1.99)	$ (2.57)
Weighted Average Number of Common Shares Outstanding	33,525,656	15,523,016	30,584,794	11,250,240
As Previously Reported [Member]
Operating expenses:
General and administrative	$ 936,887		$ 1,355,673
Research and development	201,157		810,535
Loss from Operations	(1,138,044)		(2,166,208)
Other Income (Expense)
Changes in fair value of derivative liabilities	(9,052,372)		(9,005,932)
Foreign exchange	775		775
Inducement expense	(8,256,000)		(8,256,000)
Net Income (Loss) for the Period	(18,445,641)		(19,427,365)
Other comprehensive income
Foreign exchange translation adjustment	0		0
TOTAL COMPREHENSIVE LOSS	$ (18,445,641)		$ (19,427,365)
Basic and Diluted Net Loss per Share	$ (0.55)		$ (0.64)
Weighted Average Number of Common Shares Outstanding	33,525,656		30,584,794
Adjustments [Member]
Other Income (Expense)
Changes in fair value of derivative liabilities	$ (50,026,653)		$ (49,745,653)
Inducement expense	8,256,000		8,256,000
Net Income (Loss) for the Period	(41,770,653)		(41,489,653)
Other comprehensive income
Foreign exchange translation adjustment	0		0
TOTAL COMPREHENSIVE LOSS	$ (41,770,653)		$ (41,489,653)
Basic and Diluted Net Loss per Share	$ (1.25)		$ (1.36)
Weighted Average Number of Common Shares Outstanding	33,525,656		30,584,794

XML 37 R28.htm IDEA: XBRL DOCUMENT

Restatement of Consolidated statements of Cash Flows (Unaudited) (Detail) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$ (60,216,294)	$ 753,480	$ (60,917,018)	$ (28,953,750)
Adjustments to reconcile net loss to net cash from operating activities:
Changes in fair value of derivative liabilities			58,751,585	(14,537)
Non-cash interest and finance charges			0	492,296
Stock based compensation			248,561	799,075
Changes in operating assets and liabilities:
Prepaid expenses			(60,086)
Accounts payable and accrued liabilities			149,320	322,277
NET CASH USED IN OPERATING ACTIVITIES			(1,827,638)	(611,442)
CASH FLOWS FROM FINANCING ACTIVITIES
Issuance of shares, net of issuance costs of $173,000			2,326,014	583,000
Proceeds from exercise of warrants			2,500,000
Finders' fee on exercise of warrants			(35,000)
NET CASH PROVIDED BY FINANCING ACTIVITIES			4,791,014	583,500
INCREASE IN CASH			2,963,376	(27,942)
CASH, BEGINNING OF PERIOD			141,944	48,589
CASH, END OF PERIOD	3,105,320	$ 20,647	3,105,320	$ 20,647
As Previously Reported [Member]
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	(18,445,641)		(19,427,365)
Adjustments to reconcile net loss to net cash from operating activities:
Changes in fair value of derivative liabilities			9,005,932
Inducement expense			8,256,000
Non-cash interest and finance charges			0
Stock based compensation			248,561
Changes in operating assets and liabilities:
Prepaid expenses			(60,086)
Accounts payable and accrued liabilities			149,320
NET CASH USED IN OPERATING ACTIVITIES			(1,827,638)
CASH FLOWS FROM FINANCING ACTIVITIES
Issuance of shares, net of issuance costs of $173,000			2,291,014
Proceeds from exercise of warrants			2,500,000
NET CASH PROVIDED BY FINANCING ACTIVITIES			4,791,014
INCREASE IN CASH			2,963,376
CASH, BEGINNING OF PERIOD			141,944
CASH, END OF PERIOD	3,105,320		3,105,320
Adjustments [Member]
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$ (41,770,653)		(41,489,653)
Adjustments to reconcile net loss to net cash from operating activities:
Changes in fair value of derivative liabilities			49,745,653
Inducement expense			(8,256,000)
Non-cash interest and finance charges			0
CASH FLOWS FROM FINANCING ACTIVITIES
Issuance of shares, net of issuance costs of $173,000			35,000
Finders' fee on exercise of warrants			$ (35,000)

XML 38 R29.htm IDEA: XBRL DOCUMENT

Restatement of Consolidated statements of Cash Flows (Unaudited) (Parenthetical) (Detail)	6 Months Ended
	Jun. 30, 2015 USD ($)
Accounting Changes and Error Corrections [Abstract]
Issuance costs	$ 173,000

XML 39 R30.htm IDEA: XBRL DOCUMENT

LIQUIDITY AND FINANCIAL CONDITION (Narrative) (Detail)	Jun. 30, 2015 USD ($)
Liquidity And Financial Condition Details Narrtive
Cash and cash equivalents	$ 3,105,000

XML 40 R31.htm IDEA: XBRL DOCUMENT

POTENTIALLY DILUTIVE SECURITIES - shares (Detail) - shares	6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Potentially Dilutive Securities Details
Common stock options	465,000	65,000
Common stock warrants - equity treatment	2,556,000	185,000
Common stock warrants - liability treatment	81,834,000	49,000
Convertible notes		7,000
Potentially dilutive securities	84,855,000	306,000

XML 41 R32.htm IDEA: XBRL DOCUMENT

DERIVATIVE LIABILITY - WARRANTS AND DERIVATIVE LIABILITY - CONVERSION OPTION (Detail) - $ / shares	3 Months Ended	6 Months Ended
	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Strike price	$ 1.03
Share Purchase Warrants[Member]
Contractual Life (Years)		3 years 2 months 12 days	3 years 6 months 29 days
Risk free Rate		1.10%	1.08%
Dividend yield		0.00%	0.00%
Volatility		148.00%	159.00%
Strike price		$ 0.50	$ 5.84
Fair market value of stock		$ 0.96	$ 0.02

XML 42 R33.htm IDEA: XBRL DOCUMENT

DERIVATIVE LIABILITY - WARRANTS AND DERIVATIVE LIABILITY - CONVERSION OPTION(1) (Detail) - USD ($)	Jun. 30, 2015	Dec. 31, 2014
Derivative liability - warrants	$ 69,962,000	$ 9,000
Total	69,962,000	9,000
Carrying Value [Member]
Derivative liability - warrants	69,962,000	9,000
Total	$ 69,962,000	$ 9,000
Fair Value, Inputs, Level 1 [Member]
Derivative liability - warrants
Total
Fair Value, Inputs, Level 2 [Member]
Derivative liability - warrants
Total
Fair Value, Inputs, Level 3 [Member]
Derivative liability - warrants	$ 69,962,000	$ 9,000
Total	$ 69,962,000	$ 9,000

XML 43 R34.htm IDEA: XBRL DOCUMENT

DERIVATIVE LIABILITY - WARRANTS AND DERIVATIVE LIABILITY - CONVERSION OPTION(2) (Detail)	6 Months Ended
	Jun. 30, 2015 USD ($)
Notes to Financial Statements
Balance - December 31, 2014	$ 9,000
Additions during the period	15,446,000
Exercise of warrants	(4,245,000)
Change in fair value of warrant liability	58,752,000
Balance - June 30, 2015	$ 69,962,000

XML 44 R35.htm IDEA: XBRL DOCUMENT

DERIVATIVE LIABILITY - WARRANTS AND DERIVATIVE LIABILITY - CONVERSION OPTION(3) (Detail) - USD ($)			3 Months Ended
	Mar. 06, 2015	Feb. 10, 2015	Jun. 30, 2015	Jun. 30, 2014
Notes to Financial Statements
Dividend yield (per share)	0.00%	0.00%	0.00%	0.00%
Strike price				$ 1.03
Volatility (annual)				199.00%
Risk-free rate	1.70%	1.52%		0.05%
Contractual term (years)				2 months 27 days
Fair value of Conversion Option at extinguishment				$ 708,000

XML 45 R36.htm IDEA: XBRL DOCUMENT

PROMISSORY NOTES, RELATED PARTY (Detail) - USD ($)	Jun. 30, 2015	Dec. 31, 2014
Notes to Financial Statements
Outstanding promissory notes		$ 52,942
Promissory notes officer and a director	$ 23,000

XML 46 R37.htm IDEA: XBRL DOCUMENT

Capital Stock - Additional Information (Detail)				1 Months Ended			3 Months Ended		6 Months Ended
Capital Stock - Additional Information (Detail)	May. 31, 2015 $ / shares shares	Mar. 06, 2015 USD ($) $ / shares shares	Feb. 10, 2015 USD ($) $ / shares shares	May. 31, 2015 Warrant $ / shares	Mar. 31, 2015 USD ($) $ / Equity shares	Jan. 31, 2015 USD ($) $ / shares $ / Equity shares	Jun. 30, 2015 USD ($) $ / shares shares	Jun. 30, 2014	Jun. 30, 2015 USD ($) $ / shares shares	Jun. 30, 2014 USD ($)	Oct. 14, 2009 shares
Common Stock Capital Shares Reserved For Future Issuance [Line Items]
Finders fee and issuance costs \| $									$ 35,000
Expected life of stock options		5 years	5 years						4 years 1 month 24 days
Volatility rate of stock options		155.20%	154.60%
Risk free interest rate of stock options		1.70%	1.52%					0.05%
Contractual term									2 years 5 months 16 days
Volatility									141.00%
Risk free Rate									1.50%
Stock options granted		150,000	250,000
Exercise price of stock options \| $ / shares		$ 0.20	$ 0.145
Number of shares, vested	33,333
Stock option vested term			May 31, 2015
Stock options remaining vesting period		24 months	9 months
Term of options		5 years	5 years
Estimated fair value of options granted \| $		$ 29,000	$ 33,000
Estimated fair value of options granted, per share \| $ / shares		$ 0.194	$ 0.133
Dividend yield of stock options		0.00%	0.00%				0.00%	0.00%
Intrinsic value of vested options \| $									$ 66,000	$ 0
Consultant [Member]
Common Stock Capital Shares Reserved For Future Issuance [Line Items]
Stock based compensation \| $									7,635
Management Compensation [Member]
Common Stock Capital Shares Reserved For Future Issuance [Line Items]
Stock based compensation \| $									4,850
Warrant
Common Stock Capital Shares Reserved For Future Issuance [Line Items]
Aggregate purchase price \| $									$ 9,313,000
Expected life of stock options									5 years
Volatility rate of stock options									158.00%
Risk free interest rate of stock options									1.20%
2014 Omnibus Stock Option Plan [Member]
Common Stock Capital Shares Reserved For Future Issuance [Line Items]
Options issued to acquire common shares											10,000,000
Seriesa Warrant [Member]
Common Stock Capital Shares Reserved For Future Issuance [Line Items]
Exercise price of warrants \| $ / shares	$ 0.10			$ 0.10
Seriesa Warrant [Member] \| As Previously Reported [Member]
Common Stock Capital Shares Reserved For Future Issuance [Line Items]
Exercise price of warrants \| $ / shares	1.50			1.50
Series B Warrant [Member]
Common Stock Capital Shares Reserved For Future Issuance [Line Items]
Exercise price of warrants \| $ / shares	0.20			0.20
Number of warrants issued							12,320,000		12,320,000
Series B Warrant [Member] \| As Previously Reported [Member]
Common Stock Capital Shares Reserved For Future Issuance [Line Items]
Exercise price of warrants \| $ / shares	0.40			0.40
Series C Warrant [Member]
Common Stock Capital Shares Reserved For Future Issuance [Line Items]
Exercise price of warrants \| $ / shares	0.50			$ 0.50			$ 0.50		$ 0.50
Replacement of warrants \| Warrant				2
Number of warrants issued							12,320,000		12,320,000
Warrant exercised									5,000,000
Warrant exercised, Value \| $									$ 2,500,000
Series C Warrant [Member] \| As Previously Reported [Member]
Common Stock Capital Shares Reserved For Future Issuance [Line Items]
Exercise price of warrants \| $ / shares	$ 1.00			$ 1.00
Series B And C Warrants [Member]
Common Stock Capital Shares Reserved For Future Issuance [Line Items]
Fair value of warrants \| $							$ 6,133,000		$ 6,133,000
Private Placement [Member]
Common Stock Capital Shares Reserved For Future Issuance [Line Items]
Units issued					5,000,000	7,320,000
Sales price per unit \| $ / Equity					0.20	0.20
Aggregate purchase price \| $					$ 950,000	$ 1,250,000
Finders fee and issuance costs \| $					$ 50,000	$ 214,000
Number of common stock included in equity unit					1	1
Private Placement [Member] \| Seriesa Warrant [Member]
Common Stock Capital Shares Reserved For Future Issuance [Line Items]
Number of securities callable by each warrant or right warrants					1	1
Exercise price of warrants \| $ / shares						$ 1.50
Warrant expiration period						5 years
Private Placement [Member] \| Series B Warrant [Member]
Common Stock Capital Shares Reserved For Future Issuance [Line Items]
Number of securities callable by each warrant or right warrants					1	1
Exercise price of warrants \| $ / shares						$ 0.40
Warrant expiration period						6 months
Private Placement [Member] \| Series C Warrant [Member]
Common Stock Capital Shares Reserved For Future Issuance [Line Items]
Number of securities callable by each warrant or right warrants					1	1
Exercise price of warrants \| $ / shares						$ 1.00
Warrant expiration period						5 years
Private Placement [Member] \| Series D Warrant [Member]
Common Stock Capital Shares Reserved For Future Issuance [Line Items]
Number of securities callable by each warrant or right warrants					1	1
Exercise price of warrants \| $ / shares						$ 0.75
Warrant expiration period						5 years
Private Placement [Member] \| Series E Warrant [Member]
Common Stock Capital Shares Reserved For Future Issuance [Line Items]
Number of securities callable by each warrant or right warrants					1	1
Exercise price of warrants \| $ / shares						$ 1.25
Warrant expiration period						5 years
Private Placement [Member] \| Subsequent Warrant Issuance [Member]
Common Stock Capital Shares Reserved For Future Issuance [Line Items]
Class of warrant or right, number of securities called by warrants or rights					125,000	366,000

XML 47 R38.htm IDEA: XBRL DOCUMENT

CAPITAL STOCK(1) (Detail) - $ / shares			6 Months Ended
CAPITAL STOCK(1) (Detail) - $ / shares	Mar. 06, 2015	Feb. 10, 2015	Jun. 30, 2015
Number of Warrants
Beginning balance			2,659,417
Issued \| shares			86,730,975
Exercised \| shares			(5,000,000)
Extinguished or expired \| shares			(7,500)
Ending balance			84,382,892
Weighted Average Exercise Price
Weighted average exercise price, beginning balance			$ 1.83
Issued \| $ / shares			0.54
Exercised \| $ / shares			0.50
Extinguished or expired \| $ / shares			50.00
Weighted average exercise price, ending balance			$ 0.54
Weighted Average Remaining Life
Balance, December 31, 2014	5 years	5 years	4 years 1 month 24 days
Issued			3 years 3 months
Balance, June 30, 2015			3 years 3 months 4 days

XML 48 R39.htm IDEA: XBRL DOCUMENT

CAPITAL STOCK(2) (Detail) - $ / shares	3 Months Ended	6 Months Ended	12 Months Ended
CAPITAL STOCK(2) (Detail) - $ / shares	Jun. 30, 2014	Jun. 30, 2015	Dec. 31, 2014	Dec. 31, 2013
Beginning balance		2,659,417
Issued		86,730,975
Ending balance		84,382,892	2,659,417
Weighted average exercise price, beginning balance		$ 1.83
Issued		0.54
Cancelled/Forfeited		$ 0.50
Weighted average exercise price, ending balance			$ 1.83
Weighted Average Remaining Life	2 months 27 days
Stock Options [Member]
Beginning balance		65,430	65,430
Issued		400,000
Cancelled/Forfeited			0
Ending balance		465,430	65,430	65,430
Weighted average exercise price, beginning balance		$ 18.00	$ 18.00
Issued		0.17
Cancelled/Forfeited
Weighted average exercise price, ending balance		$ 2.62	$ 18.00	$ 18.00
Issued		4 years 7 months 21 days
Weighted Average Remaining Life		4 years 5 months 27 days	4 years 15 days	5 years 15 days

XML 49 R40.htm IDEA: XBRL DOCUMENT

CAPITAL STOCK(3) (Detail) - $ / shares		6 Months Ended
CAPITAL STOCK(3) (Detail) - $ / shares	May. 31, 2015	Jun. 30, 2015
Granted		86,730,975
Vested	(33,333)
Unvested Options [Member]
Unvested, December 31, 2014		278
Granted		400,000
Vested		(82,685)
Cancelled		0
Unvested, June 30, 2015		317,593
Weighted Average Grant-Date Fair Value
Unvested, December 31, 2014 \| $ / shares		$ 18.00
Granted \| $ / shares		0.16
Vested \| $ / shares		0.21
Cancelled \| $ / shares		0
Unvested, June 30, 2015 \| $ / shares		$ 0.16

XML 50 R41.htm IDEA: XBRL DOCUMENT

Subsequent Events - Additional Information (Detail) - USD ($)	1 Months Ended	6 Months Ended
	Aug. 13, 2015	Jun. 30, 2015	Aug. 10, 2015	Jul. 31, 2015	Dec. 31, 2014
Subsequent Event [Line Items]
Proceeds from Warrant Exercises		$ 2,500,000
Common Stock, Shares, Issued as full of a dispute		38,038,921			20,318,815
Subsequent Event [Member]
Subsequent Event [Line Items]
Common Stock, Shares, Issued as full of a dispute			50,000	118,450
Subsequent Event [Member] \| Series B Warrant [Member]
Subsequent Event [Line Items]
Number of warrant exercised	7,890,000
Proceeds from Warrant Exercises	$ 1,578,000

EXCEL 51 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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how.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 53 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 55 FilingSummary.xml IDEA: XBRL DOCUMENT 3.3.1.900 html 94 182 1 false 27 0 false 6 false false R1.htm 101 - Document - Document and Entity Information Sheet http://imetrix.edgar-online.com/taxonomy/role/DocumentandEntityInformation Document and Entity Information Cover 1 false false R2.htm 103 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS Sheet http://imetrix.edgar-online.com/taxonomy/role/StatementOfFinancialPositionClassified CONDENSED CONSOLIDATED BALANCE SHEETS Statements 2 false false R3.htm 104 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://imetrix.edgar-online.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Statements 3 false false R4.htm 105 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS Sheet http://imetrix.edgar-online.com/taxonomy/role/StatementOfIncome CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS Statements 4 false false R5.htm 106 - Statement - CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (DEFICIT) AS RESTATED Sheet http://imetrix.edgar-online.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncome CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (DEFICIT) AS RESTATED Statements 5 false false R6.htm 107 - Statement - CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (DEFICIT) AS RESTATED (Parenthetical) Sheet http://imetrix.edgar-online.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncomeParenthetical CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (DEFICIT) AS RESTATED (Parenthetical) Statements 6 false false R7.htm 108 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://imetrix.edgar-online.com/taxonomy/role/StatementOfCashFlowsIndirect CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Statements 7 false false R8.htm 109 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical) Sheet http://imetrix.edgar-online.com/taxonomy/role/StatementOfCashFlowsIndirectParenthetical CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical) Statements 8 false false R9.htm 110 - Disclosure - NATURE OF OPERATIONS Sheet http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsNatureOfOperations NATURE OF OPERATIONS Notes 9 false false R10.htm 111 - Disclosure - AMENDMENT TO PREVIOUSLY REPORTED QUARTERLY FINANCIAL STATEMENTS Sheet http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsReclassifications AMENDMENT TO PREVIOUSLY REPORTED QUARTERLY FINANCIAL STATEMENTS Notes 10 false false R11.htm 112 - Disclosure - BASIS OF PRESENTATION Sheet http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsBasisOfAccounting BASIS OF PRESENTATION Notes 11 false false R12.htm 113 - Disclosure - LIQUIDITY AND FINANCIAL CONDITION Sheet http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsLiquidityAndFinancialConditionTextBlock LIQUIDITY AND FINANCIAL CONDITION Notes 12 false false R13.htm 114 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES Sheet http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock SIGNIFICANT ACCOUNTING POLICIES Notes 13 false false R14.htm 115 - Disclosure - POTENTIALLY DILUTIVE SECURITIES Sheet http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsPotentiallyDilutiveSecuritiesTextBlock POTENTIALLY DILUTIVE SECURITIES Notes 14 false false R15.htm 116 - Disclosure - DERIVATIVE LIABILITY - WARRANTS AND DERIVATIVE LIABILITY - CONVERSION OPTION Sheet http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsDerivativeLiabilityWarrantsAndDerivativeLiabilityConversionOptionTextBlock DERIVATIVE LIABILITY - WARRANTS AND DERIVATIVE LIABILITY - CONVERSION OPTION Notes 15 false false R16.htm 117 - Disclosure - PROMISSORY NOTE Sheet http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsPromissoryNoteTextBlock PROMISSORY NOTE Notes 16 false false R17.htm 118 - Disclosure - CAPITAL STOCK Sheet http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsCapitalStockTextBlock CAPITAL STOCK Notes 17 false false R18.htm 119 - Disclosure - SUBSEQUENT EVENTS Sheet http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsSubsequentEventsTextBlock SUBSEQUENT EVENTS Notes 18 false false R19.htm 120 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies) Sheet http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockPolicies SIGNIFICANT ACCOUNTING POLICIES (Policies) Policies 19 false false R20.htm 121 - Disclosure - AMENDMENT TO PREVIOUSLY REPORTED QUARTERLY FINANCIAL STATEMENTS (Tables) Sheet http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsReclassificationsTables AMENDMENT TO PREVIOUSLY REPORTED QUARTERLY FINANCIAL STATEMENTS (Tables) Tables http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsReclassifications 20 false false R21.htm 122 - Disclosure - POTENTIALLY DILUTIVE SECURITIES (Tables) Sheet http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsPotentiallyDilutiveSecuritiesTextBlockTables POTENTIALLY DILUTIVE SECURITIES (Tables) Tables http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsPotentiallyDilutiveSecuritiesTextBlock 21 false false R22.htm 123 - Disclosure - DERIVATIVE LIABILITY - WARRANTS AND DERIVATIVE LIABILITY - CONVERSION OPTION (Tables) Sheet http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsDerivativeLiabilityWarrantsAndDerivativeLiabilityConversionOptionTextBlockTables DERIVATIVE LIABILITY - WARRANTS AND DERIVATIVE LIABILITY - CONVERSION OPTION (Tables) Tables http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsDerivativeLiabilityWarrantsAndDerivativeLiabilityConversionOptionTextBlock 22 false false R23.htm 124 - Disclosure - CAPITAL STOCK (Tables) Sheet http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsCapitalStockTextBlockTables CAPITAL STOCK (Tables) Tables http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsCapitalStockTextBlock 23 false false R24.htm 125 - Disclosure - Amendment to Previously Reported Quarterly Financial Statements - Additional Information (Detail) Sheet http://imetrix.edgar-online.com/taxonomy/role/DisclosureAmendmentToPreviouslyReportedQuarterlyFinancialStatementsAdditionalInformation Amendment to Previously Reported Quarterly Financial Statements - Additional Information (Detail) Details 24 false false R25.htm 126 - Disclosure - Restatement of Condensed Consolidated Balance Sheets (Unaudited) (Detail) Sheet http://imetrix.edgar-online.com/taxonomy/role/DisclosureRestatementOfCondensedConsolidatedBalanceSheetsUnaudited Restatement of Condensed Consolidated Balance Sheets (Unaudited) (Detail) Details 25 false false R26.htm 127 - Disclosure - Restatement of Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) (Detail) Sheet http://imetrix.edgar-online.com/taxonomy/role/DisclosureRestatementOfCondensedConsolidatedBalanceSheetsUnauditedParenthetical Restatement of Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) (Detail) Details 26 false false R27.htm 128 - Disclosure - Restatement of Condensed Consolidated statements of Operation and Comprehensive Loss (Unaudited) (Detail) Sheet http://imetrix.edgar-online.com/taxonomy/role/DisclosureRestatementOfCondensedConsolidatedStatementsOfOperationAndComprehensiveLossUnaudited Restatement of Condensed Consolidated statements of Operation and Comprehensive Loss (Unaudited) (Detail) Details 27 false false R28.htm 129 - Disclosure - Restatement of Consolidated statements of Cash Flows (Unaudited) (Detail) Sheet http://imetrix.edgar-online.com/taxonomy/role/DisclosureRestatementOfConsolidatedStatementsOfCashFlowsUnaudited Restatement of Consolidated statements of Cash Flows (Unaudited) (Detail) Details 28 false false R29.htm 130 - Disclosure - Restatement of Consolidated statements of Cash Flows (Unaudited) (Parenthetical) (Detail) Sheet http://imetrix.edgar-online.com/taxonomy/role/DisclosureRestatementOfConsolidatedStatementsOfCashFlowsUnauditedParenthetical Restatement of Consolidated statements of Cash Flows (Unaudited) (Parenthetical) (Detail) Details 29 false false R30.htm 131 - Disclosure - LIQUIDITY AND FINANCIAL CONDITION (Narrative) (Detail) Sheet http://imetrix.edgar-online.com/taxonomy/role/DisclosureLIQUIDITYANDFINANCIALCONDITIONNarrative LIQUIDITY AND FINANCIAL CONDITION (Narrative) (Detail) Details http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsLiquidityAndFinancialConditionTextBlock 30 false false R31.htm 132 - Disclosure - POTENTIALLY DILUTIVE SECURITIES - shares (Detail) Sheet http://imetrix.edgar-online.com/taxonomy/role/DisclosurePOTENTIALLYDILUTIVESECURITIESShares POTENTIALLY DILUTIVE SECURITIES - shares (Detail) Details 31 false false R32.htm 133 - Disclosure - DERIVATIVE LIABILITY - WARRANTS AND DERIVATIVE LIABILITY - CONVERSION OPTION (Detail) Sheet http://imetrix.edgar-online.com/taxonomy/role/DisclosureDERIVATIVELIABILITYWARRANTSANDDERIVATIVELIABILITYCONVERSIONOPTION DERIVATIVE LIABILITY - WARRANTS AND DERIVATIVE LIABILITY - CONVERSION OPTION (Detail) Details http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsDerivativeLiabilityWarrantsAndDerivativeLiabilityConversionOptionTextBlockTables 32 false false R33.htm 134 - Disclosure - DERIVATIVE LIABILITY - WARRANTS AND DERIVATIVE LIABILITY - CONVERSION OPTION(1) (Detail) Sheet http://imetrix.edgar-online.com/taxonomy/role/DisclosureDERIVATIVELIABILITYWARRANTSANDDERIVATIVELIABILITYCONVERSIONOPTION1 DERIVATIVE LIABILITY - WARRANTS AND DERIVATIVE LIABILITY - CONVERSION OPTION(1) (Detail) Details http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsDerivativeLiabilityWarrantsAndDerivativeLiabilityConversionOptionTextBlockTables 33 false false R34.htm 135 - Disclosure - DERIVATIVE LIABILITY - WARRANTS AND DERIVATIVE LIABILITY - CONVERSION OPTION(2) (Detail) Sheet http://imetrix.edgar-online.com/taxonomy/role/DisclosureDERIVATIVELIABILITYWARRANTSANDDERIVATIVELIABILITYCONVERSIONOPTION2 DERIVATIVE LIABILITY - WARRANTS AND DERIVATIVE LIABILITY - CONVERSION OPTION(2) (Detail) Details http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsDerivativeLiabilityWarrantsAndDerivativeLiabilityConversionOptionTextBlockTables 34 false false R35.htm 136 - Disclosure - DERIVATIVE LIABILITY - WARRANTS AND DERIVATIVE LIABILITY - CONVERSION OPTION(3) (Detail) Sheet http://imetrix.edgar-online.com/taxonomy/role/DisclosureDERIVATIVELIABILITYWARRANTSANDDERIVATIVELIABILITYCONVERSIONOPTION3 DERIVATIVE LIABILITY - WARRANTS AND DERIVATIVE LIABILITY - CONVERSION OPTION(3) (Detail) Details http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsDerivativeLiabilityWarrantsAndDerivativeLiabilityConversionOptionTextBlockTables 35 false false R36.htm 137 - Disclosure - PROMISSORY NOTES, RELATED PARTY (Detail) Notes http://imetrix.edgar-online.com/taxonomy/role/DisclosurePROMISSORYNOTESRELATEDPARTY PROMISSORY NOTES, RELATED PARTY (Detail) Details 36 false false R37.htm 138 - Disclosure - Capital Stock - Additional Information (Detail) Sheet http://imetrix.edgar-online.com/taxonomy/role/DisclosureCapitalStockAdditionalInformation Capital Stock - Additional Information (Detail) Details 37 false false R38.htm 139 - Disclosure - CAPITAL STOCK(1) (Detail) Sheet http://imetrix.edgar-online.com/taxonomy/role/DisclosureCAPITALSTOCK1 CAPITAL STOCK(1) (Detail) Details http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsCapitalStockTextBlockTables 38 false false R39.htm 140 - Disclosure - CAPITAL STOCK(2) (Detail) Sheet http://imetrix.edgar-online.com/taxonomy/role/DisclosureCAPITALSTOCK2 CAPITAL STOCK(2) (Detail) Details http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsCapitalStockTextBlockTables 39 false false R40.htm 141 - Disclosure - CAPITAL STOCK(3) (Detail) Sheet http://imetrix.edgar-online.com/taxonomy/role/DisclosureCAPITALSTOCK3 CAPITAL STOCK(3) (Detail) Details http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsCapitalStockTextBlockTables 40 false false R41.htm 142 - Disclosure - Subsequent Events - Additional Information (Detail) Sheet http://imetrix.edgar-online.com/taxonomy/role/DisclosureSubsequentEventsAdditionalInformation Subsequent Events - Additional Information (Detail) Details 41 false false All Reports Book All Reports tpiv-20150630.xml tpiv-20150630.xsd tpiv-20150630_cal.xml tpiv-20150630_def.xml tpiv-20150630_lab.xml tpiv-20150630_pre.xml true true ZIP 57 0001193125-16-541467-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-16-541467-xbrl.zip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

SX704J M7]/M.U*\"$?6V5A@_RQ%N$>P;RPN>W?;!S;W.B6M(&589B4*\[KI+O$2H?K" M=<@AKZ-UV$#O67BAR7N_%VD5#G.BYC8=CX>SJBQ*'%I3@P \2@\2)E+DK\B/ MJ)6_02I$BA+H7"(E8<"14%_NHP+)Y:F.,B5UX'RB242-2KOB*WI=3($?T6V& M\7PX&;.]BM^S8KN6,C(]1_A5XJ$&(#480*.!<#A Q@/I ;ONS\!W.4HT8_17,Q5S&B7J,3M3 MCQI?U]*E)$ZPC;:U)$-BAGWW3EBQI M>IJ2'K($I-A+F$ERL;S:KFY^7-Q>KI=;V[P(&F$EW5&A% MV@S#=4CGN*B+'+D*[P[ZT'N%NRO7NSH&1P_BFYDM).*U[8;KA T2XW:)]';*:$" 1@1T2!"-";[B40$95L-<0X5^ MC'[KIWK&H4))9J=*4C;O:.=H,C./%EK7XS-M>B@U12KWWEX1-43.?C(VY MT=97DA'[[B8;J*6EB^Q0+9*]8P/=M/2,?-WTTREFO$ASAY@H6M="+&3W$\1[ MDR7+@NQSBA==F<&%=U[-Z63&P.Q72D97]X1VXA1@IGL=Q;2?_.JI*+#LV+^F MI:X5WB]Z2F/,#ED0^^I(Y/EDPEJ[A&2TQ=A&8A2QV*48PC&QD2QI()([ X#+ MET5U#,NA@16?TD)KCCVWEK?V[@.E/NFGOC$8T>\5F@X-XLH M&> ,-JZ-HJ3#DQWQ]:S:XY@D%2O_(Z VN(<55VRHEZI>K1##TZ/5T< M@R?7L_]>J&D0>4,/U/)LU+C+.[KQ* NQ<)624-0.JW8B%N'D4PFM4@DUP(IG M@QPX,=72"QBM2#&GZ(<-G]8)'\J"\,Z.,9\QUE,1= 9@Q2UFU8";)K)Q,<,O MTVTMV2OT'EP%LAF%E6/^PP'+!_OCX8 K@2Q\1=;+4<]924& E?J'E(IZX1L$ M:OW+7M'I)9H4O4\,8U3F*O27]TN3DNLTW'(9M:&HJKB_2C.:\51Z@4K^,3VX MJ75UR'AZ-IZRL$*H]":J-I"I@(P!^.?AA^'02%9V S 9#@=#^D]QA@I&YF Z M.AN<&48V%)."F13 P#MD.&/P'IC#P.H$.'B M\VOOHTL%@HBTZC9ZDF4MIJCC,P"4+H@)ZTU:2Y&V.'^9"V$I>XD9ATWSQ)6YE+G0GC M*_?)G_ !6^92.!J3Y%4<_WA $[6 69K!?D:]K\@R(%HR-)K@%'7H%B(2W19F ME*"_C0R&2AFJ(-U&$+.&((I0R@9 "I ,>65A#ZWS?&3T^&*IAV#]<+ ?"0C\ ME1.X*4]0?LZO-A4-^*W)8HV0<#:,$1X.0J]G>PA :AS<5/.GU20\>0]EI--"K1KP7VPP'> MN 'G!LW\,WI\4L) C;*LZ2CM<0@)X& :RA<4;40P\B(0&MK WU0,D_DE-$.W M:/LY8.:DU;/7$3-RB\A"SX,[XA!N7 ?]".$S+AI?>W?QSV2+P*,5?>7;(^TI M*]U1:6-,ZT'JIO6K-%<#^$FO. MUU^E+@U/V8T(.3K6XV)\+-^/I['RW4_/'(? M$=,VR98K'4'A^@7BRV*<1WP9#B&F9;XL:FI92)5HH3E.?+C]\.B^?MQ!&T-D MC'_ R!BGD(%^]=O%$6'8":YL?VL=?H66MW1VE\4+'$H?58"(LO&%[>5L-HIF MFI04H+0 )@80-7"I_&H >8*9303K&A$B)H;14*D&'1$#+U63I6L8^^!NY2"$ MDO7A&="LYD11AB2UDEH#T!,'23D!X .H"?B=",] M>]$'7JPW/ '2&8?J&G Z+M72E2YT1D>*21 M^>C9YQ3C+3.XJ&E-$/EI"ECQ MJ7%,11]Z6LA"8!*+L<4$=&.#:3YY$!1%UF/MX6K+.D!_Y>R.6TB;,^UV-NL4 ML/A[2M%0P8RP11FS^3!"1Y2MP$1!BBJ*-1%=U8U+NQ*8="]-Z$2K';TX$C3, M+*Y$]-(KG#V[*+K_G63PPZ5:W6_.H- '[!79$I[^G!GCN0 *4R-$V0==$:PC M'9@GA$N^(0LAE*,J35BU';@[AP[Z(;A%'^K*]:#]Z-"5Y/9M^6W[A+X>Q)>_ M79"??/S4PO=AR72Q%5&UB&[!J7CDF9M&#'(\( A'!)C8 (2#@FA4$ U+[AT$ MX< #\C2@8VL,Q^HT1F)UI!P8$M;L$23 )>,=I*Y;'8"?/==/U?CJBNU=:,#, M:2 IZ7W?B\L.ZYIR%KTU--9#G-Y WMZ=P(O]P2;B1CRR3,]&>51FL8BH]1)_ MM:4DR-NX@77H,;Y2)E@#69$N]&+J9\MVKI'C7COU(,5[3PNB.,R(%W+,3;,( M*$P5O,-T?P1HS9K^4P_P)45FNFE!IV0 2;O'/H0XUFNN^-/[EQ@TOH MH^4XSHLL_)#_U /8*]8Q0#&"NKV)$)=UMOC+G0D:#B3CX892$6923]$Y18]\ M20=*(J[D*IE',"81>-F\39U\(66AP I2O^R=(ZF%HDH_(JYWO6[D.IGVA759 ME=;%>$6+*RCR46=J7%A?I[->(3W=.&XKX>EDM?AFR$8:1S-23I(Q4F/1H7@T M.V#\-77LC3BZ#?P6G*,1?\]]8-G459]>D\=ZC=-6T8TM+* FC2?PE8C,)])' M4FD4^HJY (0-Q6=P=>F/Z^CZJ;_R@WNZE$A]Z?)N]66Q67U9@NO5XGQUO=K\ MBGSI7Q=W=XOH)D#.,Q?KFR_+N_O5^@:L;S?H/]I."\KW;_$Y0\D?1XX[CU=O MR4_7]M^.]@Z-C[BZLAW+V=K6 ?%"JY(N86#9!_\&<8Z9+>N#((^XVMH$F#ICSK4N.* M9?NFQ!-+_0 2'?$1)UN; MSSI&'[:%2)$'$7V0#!"9O X_VK'X*:])1@*"JNB#@^Q8-69+RU#H QN[A9S' M:Z91.?XM] ;XD"\:/7A;.7O7>R;.H=29B;RGW',),"6:C)I.SZ*97T26A&9* M&*0H:VN/)5]P#?13#D_AN7=*#1!RZL_S2Y+,;"*9B@/]E686G>@O M5X1J/."6 F)H2)[4@H5X>/%2#F,T9".!=(#H!0X:2L5$0;E4ZC%0,"TV K(J M4&?_%'G\SB[LYQ3;?F9PX?U,:4][BB\*K ML_<-(EOR71N9^W%MW*D,QM)IZK$ILKH MTN4UI?KH V+.+=_>XHUDG-3CWD9;]99&_.18$7>U(W/.@]$ $*JDBCNDVP\X MM1*6H*H@&#Z6 U;.UGV&T;F=ETZOBA>X$D_N-RZ1&\M;+JXNI\+!99EO86FI M^XDC3=Q=H)F 9QU6S@Y^^W>8/_[-?T[15)(Y>(U9V23<$PMSKR$A0"@!1$K] M]%*"1&9=B51,.4O-*9I[\H579N_B%S8+OJ06"5*N,YY,IEE8,.YNUG=U/Y)DGU**GLS0=0QHEH$+(0,B.KK MT4(8LY8PZFR?:4!98R]*K 3G!C/;-2;QGE=MZ MC@'Q Y!#''VNM+@B6'BJD%*\3(?X M[-B!3Z[RVMUZ]A;>0@__*O>%!%Y07:Y?:[:2LZ%D)8 M7&UW[%P[FR_5H$=!B]]]'/R#=3>Z@C\!*6HE?VPY< MH1]YC;C;T509;]LP6F,;)+Q0&I LB-(AHPJQ5*#@M2HX"L>%Y"!=(88GK-BNI[Y *NJ4 M2JMI-M:W&I^]^*YFH!48JF.2\W+,I9H$#Z+:(S1"?T#84GC:,P'7%KE.#G2T M1?!#[\#'M=TJ'+)5)64!C3W:)\O['09A'W"R.5+UD9K,A?L!\.@P[ MJ=B,^/1H32?=FPP.S,%M5(*UKMNE86DM!?:TG&,2\U-@B'(\%L8?I]@]R]:6-KN8FN^M'ZP"N[3T$[_ Y7/_'OH(N M;9>B8(M5TS>0?7$/:*:)6SHV#'TY CT!7I8KX;RD.3(,00@F(_0T +91 <%E M0J"O2&0;KR@F&0KJ"SKO;/_W*P_"E8-, /I!36PR7]>,3!9/=8RR8EJ*R0-, M'T0#] R6[>4GH"1R[K&)^4;O]C00_IY>KN&KTC- MWVS>SJC@RSH 6C@,0$P1?,35-&YA=B&HV$54Y#H5,E8G":E5) M2[720>BM*L8G^/P O=R'+'U41[*5P8=X3B\0$!X"0U(87Z7(6@F0=.94'2[XY,B,D1SE]0919 M&U%F/Q!EUK.TT0S-*:H09?8048WDK$!4N9PZ$6760Y390T2-:B-JU ]$C6I: M&EK@S*H0->HAHAK)68&H1=2K5I<8Y:>8ZQ'0P?J M1!@3]_CS^:2XJ$KR#%K//G8HLME(9.58K&/(3'0*:TYNJF6]7^SH/4'XRJ"X M^4ITNQL]HU*ZE!:CH"TQ(\2>H$F>G8VFX_ D64(U?;ARO<^TY$DN8J3C:,KC M=*"#O"="@J68D:H@.IP'; )^L-F&<#@+$( M<#\,WR*G-_1GC&JY@&(B25RGLCU7<30A=\5]3:./XO$D:(OS\^-');[A&<0U._LZ>V >OK" MU84OR]64*E*V?XE9"6 MPC%!A_X"',)+F_&E@8$+(.T@ M0$[JT;'!3E,IB3 @6:Z"K4&MV0YZ"/+B"7U Z*^<^/?1\26C:GE=34!'GJ.2 M*_'.+I,Y(]E(Z0] . *.;^D_IP[R:XO1["9&;S^*,(4M MG)D#$=.?W##OQYY"8/%0>%A;@,]S(FA9LXEIGIWEH[N?BH!Z%P?MQ#(4BS6G M8CGP$07(7758;RG=F-_R*NIEY&83#?J#-@]>Q8C-5(X<.WRKLH742OLX@7\8IAZ9RS]&28?$:J>%H%CJ8:$A@D3') M:C0]VWP.A\63S71T\."*FW*IU961U14=D]RRFQH51,."19!).#L@ M'IM<&*/XGD@-^C*9^K)X^K(R^L(]2$0TIL9+2G),B3.5\2%T+)&B&=[:N8P7 MJ"O'#SSBU/P;&-QZ,. V,Q%^7>'R2)2G.FN",.N96O%@@T[H@]0 WRYT #0 M0?0LC+I104GG3QPWW$?'_CO&O9].=J3##C\_>J4S/]H4"^FE5"V-ZP3Z'3S@ M.?/&O4;?Y)',6NYA$!S(!GB%.96_JP'BI0P)&_=D9(Z*^ YIX\Q<0ATDY/4B M6Z+D9B+Y(?)L?DRK#RV+:MDN"Y75VM("2>A #TT9G-UB]VP[Y+8&[#?P.5C' MYYTKK7I+)0S+61%OFV7.P[ND0HHD/&1I@I"H)MC)E-3,2VIE:&I%FIA)9C F MH!H=Z*(MR>ZC/IP5-Y#PGE:()@X+PE5[QB0J& Z;ZMTG'5DUWTXB132S@6BJ M<%-A;&F\E.E"$TX\M$"%EY#^=^4LMEO<7=._M=ZLAP/$R-YNO2-,KVGY'[H) M,;4H:\"A\(QJ/C?F,0C) .!=--2/> $4C0;"X6BHHP.F\RC:@-JY=@B.8S6\ MI-1@A6HXE*M!(:A;(".'^:9J[8=+2!:U37P ^VVMH&>R)#R-,X;3^MY=7#*N-=O4@M,B1N MJI/YL!RGR%X#-\[UA/1[@].VHM..F51&+Y3QA2^C1C#R+;8"BAP5]0.(4JL"<0#IZ@ ME\MVB9L(ZV6]T&5P)+XF&XTJ8(NI%U+$O0%L:]G9J5]:;( GQV!+#Y)JNT6E MF1U7@)2GMGX ]-:#+Y:]*R\ZJ'Q-*RBSO C/_*:C6?FZ-*3;3>E!]1F&C@0> MT[DN%0U2$CU+![%MLAQF#)UH Q@Y$! U97BRD%TL@L"S'XX!!O_&O; .!WKF M"I<*1P]IP ^7 M&?$KNV:S20Y**!ZFJ(8W[R+"V.MKNVQ7LL3QS@J,FFS8*?&W*?%U%[ +VRL+ M<^7:T@&_5-4#<@BD*="3>]BAS[\D/4PXG[_R-87@J^)%?$TUC=J#I@]!8D=/ M">E!FESQ"- V+IYK7Z\6YZOKU6:UO >+FTMPOUE?_/LOZ^O+Y=W]G\#E\FIU ML=IT(S,>7YW,4PDRJW(OHGA,>Q% /],+1 MQ<\\CZ>C L@&("2C'5>-Q$E%\O#][NN3:\3M1C)-:\NDP0'D,,*!>EK^?H!: M/-KF7] *\MKQ96Z:+FU_>W!QVY?J M+\IZ20]Z&)R(KYJ,8DLE/".]<9U]_(L,N%+=@9+Q.L'7"_1L=[=T2K=99>J! M[+&>6P>2Z7T/_NWH0# :\GO#29+P/K"\0)6,DZR,EW!+[K8!(X/(.>Z)3RF! M),>O\#0CI2?>M8WF[SL\@W=V,5 N7(=V\M_ ;\$Y(O=[[OO5>E5UASM!OH2; MC)Z.'B'JW?+_$* M'B_MKU8WBYN+U>(:7*QOT&]7ZQMM+>-JXC;N#%='5U( M<'GH/?1>[2WN1,>[UUG@+=5NI9HE\?:%$[1.)!XE(0H2JB BJ^G>9]F2&KHE M+7:C3P#3L MOIWN3YJ<6E?M.:OF4""[Y2,AHG!7+DHV6C2TVG^^68'T% MUK?+NP6>]=[K7$OS[2J]?N:(K@4(,+BP_*=;SWVU=W!W_O;9A[N5$_>876P# M^[6L@TT- BJ!(\R5^-G7\20L7L&E89@ZB,B#AS?P#H\ ;.?'I#\O2$;1LUO4 ME1;(+M+-<@,N%O>_@-N[]9?5Y?(2G/\:K4)O?@:+B\WJ"]EYUHK'VN:=P6D] M_?4;OQ6[4PT(]1+/M?=ZSLZB>QH;X%K[9E?7BJ&;8!CF5]?KO]Z#J[OUIQ-& M>=EN64-5]@CU\1'GIE&;14 _RAE GD;MUEK(1NW/]RABKVZB M>7/?L5QBV@(8YNFNW]AM%K'+"/42R_4#T[@%IOL:L:4IAAFQ3Q?E#2)VE2HU MH9XVL\97+/ M(_6,6JPF XN?*YJ,A@D,PV;CX84@^8/%MY:^.M 6TIF1=/BR M#VVS@:;<3]G?9N]Z('B"X):4P70BU2OT'MS.OHH1?Q;\KH \"KU:$>0YAY43 M6LJ^%#GDAM8IN.3]"C+WI/*/J-Z/RHU?H]S!#'>C\?=>[T%( R B:K>A6DE@ M*)2@?/NIE1@Q\-P]/IN-:?P)[-ER*-EWXEA^O.?$DE9+^'>=N-D:]0#AL?"J M.7[E>RJG"57,U-C B;K>FK])0?N>$K0C85L M&V84C+;"X."^J@DM/'YJM"H<3YGPR34B'X"$N'Y(R1&;&570\F1O;]$LBUR4 M!7:V![?()OL"MRK;Y>&O5&-R$@EXM(T;U]['-^_Q]B)$WU*>;JAD2=#,SLS) M],P,,Q#$MC9NZIA)0E=Q,D*R?$:E?-K68IW(:R;R!N+?4TU*0QB#299#3#MR M7,01U]2O]V&G2-QL RW_#L<=WGGY[-C!>K^''IKM,#^C\,O*'88H9^*UVL99 M6$5/:>.<6;IE-[!#^KA[\A&-@*,6&4)Q?7U'HALIT=?[N/$L$3VBCWX > 00 M#:'#M70COBGXY2%M0H0-0)_+J8OIQ//44IY4!T1[^^ Q_)7O'^&N[.,6'];E M8 JGQ@$WJ:O$=+N7+>(FS-1<@!2D^C:V@I&W$%GU.?2#O0 MN=@I )LMNE0@1[VD2Y<8O&=UP3C/2)U]M%D&Q=@HX9HHO"\;0"CK:_A,&T.+1@W0)PODHY>]H M@'4I0W6L)9GU$Y(@2Q,D1)5C7**(AD81*P$O44XS(R?,RFF5RJG*$0BA+^T0 MJM4CQ3&LGQW[X>B31<$MTO7F#W?SA$:VG-T5^N8!A Z_QX;XRZI=A3!G-2:) ML[#&*:0=KI(Q=8#(@X@^B ;0U'NC(]&-_HA>[EHZDI_X&-P%#&250*];H;K0 MWIJC-IICCU-/:SHV%JFB5\X.?H.[C4L6.E'SX/O LW^'MYZ]A09G5TOX=84; MC*(\B5^*-([*&$.S#&GC_#FE_B<_7+8/ !T!D"'T[#1V(S]!:BC<"T\X55N* M=:TVO:U82SU:(.D]6H[]=Q*%<6,?]V#OR/\LG-TMLI@H0I/J3L'-2KFT58)9 M!L/"^^K&;!16XZ3''8#,R&1K/3TV7A;W:M]0H_),1PGWM@-WY]!!/P1XRN-OK&]53JD9,95>J!&'=0)L MN U *Z0S(X%W=*P?R9&? ;C%OPZ!1!^_==%X,+#I388@Y(9,GM'SB"']CDB! M_E(5YMN,_FPRE*[#7DI,IT)V\ X?XM-::-_.860<9W.%]LE37KD>M!\=6EBZ M?=MXB%_$)PT Y/\.Q/__;-D.!O["LWW;>;P\XBUE>MZOXA9#%2/WP =+%*=& M8_.HRH/EL#-G3@<@9!!$'((4B\2+IY@$F,OX)#'E%%!6PT.>^J]G[-V'(-XO MTC+\MGU"[T 0I+1J[?[[Z ?/G.)?W3ZP U<@XC!E?Z\^>5?,;T/WF'FU!_XM MS4^-BT_'AK"#ZJM#:2XYO;]JO2$MX3_=WBU_6=[HQMK\18RIA&&UY!R:FL$+?]QIB \0A*2!X2^7+#-J=P.?,3G+W2/AP#-)F^AUNT MAL<^H?0>.<$W51>AB;%5H]1Q%-XBER(,(LH@(:WQ#KDN1#9Z(7)YT5D7?-WC9?+^\^'RGK3UH [#&968U]*0E\B-:$$T^J)^[ MM;RU1[:R=^0BG%OHW3]9W MP!5]6&?>%.!*.>^9D'M:T03#/28V[SL_F'.A1FB AV@>XM1.4=L=VG5?H!39N3OR2A9RN"@FI M'Y/I2WSZ,7?0MQ\=#,+^^!0>]/B^A*D@.4L%QCB7LX+#6D#MJ&$99!:V\;O3CBW5E M>=F3VG!4XUILLK4_'G*P0P@->A2"&DA6M68=@'\>?A@.C21=!-X#8S@8#LD_ MT5S/BE=+/_4'7(6KPJNTI@E$+Y:]"QO<5S8;YCZN%DY,'D0M;V*,IDE:")," M(2W]783ER&:F98.4ED\VF'?PQ?5MS;NK%2:7@PI?'WKP8KL>+8Z^@]N#Y?OV MWM[2@WUQ$3I:M&T]^X61QFA,1BF^ZO$F?H!T9(3+J3S= ;AU#_;V#7P-_ZMM M7U*-$D* HB'"4Q\@/XAFA#8S\BQR&RA04IK3?K4">'NPMJ2V:_'L'@L!K>Q) M]6E-%AO"V][3^=2(TIF$$'B)* &+D%+<-U.&/$9:GI@2H*2T9"W;RV0RO]&@ M1"A%6(3L(:JZBFY$'=0:U&W0CUEV->3"-K?LTAK8$T'/1JJ/61)1$O MGG%%TA+."B4\%>+K"6;N%L*=?X7$P,UB N](#NI>NY93<=^?T*M* UTU/\*+ MI?G9*-Z HV3IX:8T84 HZ[TZ4+[09E'H Y'SA2^GNI@H;JW9""FH)=T0C$KU M,Y<_"'QZ]GN:P,=D1MP()_,9"WGQV10W>^^)?MQ)D)> +BTAW5X8 (>>H+>C M/VWQ&0[\FW\V9B.\$=$7.)9:+@^+?,WI!F+J6KBW2_C WY4H>443_/)\B&?P MC:@;:19YZ1L/WP FJ1]S[80,#V*GHMH >*&4+YAD7U#%,T,>H)AJT8VE\)J$ M97C6CGL0L^P535C*\R'NU4<39A0+"8*8HGXHM9.1,5T4/5396DRA$G!I'Y,A MJ=#7U.$W>)#C^0VF:C3YC;T=E/0\23V@UB>$HXH?^A^.H_NWT1PNUQB)WN=& M>J^Y'EE++H+ LQ^. 0Y&N/TWWG%VG0!Q=L"/K1R$:>CKB[R-Q#+;^LUI_OKW\%=\O; M]=UF>0G^X_,"_?<._>IJ=;.XN5@MKL']9K%9XI>TG.FOM+UT>&/K2 ]4:/NC MA;.[A*_PX+[@@!36V'&_<-D[2B%4PDB-M<1L&,$IZ@7E[$"*8E03J@M0TJ0T M"U+N$HIZ42-@AED$52E%$YJB>QN2PK;2:I2R-]0BB<=&C0-D4;>X%#60D--< MG")-1!JA8A)^+VI3!"PO!Y]296@&S\8E):._(HC393IOM5;O73V XC,D/#.: MSJ-]@#2T A?0NF%,.LIG?-V0?$4/IH'2%6"F%1!NPVV>(&EX;3EO?_)3UP^1 MHU'1%3H] 6:U57,@6J% *=D1/!S>@R<=W^-[4O/W*C//>M=_7W4>I0YSXBW& M9L:0)EF.^J'%F [Z09OJ MHHE+?-AC:BJ M>0YA-!J:/"3I7L.V%ZP F,O^ :9LX^O!5]L]^H2V2D-0Y6LJL57!BW@_H8D97D08D1R MA"B(J&H.47+%I<'*KRVG,L )VF<&;B(:T@FVSX[_ K?VWD83S](8QGU> [P* M3(@[]$ETL"C!58J:[L@E1SZSF7RJ<<0U/1: V"K1@YPGN#OB*+IP GM7Z,N_ M_(:+"^&.GG9Z?CE&][U'T]BH27C5/D<' RG%JFSNQ:/)W)A&(*=,X)E;FHWT M71@1(]$)PY@5_%*\%HS;\_=FTT6W@JF72?3HN$%86(MT:3OTWA'T(RY )=?3 M)2J\L [;([V$5J\CZ@K)60_6R7?2Z_J6GN=Z%Z[G0;)R\!?.+M7X)]EF3F]L ME1QFED!8BVMKRJUX$<)D."JZ,C(L2(U+RGLR?:52I1CI;63JO+1[+#5Z,Y7H M3;VW:@L^MG=J]4WT>B.2SGAR#_ARN>7?CG9 :I.CW:NU=V<_/@7<2]':T]/B M>VHR*1[<#6-<=#GIT?X$Z'BD$G^0[/@B%-%!>SA'ZE1;U-&0JZVMT'8@O>S8P?^G7LX7+G>'Y:W(U8K M[B::4=7B+!JQ6J.8?\18<$5C@F30,'U.A@5X7! .W$./H4!E*;_Q$OD-]T5[ M&U!)N&$[C^9JU>)"T.0'^HMLY^[R[8B2-U1"G\^&>,O:X2B:"1!J8 'R%PMI MWG^0):29%E(K]*KM+0.K"@5(J18-!PGC.]/X^<^IKOYD,2%H"V?3X7 >5GG& M!A_U&.C4T+G5G.VE,=1+4UZ=V5ZD%%@M(8F4E&&6H20NM^0*+Q&HYVCA?A%- MQJO0RGI8#V09G(B?IC:GHPQNSP&B!BYZ@=[6@AE\P735J,D4SVPJGD)8EV J MAVV>.O1-7L]K3U[9;RB?O#+9J%'_:(QST.GCY%6"D!D Z9^\EMI;3WOP^3UO-'<:&S,Y_D@V(OPUT(:0[TT0B&OA4AF;9%4ACF1V2M#>HE( MO1!$ZD4?D'K1R!#,X60ZSR"U'Q/5-M(8ZJ4106H;D( MU$M!I%[V :F730QA-AK.YD8&J9>]0&H;:0SUTH@@M8U(9FV1%"*5#9,<4AG2 M2T3J4A"IRSX@==G$$.;CV5G4_3 TA&4OD-I&&D.]-")(;2.265LDA4AEPR2' M5(;T6E([>-/XW/+A#I>,0L=GH:KB894)'28'PGMT9T;4?X(0>O^ *8$T*4TI M' EB44B0?!05:ULAEK)L3JF)91(Y?#7(B6),^@N,PT=2AWC^ECQR:[V13E>X MB(#\ZP[BXR*V\_@%^@'Z#ZUG9/JW+L91'D4[$$+4HN?#,],,HS"I:CDO !6D M. 'G;R#]7,@-()R$_XX9 B%'8:&NXF"N7:G&R2JU8DZA7;,I!QS67@$OUL]K MJ)\7KG[43% Z](#)!*>K3]&?"9*H,!D9C%K1O^$0VB=CS?BN<<)[,BV?PF6< MV$/HQ,+G,DYL$'HQG;Y+ORZ)V]I [QF7VO:A:+0#P%5/,EMH6IM7>J@6XB$O M!"VS7Y&[$TF;RW7P!+W-D^6LZ:=?/#YZ\-$*X,H)/-OQ[>T7ZW"$7TBM;9GQ M:N!&M:]3+Z+X?6AG9_+<8G@J)\4T(%R# +$-0KZ1]XPX!S'K@/ ^ )1[C:ZT M[Y^*WA09J^T5T\$..#SIT!<_K,_%%%RVIB]Z4G/.2GEOW/#4Q%\A/EL%=XM7 MZ%F/\&>KBR;(^H0/8\129KIS#'E2AOC78*\3D+94$@%F, (D% * D@ MH@ L"\#"T.#025"@R^JEL^MDCJWM6X[QMXS5:H5JC2]F?/'L+0JVT"%7T#U8 M!WP)K_:8H=L[R)SSR_[R)Q5-8M87OG]\IO+BRU+P6;M+^]7>(<.[0R+*AIOP MN*<0!T2%J=&9:SJ1YN03MPQ2_ U Q"&(6 28QQ-+C72C>C)SC]7R9L/##KQ# M\8?>]=Y-@VR!&W)[IB6#I2:TOO'3^?&3#%5UO:*4.%3K(YU40JI,,IR5+$V: M=S/@*:25*J40AJLQR^P*=AQ/,&\GEA:2K&KB&,_I7'T +N&6% "!D3$ "%MC MK?&C!^JA@2.VEX.]A_V+&YTZ.BF9+[&O\MTL1[ZXN OD :W55"](V__N5!_'V!T0H"51Y3^:XI^H[6<*(G[R>2-M"9.9Y<4G"F/^3IIRI$TGQG>=XT;HQ-^ M0,+0B;E%.7HEWB^LK0 VN2X:!"ZPMG\[VA[$9QJ?D7[)5NMI.L$JC$KQ=:7? MXJ1><=?.;DH I:EW3+>W\"&2H^T_X5IO#T!,%OWX?T_9LU5#58IOJ_@2I^C=KEQO M#^W@B'VULU/GZZK'/2'/5RF,>"?WT60NWP^F^".W12GPBYW/^;I1/9D#7N#Z MB,,![CZ&U-D3XE/QBL(0E^DCQ;[+*7I,4E[=M7O,#7)"OC#+N3#ZQN;X3+[C MH\PD/FY ;O)$*]Z4>9ZFWVNC9D:WB$=,[K3='!N7,GT:0^=Z>P,Q^>(=H^MT MJ)/I$%0NAV@GN)$Y&8UE-0F*4DZALUI%SJKK@VNL*- ?Y4IJ%J1+N1UU#)*I M85KMZ@?V,TY=@#U62'P8O >!085O;-\X2."+]#!(%,\(1C=T=V^N)6.?=ACA M"R8*S-ET-C'2<85.;]/M%(&5G0;[J>=>0M=G$=>7@3"9!-.CRO078(ED,SB$?>'\PG!R9JA(XQ"NNFGGX?IV8+\J3-XTT/"(]G"B M-0IE.W>GELAJH NBBI_YRY1>UTA+@US*(+Z?)%[&27>7R4OT??IQ37ESK89< MG&P\E-9F:6S,YO(.+I;$2HV]L11'#\G?)AU94)3]9_#Q.ZB1:>@NNO.^/>]> M]5 MYP-'SKA!5[8FL@P*'8QV"BU%RD6H'G M6#O_=G0@& U),Y%)AZJY#RPOZ+UR)EGE"'5;Z7TG$3'/)J6-B,"W..F@D"V4 M4ATD*D8_Q:!1+I(P>,WYJ(,2S)C+>$L@YK/KL%*S1+UWGV*G*^\I;@YE=BE1,P?]SYC<@)?+%M)WZ_TB58_H\2K M_P](JFAW[-^G(Y>:0^V@I/_4+GWHX380#7R/._^O$UR0=?2(S/IW MW^-K#[JVW=/33]/UE(HG/Y@R)/6/9$:$P38PX!835[R)4 MR/L6LFX)/<$((T^)$R$E/GRG@4G$TW84KBH_X2FFE?CRW<%GR\86=.$Z9.%U MM [X0B:SHV5]$TY.*+'40+PZ:8NIZD 7M&>QL7&)]U_9>?VS3XX!EYN&:?LA3C'E?2,*1-AJD]PRZ^%?U M52#]RE?Y#)Y0A)0G=9T&=QU4[U)!HMZI]"; P"6__I\6575]TSX=<.Z%^KJ( M&9(_[NF&$B6',9A#G9Q[;UC;?S:?=G!6[XO*@WJ*?&T;!1.OF2B#5B4- -V@ M/=5C)A+LCN0MOW"U<%K1I/O3(UR-GZZ'UU4^+#KZR<4!:766H[-)EZ'A>S[< MTV>&D!JEK5+4WU?UJ>*)PK,^X- MZZ(P4S8;)^'!FLDFC.7I9%2C>-]O=:6KGJK-#GVIBF]CEM\&VZ-UO@8/(L?9SM-EP:C[\7J7Y6XAC&AR<7PV MFT[%<]Y^P\NU%$23YCEP96H6SHCW6,TM,^3*=)T)-_3$%JFW25^RW-^TN02W M*9Y$;_M-3G)E5'KE@9)%40T.3FD])"Y6G:*'&B7DPDLA@8M9OHM54%=?I*( M_"36/)U9:_8^N.]DK5/?:4I=YM3\6/TIA:3UF8MC\.1Z]M_A[K.S@UYJCQKO M#OD9 >ZP3L+?6 \'&&J@D_/#ZKG37DJI7.0Z-Y54Q+I!6$$/$O;!$?.?+94A M(@QR$0P0,>+?8D&2>'BB)Z5Z_BU)(#BG#2($;N316Z^IS5%5UW/J^J,:2YR'5VDRLN:) 10U*"_$^-(:J^9:^/VFIS3)W%C):?5=[. MRBTR_R +T=7-G]>HI'NX+[!L]8-_!:<(U*_"W^M MW&N]@'^6)S%+0EJ:&>:,N@%$X'BP/+"S_>W!]8\>V?LQ5:=&##+/09#,=H6E^E65&7S MY,QSJA=U5Q\L[D-JTK?40G",D;$ M#7 \&68.4"9TP%=,21?.Y$EGUI5.&:Y$S"\#ITJE:$71M>W %?JQ$CK)@SKP M$H\N?FGAF1$U1XB(@*^8#"!T=$.DH4!F/8&4HZ)@3DPH9(77:O_K_87E/UT= MW#_\JML&RU[1@0D&'S7F,*.S/#K]@A*Z!S47%0EKRK!Y5\ANJL,UBP3%/^$PB7 M(#T"IBS)B\AL(+D&;%:;,0><%8K3BL[[+70LSW9%\D:,7LHV1D,5U,TUJ W]FQEEF'MD'54,W,[KX#47SL9%"9G[Q ML @"SWXX!J2,*G#!+?H\;"ML+:!8?4A+2=,%(B60DB1,=7U(2W$FBL01;^,&UB&WB+V$>WMK=R05'J]+J:8-I%+JS9FNK>"LBQKHAR^NS'[U(^75 M-MLS&AN9V9.8C^Y!QDN.X"97\'4]KA(''!Z$S6<^FT=E MMC$I0&CUH=I6BG1F(^F48:3"Z#)0*=-'#Q!3'B^8S^K#2DT_.TI:$Q=,26_H M:"\6!R%]B"!E!E8"C7Y%DLK2=-[C^M!1NU8;6]*,#9 >%*-+$8X)D]Z4H%>8 M7 E8>E!ZGF.H\G@N]WF-B*E_$G5LQ@F#HE7I/W8K1SZ*FL_G]\O_^+R\V8#E M%_1OO6=KJZRM#"L].$&;Y:BT[H[UJ#Z(U*M=,V;S.6_&I;44K[50G/E6#^KR M2DRK!!2::_1RS."K1$OJL#E/:T1%R()XLT-CS D; -/26Y@M0S8V/BIDTX61 MG+F5P22MC)X@I?R:;.[S>M%2\WIF-'D_*\6+WINKY.L#PD&+%[)/] MO.*(RF1"O#_=,+XD'5&(#Y]JGWE*D,JL(Y7*Z%EJ9OGHR5>$'I2\O!Q(T8MU MB/I=K)R]ZSU;(LTE!-]6BB AEL1/=)]-XUW8A'+2YP2DB/<@F=Z!\&&6\/;V M>OEI>;-97(/[BU^6EY^OEV!]!6[6-^\O%O>_@,7%9O5EM='=G*^>/6?!*:X\ M'5"-TYL5H"P^IQ!^A<'%"P)&T2YNDE[7#JB6XIBUQ%&%$:XAI=' EER+W=L! MCI4K9V>_VKNC=2B9Q+&?56G_+ 9J7#0_"3=J"1T\STDH:9W"29#+K"^7,D24 MF5@&%5PU] (9?[6#ISMX(/'*?[)?-N[2">S@K3256)>*3C25LU;''L.T8YH8 M/J-%R6G..W8JMME0;&U8%#/J4I0*Z*\Y?GVX_?#HOG[<01M#=XQ_P(@=IQ"+ M?O7;QK-PU_7[M^<'-__EBW]7@++"H.+K L. 'GP]-W/F:)-(C.D+5^-UE MSR6(8Z@7ISQ1+D$FL[9,2G+BI5B),^%\^:4 %O=AL>A9C.#)W;D']S'?]83_ MG&JXLI@0WRD9CL*[\V(RX#FAH_ABK/:B&%E14G0TH+2].";WRV@#:!DV8GQR M)9<"SW#WBW<$E_V,:ECF&1#TSF>3J6$8%)+1CF5,0RT:VTE@J).@'(7MQ##3 M8L R,92@CV?Z,?*8TG:".M*L3$3A]$'=^"-<"'O?^6PXXX"0-NS3"\4&PK#Q MV*$P]5#90"(V- =\D;0@- ,3+DP3\75D-T-N2D\N9I]1F)G,#"Q>QC";C+,V MK_> 8@LITG:N,UW(M))T,K HH\S X]/.$5S6^SWTR-WJ?I#? MJ*KWKJ;P5,E8C9JWLWDF8OG IAV8]I0XV$,(+&<'W) ^V.(!%"_QNI';R,@= M=IX*B0-$'2#R(*(/R #Z8IYDV8E[N,I]8SLJ4N58 IT<@[F0\GD3L-R8*0;CQY!H1RUX4S?$\J75RC!^)6>%#I,IL",NOS M)#7@F7@141UI66EDF;LYXJGB>D]:@*7NRSZW?'N+W-ZE?3@&W!Y[#8FI7+LT MXE!\U]G*L9^3_-4C,F4>+)O.AURIF(Q88 I]V4J)D%__LM?_]?[]Z/U>C3Q7!H>WT:V^]NC$8#_'*'_6B/XJW_>K>>CFP_7H]$^#)]_ M_/CQCS_^^.#[5CKF!],[?!R]?Y]^[VM,V8^C'S[7M1>YUH^CZ]RO M[GT0?]B"-/TXNKFZ_N']U7?OK[_;7EW]>/WIQ^\__;]\:^_YS;>?]N'HW\W_ M@(VOOG\/>]R.UA_6'W),_N_1QG,#V/KP;+AOH['CC-:H5S!:0U;]%V!]2 9U M$G9'$%(W^.E=CL/71]_YX/E/'^%G;C^F#=_]Z[^,XL8_O@9VH<,?MVGSZX__ M_#S?F'MP,-[;;A :KEGHB 8C=;W^].G31_S7N'5@_QC@4>:>B5'B('!$;8'^ M[WW:[#WZU?OKF_>WUQ]> ^O=?Z$/_M7W'+ &NQ&FX)?\ M;N^#W4_OPF?[!2'__=4/MU>H_[]-/#,ZH%7D6E,WM,.WF;OS_ .F^MT(C?ME M/3N2;Q] Z-NO'X#U9/CO/1<.#? R"I-%^1'U^,@<]&-3DM>PYZ\;N.X!^L9R M]V"[<*)LPUEY@8T^<>\806#O;YH!S^"YY61D^J#\E%;X1[D%HFX8CGKL9 ME'8'((*'9"3A%&[V$(&]YUA0%DY_C^#2';O6$B+B(Z$$_P3"_8/C_1',7,OV@1F*8/!\T/;I%C8[Y)'%S<#$#DS'"R(? MC.$'+?31K0>5F1?;BP+G;0V>/3\$UC\B _[C.V]'>76D,1A;%I9:\$M BSX0^ Y-M+!K#O#0?K*9@] &'QQC0A2U. $%/#I'K!? M7+KRL&AM"Y43E"W2Y6[YC.X0<&E">5L0M7,OZ'C-U""K1=B(9!T%89O(\'Y9 M/O-M[Z5:9 B$93[[QY?99+;]-EY,'F:+\>)^-I[?+Q?P5[/E8F'X:(V^U-?Z MJG])('.KY7:ZV,+/S+]-9O,OV]G7Z69Z#[G8SJ8;K(\% ACC^8I IB;3]>SK M&'UE/AO?S>80T5_&Z_5XL=U 9 E_A1A_G:XW$.3E"D$M@.7F-/0)D.L^('+= M*TAN^@#)3:\@N>T#)+="Q>-Z^7FVV2S7WQ90A&W6T_EX.YVLQNOM-Q%BD3&Z M0";NC6<[1+<2S_RMK1M2^3=$,C1>S;;C^6:[O/^[",E4'*\E0D7(B^)X+1$J M8A<7QQ-(Z"9Z#,#O$=3TIB]MWOCYOB/&>K/P0A!L/8+Y8&&$D);<1:B^,E;I M(VWSM09F8ELV6V/K_!N=<[4U'IT&^G/U+[7-X9T1V/#R-39-+W)#VWUJ@;?S M;[3-U=S^/;*MV-I\_#,R3N =OP6OX9T#C[46>.7]_X;:M"J8*%]JF\/\O;I-_LC?D<)=:\N;];76 M-8R3^V2K2A7U6PF7S[D(P3EDJL N; Q<"_FTXM^BCPD-],(T0"H@184/.R@H MSO.+0"??Q9%O 3 _/'DO'RU@?X38?X=^0)/PW?NKZR3N[=_@KWX]>NLG(#!] M^SDV"<2C.L8C<'YZ1VWVL3OJ'ASCB446_GO[]-Q'/G*%AZU@/\ M74 DMZV:SK1+/)1F;7LCL88&?J")+?KCKXM')9!%OYS^]3$J_X>?M!'YDD+ MO/X=O!'((K?KC#[OQ(J? (NWOD^1;P<=;& M]=75NQ%D8 ?@*6G-8UZI!&+J0GAY K@EZFE[$;_]M.[FW>C*(#,><^QQV%8 M$SH-QD^-QH?NG::P72K86*H !E.WVF-%>'XSO#Y MOQH?NO*5P?07#1/C9I+A]$GCQ+;!'*&"VJ6&BG8ERU#22CCO[3D'6MN:^5\_ MGEJ<.[)#\V8#)]^U0_2):Z1:7HW>CXZ]"S][N]%QK%$ZV'^.?'P+R585LS-W'RT#BCM)9">1" ,*!8 MMBF-Y-&9'%%,,M,VTJGD O6TK0RJ41H3A4C\)RDT9:<&WN T^DZ;R:#U/"8! MBB;V4F5VD<%#G.F.\AL]%YF%O(-AG_HKV6UE4)T##YX/>!D4,O*$N[MDWMC[HB>[X9P,?O3[(-%Q6$:B.%$H+C2102,NJ<&],&BM95"^2B\I MI<<3J:4DBI^AJCE]?4:I[@O/-9E@4YO+H'T-0GB\ &MJ^"Z\,@;P%A =(@?E M8D_ SC9M&A<<'67PLX%'/Y31Q:7Q&1P>@4]AA-5#'@=WE3D@]Y#"07J1/E%E M@O&K?1J$PM='*A=SN,QG\,=2TK.&4NDE&$)*SE>NKE)YVC+.VI-&#KLIE$%WXBCFQ M%6:XU(G6\$+#Z3FYGE$Z48M'U]-E"C:;8:26CZ^ND:H/' LHXFJ M$5,B<&.U5C5^2O!ZHQA_FT54]5_REYLI"\=B7?=L=H JOP@Y8*3:+3.8U(K? MJP<3VRF68:56+%\]K(KF^@P;M0+XZF'#7CUU0O?Z+]>YS)-YD"C*;7;^J:G3 MTPV@Y]=!DDZEI@[/APJ_YJ5J\DP=LW11;R^:?B]FMQ5,W41$R'(K!>A*(Y3? MFT=8%,:ERKV.Z%Y7-?FC'D3GT7&-LCY>@/_HJ840-2)7U;2/>C#Q!%>HFOU1 M#S&FG:E6YD>5^TC/DQB*SQ_(#1N&M"Q]3+:%9>0*^#C_I#R2F-I3K!__2677J%4#R"MCQ"YG(ZB\:*\>Y+#"JQJ MN;W:4+%DO*I.UUH0GG-X'C]A ;4!(909!T"M?*BSVB] M)"*!QD])+QF$@-W8DS; M^?$7P&51PF+-P?K$]\DAO_4AK9!&I'B[%OX_!PO?5"Z/?3N $SJ)?/0X,7X_ MH63O=?'E/B&*:*T)2:&K-)ZFKW"9PIL-O$_[;RGZ+$[('>04JPL O//M\4NU M+\#QGO&-EGE"L_O(X.(7N"_V4/D9PY/*> *+"+E;ESNLW^6L.WP*8LW!9-[% MR^YF^5MYJ5:FNA&U"E@EVT-U@VH5J%B2L)E1M?_YSR7W@Z+UF0:IZF[\"B!Q M:-"J)_E60:MX*VKFFU=JL]6]NS1RW@\B5J0"B*5F-M5]^!6PJJN(-O+M#V+! M<1M%\G!R6*]4#SRMA1N'G5_U4-2:N#7S$]4K^OHI!M4%3\B KR"LG.X-U>O! M-K.D\N@U0FV3S,_6-W4?.:X#_$P4APC;8>A3R?C%\]&0O,T.T^CC5N$4/>V(> MKGZXO<(#N&Y\AB% M*(9PZ]T;CA/GF2 3:3(A-$]:DQ&%K+05!AE #<&,#0,'5*Z8M,PH+5NA@E16 M@=%03NJ^!S4KAI,TUZ /+W@QA2^EL9348\XB"#TI>U"7VE]O=(F 2RP14..) M)9Z^@RL2T/6K5C^C,Q-8>2L!UIGPQGPT F"A=0WO<_AB266F^DC]>,>+Q5 ? MWQWCIE>:'(6$Q%IV?B'$8C[U,/&OJ8HC"=&Y4CTR_O:#[2)0'P!ZHF*YVP%$ M"O;SD]0P[KZ#*'=!N**J_JP$-S8EQB'5GY3@QHFF;JO^KH2NEB(RK9>9RUO# MQ_D)82@S#?+WP MIR'%3?"MIT9&=[B9*\E.=-E'<^3\$H4N>NN[R MAONP<>Z-8/_@>'\$,WA ^R '4!([_OW-#3MV'(TPPD/(B1C/V2?6P/17VR(V]W;%ZC?S]QEFG8S-N&E/'X'F;T#6OF4E#AH2",M]!G] MJ814U[Q,66CLP[.+QP @+[R46& MJG'P-RC&<5[@L<'/]!2 !@-*R6YX10(QLH-]? ZAR4K=/[$\I5>OXNLK-OMA MN#Q>(=(?*[E-7-Y!^@)?\A6 MX'7RL?/!NVQ:X 6=I-9JEC7*OOL:2&):6QI*+&I$MX\CI'_A). MX:7" /WFKZP^L0OP:A2C4_2 /WFK]Y\]LWZ-(RBX_ 4*;SJ ^%SK6/< M!?P-(&6D5.TM*5O8!, *'GSO<.]A4P N:3/W#+?DY.7J*ING%.'")9:#(7(_ MV=SDE-$W=+)R,'+6138/R9T]O;(SLM3I7:1E5',GSXG(CQ/NYCNZ=_B]>^== MI/ 0/3\[:>QN0M',W7G^P2 ]K7;*#F=OF>[*-CU79T'0/#8;U:/@A==^N;?$]5O=Y>5_B6QQ.KE8+3T,_*%KTD\^L1R!NU$DT$ LGO"<[ 5"OY M1""8[.M%!J!:"2FM;FN6!^((Z*U: :JM DITOF5(JI7!(E10U@\KR>!54_^O M[E1CK]%3UTZ]0BU#RDX3C2!?T(3JA5WJ.W1HISK%!)H=[6IN5"_F0SA\Q@%8)$,@PK5-\K?^/?]5W/O.\ MF*9HH3$QH+5CO\NP5^OZ+A;[*HIL)@+4NK\+%P'<43H9HG7N\?T7JCS^UWK8 M7<[KIH(P9*H&JK]Y6A5#5K:;ZJ^@UL&J8=F^X55\K(!-H=)'G2)]PZOTP84- M=UQ+HR=,%1).M8WCRM?OJQ8A5:+^$M,OE*_D5QU"_OQ*Y2O[-0>/*Z56]1>) M!>!(2*+MKMI?+ZN8-"CQ(ZYV 4^FP'D[I2*&>ZQ8,&;J DH 3>S =+P@\L$8 M8F7A F/>R@)\D M:S:FSAVCOW=XA"L#L>310WH/*>>!"5P#+H)S@\X&E:BKI-/&\%EEH*S5FO\9)5; >"5@- MJI>4%7)2\GBWZRB'+\!_]/J.8*G$+"[)LJ-">3=+%;B8NH'R#R0).\R(]8^+ M1X+ZE:%;0;.A^.RR\+1D^P)) R%)1H)]7T3BC MM)9">1# K5&V\HJ-Y-%Y'_E(BC+)3-M(IY(+U-.V/2R1+8$TAR4DR>0B8R6=NLC+R7' G=WR;RQI4-/9,(Y&?SH]^%DSJ?_T[Q2 M^28R:,017MP+@]9:3BFYY'9<>DB36DJB.)<9OO!:\ ?7DSE/CT<=>OO2HPR@ZP)AH<2XD ML).MJ(VRO@8##.6>RD@15*Q,9F4XZ)>B>H6S%(3HQ'NB>N$KIBFX(*]9>J;J ME9@JHD31956OM20\ZN_T_%.]X()P /D-[*H'"%9U-5!09&A::IZ;37!C.J95 M3PUO AS?1E4S'US01J7X1E5/""_WXA7.U[I1:*I7EZL&(]6MIWHAN&HPL2-G M5"_Q5@VKHC>[6;$VU;!AKQXUU=?6TH'4O*^WD0ZDYIU=IP,-"$VR>S%%55DW MB$ZRDIMDQ?)J%Q E6TE5]](-*QE-%D95[O'$:$/E:Y!5MJT54R:ZJS8V!'RH M:6:JO[!:#2:>.$W5'TEM:IOM\IG3 :<22R\'> EYQ;EC >*]]+%N8N$3 NJU M^!E9"FL\/25SA(D(QE&XAYODSVP]TSDYZ]$+#M*JJGS4)ZU[0?DR"N'F=RVX M 7C)SW?1N8XZU[%^UE%%@<;963Y?G&*MI%,U/E#U8DS=U0^W5Y@V7,^8](WL MV=(3PGAZ] 5=ILAE=.@+_>6"MZR7SIK265,Z:XHKFI7,J,Z:$LV!SIK2Q5 O M((M'<(B]HN9=P2'VBEIWA4>(\UZQ=.@])[!<]RC5H^U;7J;G-V;5 YHZ ?3\ MU2PU8YXZ ;-P8U<]'U: M611MQ7:K&BACWP[@ MA$XB'_XW%A)PB2YWD+^*((G\X3.%UR897J;<4?18G MY Z2GB$ \%JY1P &.]XQOU\R3@=U'/Z:@PVAU&"V1S6&&T0ZR9/PO\*3< MPVTP?H$*U1-81&@W+'?X9I+S//%=;6H.IH,^U3:REMFA\GB6WL%4]X!6 :M$ M*5'=^UD%*I;^J7PXL?@8!1KP.C2V(I0<-A =(%L5TZ+UJUD\K!<:SH7A5]>2 MI6-E*P)=ZD!H%"L+E?!'[^(PK7NA43V EMO83BY33/77J9YE5!.W9O[>>F6F M/L6@NN )Q6&H"6M94$"]\E-#0JZ9GXGGG!?JN5']O;'VIZ/H]E']<;+6JGNK MFO@3 FKG+]+(PAER\Q,]:E6#1QJ>DA''C=WN) M/.(_]9"F7V^D414?%7".?6 $4 N/_V702NG0JZ#W ]1I[3^QO&2''%4900<: MRPHT/EUL,Y?G]3D*^S4'ZP??Q'?0N!DE]^X'9\=3)*FV7W):51B@'_RM"L^G MBM"AS=0Z&? MM[><6M&>"8 5//C>(:4&W?F/]51H/)7VD\W-+X;O&RBP#_BF'5#E ;.+3C?0 MZ08ZW8#(YC#3#9* (8 +*T"E%-_M:3R2&P\\34*G"RCIXVC31IR?"VYKA.H^ MY*X KV3>5-T=W=TJ)UL[5,^CZ0I?VCFL>O)-&U'[E:=#IYM4!+F=7:$S5"I. M0Q5W@2[G+D:0,.W(JJ>N5/=/L9?KJ?>G7@KED,*N12/(Y_%5/;NB&:I5/"C- M7N[N?Q9@?>]9\?6&4ANZZ@']XH$\-]^K'L0O"$->5U4&9Q4#S9!.'S& 5HD@ MR#"M8W^Y%'G)BCC,$%33PB(.P1Q6-S6L)<]X C:AX8>7@MBO-WG,:A@_8LRF M[C#E7D4;':T@1*4%LS-92Z-14^-I(H5-3K=,I=/U'4Z?0Z12Z7J30K?!, M[$%HFY ;G4_74L;08\@3MWG>;LA1- 2NN_,$]F!'SF?_^#*;S+;?QHO)PVPQ M7MS/QO/[Y0+^:K9<+)"Y"06QR-AT2 Z@QW[@/^A)J1?#P1$>)2_/L#O)2B7, MTP*O(;[_!E5P0>C4S4^T./9F+JK'VZO,&WX.>UL%>36@PT_"H7N&P0Q MN4P:#GJ<"5?%F8#0L)T +0NT*BAS(7APJ75!N=;@\8%R@8BJ&IK7SLH[-6JP M]MM%R??5:DZJ&XX/Z-"G:5I"QA8B87/>KN5S4E;L M7%026HG^>N(W"N*W&;<^,/#-K80:6J^VJ$O]U94))'041*/[ J# @1?DA1>> M9&H<$D;CO,V.5O6B5PL/XFK#]6'=]!*M#UJ<\DG6^UY.VH2 M),FA:HAB6\!1A9ZJ089M TF2SZK&% K&\O0<435*4!1L@A7%9HZG_H<@E)V; M)S?4&E-S47;JR70]^SI&EZ7Y;'PWF\^VWWX9K]?CQ78S7DP(?[U?+KY.UYO9 M)ZN.Q+9" M=/<'P_8_&_YO(,06A^6.5#* U5(&=H@43,0X"*)#K'*BF&PS!-;$1B$3KH5* MC%/@Y.[>-]ZVP#_4X EWZQLO7SU431LI:#5GZF2 OO"WMH/?'GP T@3$BMP1 MNTMYN133,X/GU"M<01[R.\&#,99$&WA"_096OFV":PIOW-V%2#&L1ZPBW]P; M 4AO ,12%:7-I18'.!'T 4^1 &(?J5S,2RH7$AI*I9=9)H-2\D*"WBQ 9R+& M'UU(?06FPG6\H5$;CD4"'JBHRIZDN)+NGRX)1KXFDDHHUQ^+M77<)R. MN[?CCW^S@0]%V?YM#EZ PS T<786YHV(/Q C>4VWX=&:2L5WYCY'88!!(9/. MTZ,O'-Q4YN"F9QS<5N;@M@\"KII @?E5_C>ON$+RVD;9DF]T(>]] = :P-$U U5OWW5!*E5?ZEVXAU >NL&& MK*(KJ'H#;TV>%?/B;()4Q\^VZ,SN$G#/W=6]8D>]*0_.QG*O'4ZZ26DC+* Q"P[7@V?$+0"HZL,8OP#>>P!H@1QHJ M!^NY6%)'AH,2@VY8^'9,B;9?7+2^W\%1IVI,0@/4Z^3?7+Q1I%-]0M5@AK[@ M7I;_6<,@ T^Z1T]5W+O63U0-N6@P#RQ[0G>% WI@$%NMEY]GF\UR_6VQW$XW MZ^E\O)U.5N/U]IN0N %4[-'&%1W1NH28 ]=$A;C7P#'B!SA0T4<#;@3F8Q?- MQI)Q$\'K,GDX]S[RT1JFW!1(+653G(,4JNP+SS6Y6:!V'8C=K6L!UG2'U+PU MJ152UN H(&Y4?;MDXD07#]U=$'MP>";/?^,: JD;W'!F[L[S#_C[8D+OGIY\ M[.!-*QWA^^1R%S^R,(9_1/?.](]?('L^IBC]#6Y!JWDO;G 91];8P8,#BWR? M01="-Z!90#D[2^$+J?Q;^!5&JF^QC93WAPI!#4E, X-B>OO>4,_,UV3UZ T' M:4Q)LH]/(DZH497UQFHAM/?XZ6?;Q_LP?A2R/,"7UK$]&FO[M(0,V2U?')XE M 0/V9A\-QT./.4\/<%]M6V5&5QAT &JW;%+83"R#W-J7U%_TJ4ZHV8Q5S#;5U_P58#Y[_$(50J4X?S9Q3 M2@XT'4T.-Z2"!$U&$O4*51 Y<&&&]-(M9VWDU=\O>[.IV$@>G?SY$O3V0N8W M'OZ+:XA'Z%6FRV1V$T/39<(W8U9&L+"@3-W"EP^\PBH!S]!)C M7DS.I-RNG+GQDS S%X&PW.V ?R[]*W862NO9I+%H.V\LA);EP;4?HR V#3B& MN_W#V^Z]*(!GWH,7^2$ +GUR^3O+V-,K'-<"(&$F7H#,,D64QD(P1F^<^Q$\ MEM$2.MI=THE-#V_Z$JC47TKPEN&D%3D7Q@'^F#-[,R_F'!VE\&,"UX!WT)4/ M7FRXGIVW-7CVX'JVF&NHM)M,7KZX ;R-VCL;6.PIH;87\X8$E*,@&">+EO%X M!*F=0 KNT!O.'&]84!N+I(43C;O6T+CGI."^-0HFG!1,6J-@RDG!M T*ZD;U MX/\<(TB^PH,"_D,WO+7RG4$%7^/_%.BG&5:%?F)0(=6QJIF+!EZ&>^!O]X:; M!#,=?4\S-X0Z26";^!:$>#[38&13,ZC5J5-71*[CLJ=!F#N_G0\.?C7J1!61 M7)V$@G:?3\4F8%#X'KT2<0!$%.X]W_Z3?1X)_XH#_;P*W_I'*]/GH]H%A?'M06D?"7*Q^%H6%:'V#]2FY MJPN;]&+R8NIH_DS!7^BE# Z8-T4<">9:R'Z.;*!LXUP;G^IFI5 I(PJ#0@!3 MK773Y'M2*^"G!EB>5VD+;<7,8_08@-\C.'9BYDJ]UPRS6$D7*6A"FFS+-ORW MG(N!A2BUO0SJMW:(B)BY%KI[1P;KX1ARVUY0_8L=[G' .=IO>_MYZTW=$-XM MF"*NZBA"5GVR<)E52<_:M/)EJA9*;BACGEEV_[>"\XBV:KUE5F(@1@[7BGWMY:BH6IF$7>P>QYB9FSY12)%>\&;Z,<](G2K M5L)^?81.?;L90G_1"!%]ST>$OE,K@Z\^0J>^\0PAM6JYU$?HU'>?(:16P99: M")7=Z#*PM-!F! =E,"E8I[9YD'^6S4Z/;E4Z.5L@A"7AWTK7\A((H\#\:Z4K M@ F$G/^2KG1MKQ;$*4=B@]*5U,5 *C!W5.GB7!V@79[OWET]K\$B7"4//X-3 M+=.#?/%PGDR=8?U)8\W&NLWPSN,T7->PV/:_E&4+$]%19&,V,?HFV.6TE%1\ MO=872M9!6RV1,T-5WQGKG+>%DAT9F/JZ6 (FHY9!AJ*^(5;6J*E56C)4]4VP M,JJUZL%?ZPNA$*#+U %]4>0P=I(>@[S6U[XJR"51;T?X;M0*L.G3K8">)I6A MK^]D;:%/2;O*H-<7,);<:#?+()L%?6%KRVC'S([*)D!?\AIM@XII61GN^EK8 M"N[,,BT9^OKZV-:Y2RS[D@&OKY.M+/NR7.ML O1%L[L)8"5Y9S.B+[!=^F5* M'NV\U>[+TOG@?5(D U5?<]O2\IM6$,OF2-^'3TJ0%^:'GN6<(GBE6K*:8 @9 MV8$IA,KE^PF&\"1O-87M1L/&WKSD@@\I?+<:/B9\E!H)*7S?:?B(\#76$HX' MBW(G"_O-BOK@)7.@>O8X?Q'X_#:F%>G/-$"U;/'<9=D+1T5I/?H,+K5LB%W4 MV,HC32+M.,)XD'Y'E\C'J]EV/-]L ME_=_OZ[VZKB8:F[MO]!7\@I:&E9-(8'=MI?U7FDZ4ZE5?.&Y+]@"?I(]=>ZQ MH\Q3+T@;5+5F_4:$D(#&+-NX[6+RI"\-$;%3G[P7,,N#"_[2$!'+Y8/%YT%+ M>)U_1Z-5X3N_W@P=KY,CCE6+O.NO]Q+9LJ!K@LAN V+19 P2ZP?/WP$;N1^D M8EV5C$%B73Q89R6^0,VU)K#%QC*\^ M2="]J:3"=T_=X&$1L,TJFT^P&.;:;/J MOKJV@N5ZQ (NP;*N=*W77LQ.$X]4=S5C>Q;D>J-FD*M(.M'2]%PX-\R'LLEM M>^E(Y]>(QZ[572AA^7>'B*8.+!Q,J)Q&2P<6ZL!"M9&5N6H;%&BE%S[*E9$XENVAWY5G7WA*2OB">REM-&AM?W!6H?6EH8))I4$3JZ!03[Y M^RPBD-5'*A?STS*$--*SAE+I+=15HM$:-Y(61!HOY#2KFAXC6FC7SP T&OZJ M%RA@VH/.0G6*$Z[J$XN5).#YNVAG8*J^AN@RMK-PQ1H+L/>!'-W"RXY5K!.0 MW.O @&[!Y; _JQK6+%E(%"+NZL=[]=9U+PW>%D.[+DTRMQ-3IVB9QFX@;Q!" MIU;D5B_E2U&HJQ>/50/T?EA=FR40J;4-NG:--,HK&I:N7E[QGGQC5_;)BAH( MS>447.]9K-BMCA73L6(ZNDDD'YU7EJQ)Q1 ]^,>$A=-W;5MQQ].^II&K^;6! M1NHCKO&LN3K2B';2(C*(6C0^$O'6^,K&=^AR^92!DON&Q((&2+>7[M3 M(HB?&BYFLD0 []=UC)V.L1,58T7'B>G(N0J1F'Z;@^Q! B'OHSKUT:+)5W:_9G6KO0,QNY2O5T=BU]:QC'E ]-5VN& M>:PS-0M3#C3B1Z<<]" .A^HTTHD'?4X\T.N7::RLEVDPA *_DJ1#F5NT7OZ! M!IS?JRXBWV XND$W(%?0#"\FZ4 'GNK T_J!IYOH,0"_1VB5O."U85EV3./, MW7G^ =,@(R#UWC&"X%@2?^FOT7*"&V[0'59V^3L D/Y ;6%(EANM9) M3?M ,_P>*_""TKHGE#-//'I[F5ICJ=Z15R"9Q[SJ]DX.'><8 M4-EI=82G3#=3_:5*'J#X%*D+J Y3 2NJNMRHLLL086*_J4;4$U27WRSMB(7. M42-1WX+$B1!#9T@QTJN(*K:ZM+CU Z,3G;YDLUV*/EEZ?V#@=*Y1MOTXDS3; M[<(+0;#U'FS7<$W;<(Y&[&!AH.) R]WR&22EW&08;@E4D.]_A(8RKJU+_\EP M[3\Q!?>0",^QK7C9N]8J-YG+'0'R$FN(F+%E;DJAZ.0W,&F9='?-Z>'N70,3 MJ1'VSC;E;=X!;88.43F?&C*'Y^V4W+H$./3.S>.!E6"]?WNT?X-C+("W0BOL M&S#\F0LG&6SAVKB#W_Z-NJ=Y^BJZS[E@N^B]?V<$-KSZCTW3B]S0=I]D[/IS M(LAK^;R=5K@O1N$F+)*+WKES^_?(ME "L6L=_PP1C^.?,ODF(LZ"]UN$T O> MKC)V\O'K);ORO)W,'4:E^NB.XYZNB]Y &_O)Q3JO&V9"907EE6G#'O7VCYAU M>4Y.R0)E=) 22<&'+"6L@J^SS!U8/C\%4R\G&GHSEH*4_D)ORCH!G'!5Q EA MIQ?^L?4_41"B>9B P/1MO%JH09T5AQG.1JV.T$5OV17\"\36<)RWB>U$H?T" M-L",(!OUST^*_LGY*8+ZR=E3:Y_BM$_>R=*;IQ0D>8;8C;D'5N0 >.&&9%IG M)$Y?32>"Z* H-I29%:6W^JGAH[<4 BA'<^Q.H M8KP8",2Y;3S:#B0_";U"+]D1_GJ/\D?] ('Z+-ZX(Y PI6_I(YS@( "8D_3R4UY^!@3)GK7%X3#M?NFLDSGTHK;&9G;21 M&X\I)../\"$2L:1F0KZ_B [ ]R)XZ*%;960'>YSL_^2#>#F0B"GM,U#!U@1' M-"5XNWX&X=ZS/,=[>B-A1VS7;]%*9DWU%)AR7)H+)=4K&)5C2!1_JC]S7 Y+ MN52^Z,#J%833#@+/?T-M!)OF*&.3;'&4I@,]_GJY$ZC3<=%*^KWQ;(?H%TC- M%KK\R2,3%C^YH5[ZXI8^92KTPC_%I ]694S1WG/@W 1Q?2_$1'IS3E(0RV,% M:H\G)2SB2&WZ@@&*4/5M]#XTIO^+:X?!VG./P1/%C4&]4,85XD'UW M%?GFW@B.J#/)Y^ZF161+UOS*6U!?8;F6^47?4H7)NNXNM3T\MD^+/TB-1E2H M@E:Y0D%MWZ/,\BJU0'H4Z/>URP\ !:B 1 " :"6 M !T<&EV+3(P,34P-C,P+GAS9%!+ 0(4 Q0 ( !R$CDA9'6)U6 P /.J M 5 " 9JF !T<&EV+3(P,34P-C,P7V-A;"YX;6Q02P$" M% ,4 " "010( %0 @ $ELP ='!I M=BTR,#$U,#8S,%]D968N>&UL4$L! A0#% @ '(2.2,RM'17O30 2#\$ M !4 ( !%]( '1P:78M,C Q-3 V,S!?;&%B+GAM;%!+ 0(4 M Q0 ( !R$CDBEXPOP;B\ ,VS P 5 " 3D@ 0!T<&EV G+3(P,34P-C,P7W!R92YX;6Q02P4& 8 !@"* 0 VD\! end